Novel human kielin-like proteins and polynucleotides encoding the same

ABSTRACT

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

[0001] The present application claims the benefit of U.S. Provisional Application Nos. 60/302,949 and 60/315,634, which were filed on Jul. 3, 2001 and Aug. 29, 2001, respectively, and are herein incorporated by reference in their entirety.

INTRODUCTION

[0002] The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins sharing sequence similarity with animal kielin proteins. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that either lack or overexpress the disclosed polynucleotides, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed polynucleotides, which can be used for diagnosis, drug screening, clinical trial monitoring, the treatment of diseases and disorders, and cosmetic or nutriceutical applications.

BACKGROUND OF THE INVENTION

[0003] Kielins are secreted proteins that have been implicated in a number of biological processes and anomalies such as development and signal transduction. Therefore, kielins are good drug targets.

SUMMARY OF THE INVENTION

[0004] The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with animal kielin and chordin proteins, and other animal proteins including, but not limited to, human secreted proteins. The novel human nucleic acid sequence described herein encode alternative proteins/open reading frames (ORFs) of 1628, 1593, 1057, 1477, 1512, 1570, 1535, 1251, 1192, 1207, 759 and 1342 amino acids in length (SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24, respectively).

[0005] The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPS, or portions thereof, that compete with native NHPs, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and open reading frame or regulatory sequence replacement constructs) or to enhance the expression of the described NHPs (e.g., expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP sequence, or “knock-outs” (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cell (“ES cell”) lines that contain gene trap mutations in a murine homolog of at least one of the described NHPs. When the unique NHP sequences described in SEQ ID NOS:1-25 are “knocked-out” they provide a method of identifying phenotypic expression of the particular gene, as well as a method of assigning function to previously unknown genes. In addition, animals in which the unique NHP sequences described in SEQ ID NOS:1-25 are “knocked-out” provide an unique source in which to elicit antibodies to homologous and orthologous proteins, which would have been previously viewed by the immune system as “self” and therefore would have failed to elicit significant antibody responses.

[0006] Additionally, the unique NHP sequences described in SEQ ID NOS:1-25 are useful for the identification of protein coding sequences, and mapping an unique gene to a particular chromosome. These sequences identify biologically verified exon splice junctions, as opposed to splice junctions that may have been bioinformatically predicted from genomic sequence alone. The sequences of the present invention are also useful as additional DNA markers for restriction fragment length polymorphism (RFLP) analysis, and in forensic biology, particularly given the presence of nucleotide polymorphisms within the described sequences, as described below.

[0007] Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists of, NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP products, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

[0008] The Sequence Listing provides the sequences of NHP ORFs encoding the described NHP amino acid sequences. SEQ ID NO:25 describes a NHP ORF and flanking regions.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The NHPs described for the first time herein are novel proteins that are apparently expressed in, inter alia, human cell lines, brain, bone marrow, adrenal gland, liver, lymph node, mammary gland, prostate, pancreas, pituitary, placenta, thymus, trachea, skeletal muscle, kidney, thyroid, testis, activated T-cells, spleen, fetal brain, lung, umbilical vein endothelium, and fetal kidney cells.

[0010] The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described polynucleotides, including the specifically described NHPs, and related NHP products; (b) nucleotides that encode one or more portions of a NHP corresponding to a NHP functional domain(s), and the polypeptide products specified by such nucleotide sequences, including, but not limited to, the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs, in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including, but not limited to, soluble proteins and peptides in which all or a portion of the signal sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of a NHP, or one of its domains (e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.), fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides, such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs, comprising a sequence first disclosed in the Sequence Listing.

[0011] As discussed above, the present invention includes the human DNA sequences presented in the Sequence Listing (and vectors comprising the same), and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C. (Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., N.Y., at p. 2.10.3) and encodes a functionally equivalent expression product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, e.g., washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra), yet still encode a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species, and mutant NHPs, whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Pat. No. 5,837,458 herein incorporated by reference). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

[0012] Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package, as described herein, using standard default settings).

[0013] The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described herein. In instances where the nucleic acid molecules are deoxyoligonucleotides (“DNA oligos”), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80 bases long, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

[0014] Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a microarray or high-throughput “chip” format). Additionally, a series of NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. An oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one or more of the sequences of SEQ ID NOS:1-25 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (i.e., gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the sequences of SEQ ID NOS:1-25, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing biopolymers on, solid support matrices, and conducting binding studies thereon, are disclosed in, inter alia, U.S. Pat. Nos. 5,700,637, 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405, the disclosures of which are herein incorporated by reference in their entirety.

[0015] Addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-25 can be used to identify and characterize the temporal and tissue specific expression of a gene. These addressable arrays incorporate oligonucleotide sequences of sufficient length to confer the required specificity, yet be within the limitations of the production technology. The length of these probes is usually within a range of between about 8 to about 2000 nucleotides. Preferably the probes consist of 60 nucleotides, and more preferably 25 nucleotides, from the sequences first disclosed in SEQ ID NOS:1-25.

[0016] For example, a series of NHP oligonucleotide sequences, or the complements thereof, can be used in chip format to represent all or a portion of the described sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length, can partially overlap each other, and/or the sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 8 nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences can begin at any nucleotide present within a sequence in the Sequence Listing, and proceed in either a sense (5′-to-3′) orientation vis-a-vis the described sequence or in an antisense orientation.

[0017] Microarray-based analysis allows the discovery of broad patterns of genetic activity, providing new understanding of gene functions, and generating novel and unexpected insight into transcriptional processes and biological mechanisms. The use of addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-25 provides detailed information about transcriptional changes involved in a specific pathway, potentially leading to the identification of novel components, or gene functions that manifest themselves as novel phenotypes.

[0018] Probes consisting of sequences first disclosed in SEQ ID NOS:1-25 can also be used in the identification, selection, and validation of novel molecular targets for drug discovery. The use of these unique sequences permits the direct confirmation of drug targets, and recognition of drug dependent changes in gene expression that are modulated through pathways distinct from the intended target of the drug. These unique sequences therefore also have utility in defining and monitoring both drug-action and toxicity.

[0019] As an example of utility, the sequences first disclosed in SEQ ID NOS:1-25 can be utilized in microarrays, or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. These investigations can also be carried out using the sequences first disclosed in SEQ ID NOS:1-25 in silico, and by comparing previously collected genetic databases and the disclosed sequences using computer software known to those in the art.

[0020] Thus the sequences first disclosed in SEQ ID NOS:1-25 can be used to identify mutations associated with a particular disease, and also in diagnostic or prognostic assays.

[0021] Although the presently described sequences have been specifically described using nucleotide sequence, it should be appreciated that each of the sequences can uniquely be described using any of a wide variety of additional structural attributes, or combinations thereof. For example, a given sequence can be described by the net composition of the nucleotides present within a given region of the sequence, in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in SEQ ID NOS:1-25. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences, can be used to structurally describe a given sequence. Such restriction maps, which are typically generated by widely available computer programs (e.g., the University of Wisconsin GCG sequence analysis package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, Mich., etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the sequence that can be described by the relative position of the sequence relative to one or more additional sequence(s) or one or more restriction sites present in the disclosed sequence.

[0022] For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for 17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-base oligos). These nucleic acid molecules may encode or act as NHP antisense molecules, useful, for example, in NHP gene regulation and/or as antisense primers in amplification reactions of NHP nucleic acid sequences. With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

[0023] Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety that is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[0024] The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0025] In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[0026] In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2′-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330). Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

[0027] Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. USA 85:7448-7451), etc.

[0028] Low stringency conditions are well-known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (and periodic updates thereof), and Ausubel et al., 1989, supra.

[0029] Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

[0030] For example, the present sequences can be used in restriction fragment length polymorphism (RFLP) analysis to identify specific individuals. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification (as generally described in U.S. Pat. No. 5,272,057, incorporated herein by reference). In addition, the sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another “identification marker” (i.e., another DNA sequence that is unique to a particular individual). Actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments.

[0031] Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or “wobble” oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be genomic DNA, or total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known to express, or suspected of expressing, an allele of a NHP gene. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

[0032] PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known to express, or suspected of expressing, a NHP gene, such as, for example, testis tissue). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5′ end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be “tailed” using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see, e.g., Sambrook et al., 1989, supra.

[0033] A cDNA encoding a mutant NHP sequence can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known to express, or suspected of expressing, a NHP, in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5′ end of the normal sequence. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well-known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

[0034] Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of carrying, or known to carry, a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, paralysis or palsy, nerve damage or degeneration, an inflammatory disorder, vision disorders, etc.), or a cDNA library can be constructed using RNA from a tissue known to express, or suspected of expressing, a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP sequences can then be purified and subjected to sequence analysis according to methods well-known to those skilled in the art.

[0035] Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known to express, or suspected of expressing, a mutant NHP allele in an individual suspected of carrying, or known to carry, such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against a normal NHP product, as described below (for screening techniques, see, for example, Harlow and Lane, eds., 1988, “Antibodies: A Laboratory Manual”, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).

[0036] Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expression product with altered function (e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to cross-react with a corresponding mutant NHP expression product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well-known in the art.

[0037] The invention also encompasses: (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculovirus as described in U.S. Pat. No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP sequence under the control of an exogenously introduced regulatory element (i.e., gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators, and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include, but are not limited to, the cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α-mating factors.

[0038] The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of a NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP sequence (transcription factor inhibitors, antisense and ribozyme molecules, or open reading frame sequence or regulatory sequence replacement constructs), or promote the expression of a NHP (e.g., expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enhancers, etc.).

[0039] The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs, or inappropriately expressed NHPs, for the diagnosis of disease. The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of a NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for a NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

[0040] Finally, the NHP products can be used as therapeutics. For example, soluble derivatives, such as a mature NHP, NHP peptides/domains corresponding to a NHP, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), or antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway), can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of a soluble NHP, a NHP-IgFc fusion protein, or an anti-idiotypic antibody (or its Fab) that mimics a NHP, could activate or effectively antagonize the endogenous NHP receptor. Soluble NHPs can also be modified by proteolytic cleavage to active peptide products (e.g., any novel peptide sequence initiating at any one of the amino acids presented in the Sequence Listing and ending at any downstream amino acid). Such products or peptides can be further subject to modification such as the construction of NHP fusion proteins and/or can be derivatized by being combined with pharmaceutically acceptable agents such as, but not limited to, polyethylene glycol (PEG).

[0041] Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products in vivo; these genetically engineered cells function as “bioreactors” in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding a functional NHP, mutant NHPs, as well as antisense and ribozyme molecules, can also be used in “gene therapy” approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

[0042] Various aspects of the invention are described in greater detail in the subsections below.

THE NHP SEQUENCES

[0043] The cDNA sequences and corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides were obtained by aligning cDNAs from human kidney, fetal kidney, prostate, and lymph node mRNAs (Edge Biosystems, Gaithersburg, Md., Clontech, Palo Alto, Calif.) and human genomic DNA sequence. The described sequences are apparently encoded on human chromosome 7 (see GENBANK accession no. AC024952). As such, the described sequences are useful for mapping the coding region of the human genome and for identifying exon splice junctions.

[0044] A T/A polymorphism was identified in the disclosed sequences at the nucleotide position represented by, for example, position 550 of SEQ ID NOS:1 or 3, or position 349 of SEQ ID NOS:11 or 13, which can result in a cys or ser at the region corresponding to, for example, amino acid (aa) position 184 of SEQ ID NOS:2 or 4, or aa position 117 of SEQ ID NOS:12 or 14. As these polymorphisms are coding single nucleotide polymorphisms, they are particularly useful in forensic analysis.

[0045] An additional application of the described novel human polynucleotide sequences is their use in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the described novel sequences using, for example, polynucleotide shuffling or related methodologies. Such approaches are described in U.S. Pat. Nos. 5,830,721 and 5,837,458, which are herein incorporated by reference in their entirety.

[0046] NHP gene products can also be expressed in transgenic animals. Animals of any species, including, but not limited to, worms, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, birds, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees, may be used to generate NHP transgenic animals.

[0047] Any technique known in the art may be used to introduce a NHP transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Pat. No. 4,873,191); retrovirus-mediated gene transfer into germ lines (Van der Putten et al., 1985, Proc. Natl. Acad. Sci. USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57:717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, which is incorporated by reference herein in its entirety.

[0048] The present invention provides for transgenic animals that carry a NHP transgene in all their cells, as well as animals that carry a transgene in some, but not all their cells, i.e., mosaic animals or somatic cell transgenic animals. A transgene may be integrated as a single transgene, or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. A transgene may also be selectively introduced into and activated in a particular cell-type by following, for example, the teaching of Lasko et al., 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236. The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell-type of interest, and will be apparent to those of skill in the art.

[0049] When it is desired that a NHP transgene be integrated into the chromosomal site of the endogenous NHP gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous NHP gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous NHP gene (i.e., “knockout” animals).

[0050] The transgene can also be selectively introduced into a particular cell-type, thus inactivating the endogenous NHP gene in only that cell-type, by following, for example, the teaching of Gu et al., 1994, Science 265:103-106. The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell-type of interest, and will be apparent to those of skill in the art.

[0051] Once transgenic animals have been generated, the expression of the recombinant NHP gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques that include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-PCR. Samples of NHP gene-expressing tissue may also be evaluated immunocytochemically using antibodies specific for the NHP transgene product.

[0052] The present invention also provides for “knock-in” animals. Knock-in animals are those in which a polynucleotide sequence (i.e., a gene or a cDNA) that the animal does not naturally have in its genome is inserted in such a way that it is expressed. Examples include, but are not limited to, a human gene or cDNA used to replace its murine ortholog in the mouse, a murine cDNA used to replace the murine gene in the mouse, and a human gene or cDNA or murine cDNA that is tagged with a reporter construct used to replace the murine ortholog or gene in the mouse. Such replacements can occur at the locus of the murine ortholog or gene, or at another specific site. Such knock-in animals are useful for the in vivo study, testing and validation of, intra alia, human drug targets, as well as for compounds that are directed at the same, and therapeutic proteins.

NHPS AND NHP POLYPEPTIDES

[0053] NHPS, NHP polypeptides, NHP peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include, but are not limited to, the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products related to a NHP, and as reagents in assays for screening for compounds that can be used as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc.) in order to treat disease, or to therapeutically augment the efficacy of therapeutic agents.

[0054] The Sequence Listing discloses the amino acid sequences encoded by the described NHP sequences. Bioinformatic analysis reveals that the NHPs are similar to, for example, kielins and chordins (note the high cysteine content). The NHPs display initiator methionines in DNA sequence contexts consistent with translation initiation sites, and incorporate signal sequences and hydrophobic sequences similar to those found in membrane and secreted proteins.

[0055] The NHP amino acid sequences of the invention include the amino acid sequences presented in the Sequence Listing, as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP product encoded by the NHP nucleotide sequences described herein are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well-known, and, accordingly, each amino acid presented in the Sequence Listing is generically representative of the well-known nucleic acid “triplet” codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of “Molecular Cell Biology”, 1986, J. Darnell et al., eds., Scientific American Books, New York, N.Y., herein incorporated by reference), are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

[0056] The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences, as judged by any of a number of criteria, including, but not limited to, the ability to bind and cleave a substrate of a NHP, the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequences encoded by the NHP nucleotide sequences described herein, but that result in a silent change, thus producing a functionally equivalent expression product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[0057] A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, the NHP peptides or polypeptides are thought to be soluble or secreted molecules, the peptides or polypeptides can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, in situ. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well-known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of a NHP, but to assess biological activity, e.g., in certain drug screening assays.

[0058] The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP nucleotide sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing NHP nucleotide sequences and promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0059] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing a NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in-frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke and Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads, followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target expression product can be released from the GST moiety.

[0060] In an exemplary insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign polynucleotide sequences. The virus grows in Spodoptera frugiperda cells. A NHP coding sequence can be cloned individually into a non-essential region (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of a NHP coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted sequence is expressed (e.g., see Smith et al., 1983, J. Virol. 46:584; Smith, U.S. Pat. No. 4,215,051).

[0061] In mammalian host cells, a number of viral-based expression systems can be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric sequence may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., see Logan and Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, may be provided. Furthermore, the initiation codon should be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bitter et al., 1987, Methods in Enzymol. 153:516-544).

[0062] In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the expression product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and expression products. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for the desired processing of the primary transcript, glycosylation, and phosphorylation of the expression product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

[0063] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines that stably express the NHP sequences described herein can be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci, which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines that express a NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of a NHP product.

[0064] A number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes, which can be employed in tk⁻, hgprt⁻ or aprt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147).

[0065] Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. Another exemplary system allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976). In this system, the sequence of interest is subcloned into a vaccinia recombination plasmid such that the sequence's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺ ·nitriloacetic acid-agarose columns, and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

[0066] Also encompassed by the present invention are fusion proteins that direct a NHP to a target organ and/or facilitate transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching an appropriate signal sequence to a NHP would also transport a NHP to a desired location within the cell. Alternatively targeting of a NHP or its nucleic acid sequence might be achieved using liposome or lipid complex based delivery systems. Such technologies are described in “Liposomes: A Practical Approach”, New, R. R. C., ed., Oxford University Press, N.Y., and in U.S. Pat. Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures, which are herein incorporated by reference in their entirety. Additionally embodied are novel protein constructs engineered in such a way that they facilitate transport of NHPs to a target site or desired organ, where they cross the cell membrane and/or the nucleus, where the NHPs can exert their functional activity. This goal may be achieved by coupling of a NHP to a cytokine or other ligand that provides targeting specificity, and/or to a protein transducing domain (see generally U.S. Provisional Patent Application Ser. Nos. 60/111,701 and 60/056,713, both of which are herein incorporated by reference, for examples of such transducing sequences), to facilitate passage across cellular membranes, and can optionally be engineered to include nuclear localization signals.

[0067] Additionally contemplated are oligopeptides that are modeled on an amino acid sequence first described in the Sequence Listing. Such NHP oligopeptides are generally between about 10 to about 100 amino acids long, or between about 16 to about 80 amino acids long, or between about 20 to about 35 amino acids long, or any variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such NHP oligopeptides can be of any length disclosed within the above ranges and can initiate at any amino acid position represented in the Sequence Listing.

[0068] The invention also contemplates “substantially isolated” or “substantially pure” proteins or polypeptides. By a “substantially isolated” or “substantially pure” protein or polypeptide is meant a protein or polypeptide that has been separated from at least some of those components that naturally accompany it. Typically, the protein or polypeptide is substantially isolated or pure when it is at least 60%, by weight, free from the proteins and other naturally-occurring organic molecules with which it is naturally associated in vivo. Preferably, the purity of the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight. A substantially isolated or pure protein or polypeptide may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding the protein or polypeptide, or by chemically synthesizing the protein or polypeptide.

[0069] Purity can be measured by any appropriate method, e.g., column chromatography such as immunoaffinity chromatography using an antibody specific for the protein or polypeptide, polyacrylamide gel electrophoresis, or HPLC analysis. A protein or polypeptide is substantially free of naturally associated components when it is separated from at least some of those contaminants that accompany it in its natural state. Thus, a polypeptide that is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially isolated or pure proteins or polypeptides include eukaryotic proteins synthesized in E. coli, other prokaryotes, or any other organism in which they do not naturally occur.

ANTIBODIES TO NHP PRODUCTS

[0070] Antibodies that specifically recognize one or more epitopes of a NHP, epitopes of conserved variants of a NHP, or peptide fragments of a NHP, are also encompassed by the invention. Such antibodies include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′)₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

[0071] The antibodies of the invention may be used, for example, in the detection of a NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of a NHP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of a NHP expression product. Additionally, such antibodies can be used in conjunction with gene therapy to, for example, evaluate normal and/or engineered NHP-expressing cells prior to their introduction into a patient. Such antibodies may additionally be used in methods for the inhibition of abnormal NHP activity. Thus, such antibodies may be utilized as a part of treatment methods.

[0072] For the production of antibodies, various host animals may be immunized by injection with a NHP, a NHP peptide (e.g., one corresponding to a functional domain of a NHP), a truncated NHP polypeptide (a NHP in which one or more domains have been deleted), functional equivalents of a NHP, or mutated variants of a NHP. Such host animals may include, but are not limited to, pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including, but not limited to, Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, chitosan, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Alternatively, the immune response could be enhanced by combination and/or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, ovalbumin, cholera toxin, or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

[0073] Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class, including IgG, IgM, IgE, IgA, and IgD, and any subclass thereof. The hybridomas producing the mAbs of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

[0074] In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Pat. Nos. 6,114,598, 6,075,181 and 5,877,397 and their respective disclosures, which are herein incorporated by reference in their entirety. Also encompassed by the present invention is the use of fully humanized monoclonal antibodies, as described in U.S. Pat. No. 6,150,584 and respective disclosures, which are herein incorporated by reference in their entirety.

[0075] Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 341:544-546) can be adapted to produce single chain antibodies against NHP expression products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[0076] Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: F(ab′)₂ fragments, which can be produced by pepsin digestion of an antibody molecule; and Fab fragments, which can be generated by reducing the disulfide bridges of F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0077] Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that “mimic” a given NHP, using techniques well-known to those skilled in the art (see, e.g., Greenspan and Bona, 1993, FASEB J. 7:437-444; and Nissinoff, 1991, J. Immunol. 147:2429-2438). For example, antibodies that bind to a NHP domain and competitively inhibit the binding of a NHP to its cognate receptor can be used to generate anti-idiotypes that “mimic” the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies, or Fab fragments of such anti-idiotypes, can be used in therapeutic regimens involving a NHP signaling pathway.

[0078] Additionally given the high degree of relatedness of mammalian NHPS, NHP knock-out mice (having never seen a NHP, and thus never been tolerized to a NHP) have an unique utility, as they can be advantageously applied to the generation of antibodies against the disclosed mammalian NHPs (i.e., a NHP will be immunogenic in NHP knock-out animals).

[0079] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are herein incorporated by reference in their entirety.

1 25 1 4884 DNA homo sapiens 1 atggccgggg tcggggccgc tgcgctgtcc cttctcctgc acctcggggc cctggcgctg 60 gccgcgggcg cggaaggtgg ggctgtcccc agggagcccc ctgggcagca gacaactgcc 120 cattcctcag tccttgctgg gaactcccag gagcagtggc accccctgcg agagtggctg 180 gggcgactgg aggctgcagt gatggagctc agagaacaga ataaggacct gcagacgagg 240 gtgaggcagc tggagtcctg tgagtgccac cctgcatctc cccagtgctg ggggctgggg 300 cgtgcctggc ccgagggggc acgctgggag cctgacgcct gcacagcctg cgtctgccag 360 gatggggccg ctcactgtgg cccccaagca cacctgcccc attgcagggg ctgcagccaa 420 aatggccaga cctacggcaa cggggagacc ttctccccag atgcctgcac cacctgccgc 480 tgtctggaag gtaccatcac ttgcaaccag aagccatgcc caagaggacc ctgccctgag 540 ccaggagcat gctgcccgca ctgtaagcca ggctgtgatt atgaggggca gctttatgag 600 gagggggtca ccttcctgtc cagctccaac ccttgtctac agtgcacctg cctgaggagc 660 cgagttcgct gcatggccct gaagtgcccg cctagcccct gcccagagcc agtgctgagg 720 cctgggcact gctgcccaac ctgccaaggc tgcacagaag gtggctctca ctgggaacat 780 ggccaagagt ggacaacacc tggggacccc tgccgaatct gccggtgcct ggagggtcac 840 atccagtgcc gccagcgaga atgtgccagc ctgtgtccat acccagcccg gcccctccca 900 ggcacctgct gccctgtgtg tgatggctgt ttcctaaacg ggcgggagca ccgcagcggg 960 gagcctgtgg gctcagggga cccctgctcg cactgccgct gtgctaatgg gagtgtccag 1020 tgtgagcctc tgccctgccc gccagtgccc tgcagacacc caggcaagat ccctgggcag 1080 tgctgccctg tctgcgatgg ctgtgagtac cagggacacc agtatcagag ccaggagacc 1140 ttcagactcc aagagcgggg cctctgtgtc cgctgctcct gccaggctgg cgaggtctcc 1200 tgtgaggagc aggagtgccc agtcaccccc tgtgccctgc ctgcctctgg ccgccagctc 1260 tgcccagcct gtgagctgga tggagaggag tttgctgagg gagtccagtg ggagcctgat 1320 ggtcggccct gcaccgcctg cgtctgtcaa gatggggtac ccaagtgcgg ggctgtgctc 1380 tgccccccag ccccctgcca gcaccccacc cagccccctg gtgcctgctg ccccagctgt 1440 gacagctgca cctaccacag ccaagtgtat gccaatgggc agaacttcac ggatgcagac 1500 agcccttgcc atgcctgcca ctgtcaggat ggaactgtga catgctcctt ggttgactgc 1560 cctcccacga cctgtgccag gccccagagt ggaccaggcc agtgttgccc caggtgccca 1620 gactgcatcc tggaggaaga ggtgtttgtg gacggcgaga gcttctccca cccccgagac 1680 ccctgccagg agtgccgatg ccaggaaggc catgcccact gccagcctcg cccctgcccc 1740 agggccccct gtgcccaccc gctgcctggg acctgctgcc cgaacgactg cagcggctgt 1800 gcctttggcg ggaaagagta ccccagcgga gcggacttcc cccacccctc tgacccctgc 1860 cgtctgtgtc gctgtctgag cggcaacgtg cagtgcctgg cccgccgctg cgtgccgctg 1920 ccctgtccag agcctgtcct gctgccggga gagtgctgcc cgcagtgccc agccgcccca 1980 gcccccgccg gctgcccacg gcccggcgcg gcccacgccc gccaccagga gtacttctcc 2040 ccgcccggcg atccctgccg ccgctgcctc tgcctcgacg gctccgtgtc ctgccagcgg 2100 ctgccctgcc cgcccgcgcc ctgcgcgcac ccgcgccagg ggccttgctg cccctcctgc 2160 gacggctgcc tgtaccaggg gaaggagttt gccagcgggg agcgcttccc atcgcccact 2220 gctgcctgcc acctctgcct ttgctgggag ggcagcgtga gctgcgagcc caaggcatgt 2280 gcccctgcac tgtgcccctt ccctgccagg ggcgactgct gccctgactg tgatggctgt 2340 gagtacctgg gggagtccta cctgagtaac caggagttcc cagacccccg agaaccctgc 2400 aacctgtgta cctgtcttgg aggcttcgtg acctgcggcc gccggccctg tgagcctccg 2460 ggctgcagcc acccactcat cccctctggg cactgctgcc cgacctgcca gggatgccgc 2520 taccatggcg tcactactgc ctccggagag acccttcctg acccacttga ccctacctgc 2580 tccctctgca cctgccagga aggttccatg cgctgccaaa agaagccatg tgccccagct 2640 ctctgccccc acccctctcc aggcccctgc ttctgccctg tttgccacag ttgtctctct 2700 cagggccggg agcaccagga tggggaggag tttgagggac cagcaggcag ctgtgagtgg 2760 tgtcgctgtc aggctggcca ggtcagctgt gtgcggctgc agtgcccacc ccttccctgc 2820 aagctccagg tcaccgagcg ggggagctgc tgccctcgct gcagaggctg cctggctcat 2880 ggggaagagc accccgaagg cagtagatgg gtgccccccg acagtgcctg ctcctcctgt 2940 gtgtgtcacg agggcgtcgt cacctgtgca cgcatccagt gcatcagctc ttgcgcccag 3000 ccccgccaag ggccccatga ctgctgtcct caatgctctg actgtgagca tgagggccgg 3060 aagtacgagc ctggggagag cttccagcct ggggcagacc cctgtgaagt gtgcatctgc 3120 gagccacagc ctgaggggcc tcccagcctt cgctgtcacc ggcggcagtg tcccagcctg 3180 gtgggctgcc cccccagcca gctcctgccc cctgggcccc agcactgctg tcccacctgt 3240 gccgaggcct tgagtaactg ttcagagggc ctgctgggat ctgagctagc cccaccagac 3300 ccctgctaca cgtgccagtg ccaggacctg acatggctct gcatccacca ggcttgtcct 3360 gagctcagct gtcccctctc agagcgccac actccccctg ggagctgctg ccccgtatgc 3420 cgggaatgtg tggtggaggc cgagggccgg agagtggcag atggagagag ctggcgggac 3480 cccagcaatg cgtgcatcgc ctgcacctgc catcggggcc atgtggagtg ccacctcgag 3540 gagtgccagg ccctctcctg cccccatggc tgggcgaagg tgccccaggc tgacagctgc 3600 tgtgagcgat gccaagctcc cacccagtcc tgcgtgcacc agggccgtga ggtggcctct 3660 ggagagcgct ggactgtgga cacctgcacc agctgctcct gcatggcggg caccgtgcgt 3720 tgccagagcc agcgctgctc accgctctcg tgtggccccg acaaggcccc tgccctgagt 3780 cctggcagct gctgcccccg ctgcctgcct cggcccgctt cctgcatggc cttcggagac 3840 ccccattacc gcaccttcga cggccgcctg ctgcacttcc agggcagttg cagctatgtg 3900 ctggccaagg actgccacag cggggacttc agtgtgcacg tgaccaatga tgaccggggc 3960 cggagcggtg tggcctggac ccaggaggtg gcggtgctgc tgggagacat ggccgtgcgg 4020 ctgctgcagg acggggcagt cacggtggat gggcacccgg tggccttgcc cttcctgcag 4080 gagccgctgc tgtatgtgga gctgcgagga cacactgtga tcctgcacgc ccagcccggg 4140 ctccaggtgc tgtgggatgg gcagtcccag gtggaggtga gcgtacctgg ctcctaccag 4200 ggccggactt gtgggctctg tgggaacttc aatggctttg cccaggacga tctgcagggc 4260 cctgaggggc tgctcctgcc ctcggaggct gcgtttggga atagctggca ggtctcagag 4320 gggctgtggc ctggccggcc ctgttctgca ggccgagagg tggatccgtg ccgggcagca 4380 ggttaccgtg ccaggcgtga ggccaatgcc cggtgtgggg tgctgaagtc ctccccattc 4440 agtcgctgcc atgctgtggt gccaccggag cccttctttg ccgcctgtgt gtatgacctg 4500 tgtgcctgtg gccctggctc ctccgctgat gcctgcctct gtgatgccct ggaagcctac 4560 gccagtcact gtcgccaggc aggagtgaca cctacctggc gaggccccac gctgtgtgtg 4620 gtaggctgcc ccctggagcg tggcttcgtg tttgatgagt gcggcccacc ctgtccccgc 4680 acctgcttca atcagcatat ccccctgggg gagctggcag cccactgcgt gaggccctgc 4740 gtgcccggct gccagtgccc tgcaggcctg gtggagcatg aggcccactg catcccaccc 4800 gaggcctgcc cccaagtcct gctcactgga gaccagccac ttggtgctcg gcccagcccc 4860 agccgggagc cccaggagac accc 4884 2 1628 PRT homo sapiens 2 Met Ala Gly Val Gly Ala Ala Ala Leu Ser Leu Leu Leu His Leu Gly 1 5 10 15 Ala Leu Ala Leu Ala Ala Gly Ala Glu Gly Gly Ala Val Pro Arg Glu 20 25 30 Pro Pro Gly Gln Gln Thr Thr Ala His Ser Ser Val Leu Ala Gly Asn 35 40 45 Ser Gln Glu Gln Trp His Pro Leu Arg Glu Trp Leu Gly Arg Leu Glu 50 55 60 Ala Ala Val Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg 65 70 75 80 Val Arg Gln Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys 85 90 95 Trp Gly Leu Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp 100 105 110 Ala Cys Thr Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro 115 120 125 Gln Ala His Leu Pro His Cys Arg Gly Cys Ser Gln Asn Gly Gln Thr 130 135 140 Tyr Gly Asn Gly Glu Thr Phe Ser Pro Asp Ala Cys Thr Thr Cys Arg 145 150 155 160 Cys Leu Glu Gly Thr Ile Thr Cys Asn Gln Lys Pro Cys Pro Arg Gly 165 170 175 Pro Cys Pro Glu Pro Gly Ala Cys Cys Pro His Cys Lys Pro Gly Cys 180 185 190 Asp Tyr Glu Gly Gln Leu Tyr Glu Glu Gly Val Thr Phe Leu Ser Ser 195 200 205 Ser Asn Pro Cys Leu Gln Cys Thr Cys Leu Arg Ser Arg Val Arg Cys 210 215 220 Met Ala Leu Lys Cys Pro Pro Ser Pro Cys Pro Glu Pro Val Leu Arg 225 230 235 240 Pro Gly His Cys Cys Pro Thr Cys Gln Gly Cys Thr Glu Gly Gly Ser 245 250 255 His Trp Glu His Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg 260 265 270 Ile Cys Arg Cys Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys 275 280 285 Ala Ser Leu Cys Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys 290 295 300 Pro Val Cys Asp Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly 305 310 315 320 Glu Pro Val Gly Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn 325 330 335 Gly Ser Val Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg 340 345 350 His Pro Gly Lys Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys 355 360 365 Glu Tyr Gln Gly His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln 370 375 380 Glu Arg Gly Leu Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser 385 390 395 400 Cys Glu Glu Gln Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser 405 410 415 Gly Arg Gln Leu Cys Pro Ala Cys Glu Leu Asp Gly Glu Glu Phe Ala 420 425 430 Glu Gly Val Gln Trp Glu Pro Asp Gly Arg Pro Cys Thr Ala Cys Val 435 440 445 Cys Gln Asp Gly Val Pro Lys Cys Gly Ala Val Leu Cys Pro Pro Ala 450 455 460 Pro Cys Gln His Pro Thr Gln Pro Pro Gly Ala Cys Cys Pro Ser Cys 465 470 475 480 Asp Ser Cys Thr Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe 485 490 495 Thr Asp Ala Asp Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr 500 505 510 Val Thr Cys Ser Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro 515 520 525 Gln Ser Gly Pro Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu 530 535 540 Glu Glu Glu Val Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp 545 550 555 560 Pro Cys Gln Glu Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro 565 570 575 Arg Pro Cys Pro Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys 580 585 590 Cys Pro Asn Asp Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro 595 600 605 Ser Gly Ala Asp Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg 610 615 620 Cys Leu Ser Gly Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu 625 630 635 640 Pro Cys Pro Glu Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys 645 650 655 Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His 660 665 670 Ala Arg His Gln Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg 675 680 685 Cys Leu Cys Leu Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro 690 695 700 Pro Ala Pro Cys Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys 705 710 715 720 Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe 725 730 735 Pro Ser Pro Thr Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser 740 745 750 Val Ser Cys Glu Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro 755 760 765 Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly 770 775 780 Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys 785 790 795 800 Asn Leu Cys Thr Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro 805 810 815 Cys Glu Pro Pro Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys 820 825 830 Cys Pro Thr Cys Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser 835 840 845 Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr 850 855 860 Cys Gln Glu Gly Ser Met Arg Cys Gln Lys Lys Pro Cys Ala Pro Ala 865 870 875 880 Leu Cys Pro His Pro Ser Pro Gly Pro Cys Phe Cys Pro Val Cys His 885 890 895 Ser Cys Leu Ser Gln Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu 900 905 910 Gly Pro Ala Gly Ser Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val 915 920 925 Ser Cys Val Arg Leu Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val 930 935 940 Thr Glu Arg Gly Ser Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His 945 950 955 960 Gly Glu Glu His Pro Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala 965 970 975 Cys Ser Ser Cys Val Cys His Glu Gly Val Val Thr Cys Ala Arg Ile 980 985 990 Gln Cys Ile Ser Ser Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys 995 1000 1005 Cys Pro Gln Cys Ser Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro 1010 1015 1020 Gly Glu Ser Phe Gln Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys 1025 1030 1035 1040 Glu Pro Gln Pro Glu Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln 1045 1050 1055 Cys Pro Ser Leu Val Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly 1060 1065 1070 Pro Gln His Cys Cys Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser 1075 1080 1085 Glu Gly Leu Leu Gly Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr 1090 1095 1100 Cys Gln Cys Gln Asp Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro 1105 1110 1115 1120 Glu Leu Ser Cys Pro Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys 1125 1130 1135 Cys Pro Val Cys Arg Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val 1140 1145 1150 Ala Asp Gly Glu Ser Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys 1155 1160 1165 Thr Cys His Arg Gly His Val Glu Cys His Leu Glu Glu Cys Gln Ala 1170 1175 1180 Leu Ser Cys Pro His Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys 1185 1190 1195 1200 Cys Glu Arg Cys Gln Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg 1205 1210 1215 Glu Val Ala Ser Gly Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys 1220 1225 1230 Ser Cys Met Ala Gly Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro 1235 1240 1245 Leu Ser Cys Gly Pro Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys 1250 1255 1260 Cys Pro Arg Cys Leu Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp 1265 1270 1275 1280 Pro His Tyr Arg Thr Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser 1285 1290 1295 Cys Ser Tyr Val Leu Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val 1300 1305 1310 His Val Thr Asn Asp Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln 1315 1320 1325 Glu Val Ala Val Leu Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp 1330 1335 1340 Gly Ala Val Thr Val Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln 1345 1350 1355 1360 Glu Pro Leu Leu Tyr Val Glu Leu Arg Gly His Thr Val Ile Leu His 1365 1370 1375 Ala Gln Pro Gly Leu Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu 1380 1385 1390 Val Ser Val Pro Gly Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly 1395 1400 1405 Asn Phe Asn Gly Phe Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu 1410 1415 1420 Leu Leu Pro Ser Glu Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu 1425 1430 1435 1440 Gly Leu Trp Pro Gly Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro 1445 1450 1455 Cys Arg Ala Ala Gly Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys 1460 1465 1470 Gly Val Leu Lys Ser Ser Pro Phe Ser Arg Cys His Ala Val Val Pro 1475 1480 1485 Pro Glu Pro Phe Phe Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly 1490 1495 1500 Pro Gly Ser Ser Ala Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr 1505 1510 1515 1520 Ala Ser His Cys Arg Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro 1525 1530 1535 Thr Leu Cys Val Val Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp 1540 1545 1550 Glu Cys Gly Pro Pro Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro 1555 1560 1565 Leu Gly Glu Leu Ala Ala His Cys Val Arg Pro Cys Val Pro Gly Cys 1570 1575 1580 Gln Cys Pro Ala Gly Leu Val Glu His Glu Ala His Cys Ile Pro Pro 1585 1590 1595 1600 Glu Ala Cys Pro Gln Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala 1605 1610 1615 Arg Pro Ser Pro Ser Arg Glu Pro Gln Glu Thr Pro 1620 1625 3 4779 DNA homo sapiens 3 atggccgggg tcggggccgc tgcgctgtcc cttctcctgc acctcggggc cctggcgctg 60 gccgcgggcg cggaaggtgg ggctgtcccc agggagcccc ctgggcagca gacaactgcc 120 cattcctcag tccttgctgg gaactcccag gagcagtggc accccctgcg agagtggctg 180 gggcgactgg aggctgcagt gatggagctc agagaacaga ataaggacct gcagacgagg 240 gtgaggcagc tggagtcctg tgagtgccac cctgcatctc cccagtgctg ggggctgggg 300 cgtgcctggc ccgagggggc acgctgggag cctgacgcct gcacagcctg cgtctgccag 360 gatggggccg ctcactgtgg cccccaagca cacctgcccc attgcagggg ctgcagccaa 420 aatggccaga cctacggcaa cggggagacc ttctccccag atgcctgcac cacctgccgc 480 tgtctggaag gtaccatcac ttgcaaccag aagccatgcc caagaggacc ctgccctgag 540 ccaggagcat gctgcccgca ctgtaagcca ggctgtgatt atgaggggca gctttatgag 600 gagggggtca ccttcctgtc cagctccaac ccttgtctac agtgcacctg cctgaggagc 660 cgagttcgct gcatggccct gaagtgcccg cctagcccct gcccagagcc agtgctgagg 720 cctgggcact gctgcccaac ctgccaaggc tgcacagaag gtggctctca ctgggaacat 780 ggccaagagt ggacaacacc tggggacccc tgccgaatct gccggtgcct ggagggtcac 840 atccagtgcc gccagcgaga atgtgccagc ctgtgtccat acccagcccg gcccctccca 900 ggcacctgct gccctgtgtg tgatggctgt ttcctaaacg ggcgggagca ccgcagcggg 960 gagcctgtgg gctcagggga cccctgctcg cactgccgct gtgctaatgg gagtgtccag 1020 tgtgagcctc tgccctgccc gccagtgccc tgcagacacc caggcaagat ccctgggcag 1080 tgctgccctg tctgcgatgg ctgtgagtac cagggacacc agtatcagag ccaggagacc 1140 ttcagactcc aagagcgggg cctctgtgtc cgctgctcct gccaggctgg cgaggtctcc 1200 tgtgaggagc aggagtgccc agtcaccccc tgtgccctgc ctgcctctgg ccgccagctc 1260 tgcccagcct gtgagctgga tggagaggag tttgctgagg gagtccagtg ggagcctgat 1320 ggtcggccct gcaccgcctg cgtctgtcaa gatggggtac ccaagtgcgg ggctgtgctc 1380 tgccccccag ccccctgcca gcaccccacc cagccccctg gtgcctgctg ccccagctgt 1440 gacagctgca cctaccacag ccaagtgtat gccaatgggc agaacttcac ggatgcagac 1500 agcccttgcc atgcctgcca ctgtcaggat ggaactgtga catgctcctt ggttgactgc 1560 cctcccacga cctgtgccag gccccagagt ggaccaggcc agtgttgccc caggtgccca 1620 gactgcatcc tggaggaaga ggtgtttgtg gacggcgaga gcttctccca cccccgagac 1680 ccctgccagg agtgccgatg ccaggaaggc catgcccact gccagcctcg cccctgcccc 1740 agggccccct gtgcccaccc gctgcctggg acctgctgcc cgaacgactg cagcggctgt 1800 gcctttggcg ggaaagagta ccccagcgga gcggacttcc cccacccctc tgacccctgc 1860 cgtctgtgtc gctgtctgag cggcaacgtg cagtgcctgg cccgccgctg cgtgccgctg 1920 ccctgtccag agcctgtcct gctgccggga gagtgctgcc cgcagtgccc agccgcccca 1980 gcccccgccg gctgcccacg gcccggcgcg gcccacgccc gccaccagga gtacttctcc 2040 ccgcccggcg atccctgccg ccgctgcctc tgcctcgacg gctccgtgtc ctgccagcgg 2100 ctgccctgcc cgcccgcgcc ctgcgcgcac ccgcgccagg ggccttgctg cccctcctgc 2160 gacggctgcc tgtaccaggg gaaggagttt gccagcgggg agcgcttccc atcgcccact 2220 gctgcctgcc acctctgcct ttgctgggag ggcagcgtga gctgcgagcc caaggcatgt 2280 gcccctgcac tgtgcccctt ccctgccagg ggcgactgct gccctgactg tgatggctgt 2340 gagtacctgg gggagtccta cctgagtaac caggagttcc cagacccccg agaaccctgc 2400 aacctgtgta cctgtcttgg aggcttcgtg acctgcggcc gccggccctg tgagcctccg 2460 ggctgcagcc acccactcat cccctctggg cactgctgcc cgacctgcca gggatgccgc 2520 taccatggcg tcactactgc ctccggagag acccttcctg acccacttga ccctacctgc 2580 tccctctgca cctgccaggg ccgggagcac caggatgggg aggagtttga gggaccagca 2640 ggcagctgtg agtggtgtcg ctgtcaggct ggccaggtca gctgtgtgcg gctgcagtgc 2700 ccaccccttc cctgcaagct ccaggtcacc gagcggggga gctgctgccc tcgctgcaga 2760 ggctgcctgg ctcatgggga agagcacccc gaaggcagta gatgggtgcc ccccgacagt 2820 gcctgctcct cctgtgtgtg tcacgagggc gtcgtcacct gtgcacgcat ccagtgcatc 2880 agctcttgcg cccagccccg ccaagggccc catgactgct gtcctcaatg ctctgactgt 2940 gagcatgagg gccggaagta cgagcctggg gagagcttcc agcctggggc agacccctgt 3000 gaagtgtgca tctgcgagcc acagcctgag gggcctccca gccttcgctg tcaccggcgg 3060 cagtgtccca gcctggtggg ctgccccccc agccagctcc tgccccctgg gccccagcac 3120 tgctgtccca cctgtgccga ggccttgagt aactgttcag agggcctgct gggatctgag 3180 ctagccccac cagacccctg ctacacgtgc cagtgccagg acctgacatg gctctgcatc 3240 caccaggctt gtcctgagct cagctgtccc ctctcagagc gccacactcc ccctgggagc 3300 tgctgccccg tatgccggga atgtgtggtg gaggccgagg gccggagagt ggcagatgga 3360 gagagctggc gggaccccag caatgcgtgc atcgcctgca cctgccatcg gggccatgtg 3420 gagtgccacc tcgaggagtg ccaggccctc tcctgccccc atggctgggc gaaggtgccc 3480 caggctgaca gctgctgtga gcgatgccaa gctcccaccc agtcctgcgt gcaccagggc 3540 cgtgaggtgg cctctggaga gcgctggact gtggacacct gcaccagctg ctcctgcatg 3600 gcgggcaccg tgcgttgcca gagccagcgc tgctcaccgc tctcgtgtgg ccccgacaag 3660 gcccctgccc tgagtcctgg cagctgctgc ccccgctgcc tgcctcggcc cgcttcctgc 3720 atggccttcg gagaccccca ttaccgcacc ttcgacggcc gcctgctgca cttccagggc 3780 agttgcagct atgtgctggc caaggactgc cacagcgggg acttcagtgt gcacgtgacc 3840 aatgatgacc ggggccggag cggtgtggcc tggacccagg aggtggcggt gctgctggga 3900 gacatggccg tgcggctgct gcaggacggg gcagtcacgg tggatgggca cccggtggcc 3960 ttgcccttcc tgcaggagcc gctgctgtat gtggagctgc gaggacacac tgtgatcctg 4020 cacgcccagc ccgggctcca ggtgctgtgg gatgggcagt cccaggtgga ggtgagcgta 4080 cctggctcct accagggccg gacttgtggg ctctgtggga acttcaatgg ctttgcccag 4140 gacgatctgc agggccctga ggggctgctc ctgccctcgg aggctgcgtt tgggaatagc 4200 tggcaggtct cagaggggct gtggcctggc cggccctgtt ctgcaggccg agaggtggat 4260 ccgtgccggg cagcaggtta ccgtgccagg cgtgaggcca atgcccggtg tggggtgctg 4320 aagtcctccc cattcagtcg ctgccatgct gtggtgccac cggagccctt ctttgccgcc 4380 tgtgtgtatg acctgtgtgc ctgtggccct ggctcctccg ctgatgcctg cctctgtgat 4440 gccctggaag cctacgccag tcactgtcgc caggcaggag tgacacctac ctggcgaggc 4500 cccacgctgt gtgtggtagg ctgccccctg gagcgtggct tcgtgtttga tgagtgcggc 4560 ccaccctgtc cccgcacctg cttcaatcag catatccccc tgggggagct ggcagcccac 4620 tgcgtgaggc cctgcgtgcc cggctgccag tgccctgcag gcctggtgga gcatgaggcc 4680 cactgcatcc cacccgaggc ctgcccccaa gtcctgctca ctggagacca gccacttggt 4740 gctcggccca gccccagccg ggagccccag gagacaccc 4779 4 1593 PRT homo sapiens 4 Met Ala Gly Val Gly Ala Ala Ala Leu Ser Leu Leu Leu His Leu Gly 1 5 10 15 Ala Leu Ala Leu Ala Ala Gly Ala Glu Gly Gly Ala Val Pro Arg Glu 20 25 30 Pro Pro Gly Gln Gln Thr Thr Ala His Ser Ser Val Leu Ala Gly Asn 35 40 45 Ser Gln Glu Gln Trp His Pro Leu Arg Glu Trp Leu Gly Arg Leu Glu 50 55 60 Ala Ala Val Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg 65 70 75 80 Val Arg Gln Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys 85 90 95 Trp Gly Leu Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp 100 105 110 Ala Cys Thr Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro 115 120 125 Gln Ala His Leu Pro His Cys Arg Gly Cys Ser Gln Asn Gly Gln Thr 130 135 140 Tyr Gly Asn Gly Glu Thr Phe Ser Pro Asp Ala Cys Thr Thr Cys Arg 145 150 155 160 Cys Leu Glu Gly Thr Ile Thr Cys Asn Gln Lys Pro Cys Pro Arg Gly 165 170 175 Pro Cys Pro Glu Pro Gly Ala Cys Cys Pro His Cys Lys Pro Gly Cys 180 185 190 Asp Tyr Glu Gly Gln Leu Tyr Glu Glu Gly Val Thr Phe Leu Ser Ser 195 200 205 Ser Asn Pro Cys Leu Gln Cys Thr Cys Leu Arg Ser Arg Val Arg Cys 210 215 220 Met Ala Leu Lys Cys Pro Pro Ser Pro Cys Pro Glu Pro Val Leu Arg 225 230 235 240 Pro Gly His Cys Cys Pro Thr Cys Gln Gly Cys Thr Glu Gly Gly Ser 245 250 255 His Trp Glu His Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg 260 265 270 Ile Cys Arg Cys Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys 275 280 285 Ala Ser Leu Cys Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys 290 295 300 Pro Val Cys Asp Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly 305 310 315 320 Glu Pro Val Gly Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn 325 330 335 Gly Ser Val Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg 340 345 350 His Pro Gly Lys Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys 355 360 365 Glu Tyr Gln Gly His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln 370 375 380 Glu Arg Gly Leu Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser 385 390 395 400 Cys Glu Glu Gln Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser 405 410 415 Gly Arg Gln Leu Cys Pro Ala Cys Glu Leu Asp Gly Glu Glu Phe Ala 420 425 430 Glu Gly Val Gln Trp Glu Pro Asp Gly Arg Pro Cys Thr Ala Cys Val 435 440 445 Cys Gln Asp Gly Val Pro Lys Cys Gly Ala Val Leu Cys Pro Pro Ala 450 455 460 Pro Cys Gln His Pro Thr Gln Pro Pro Gly Ala Cys Cys Pro Ser Cys 465 470 475 480 Asp Ser Cys Thr Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe 485 490 495 Thr Asp Ala Asp Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr 500 505 510 Val Thr Cys Ser Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro 515 520 525 Gln Ser Gly Pro Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu 530 535 540 Glu Glu Glu Val Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp 545 550 555 560 Pro Cys Gln Glu Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro 565 570 575 Arg Pro Cys Pro Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys 580 585 590 Cys Pro Asn Asp Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro 595 600 605 Ser Gly Ala Asp Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg 610 615 620 Cys Leu Ser Gly Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu 625 630 635 640 Pro Cys Pro Glu Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys 645 650 655 Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His 660 665 670 Ala Arg His Gln Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg 675 680 685 Cys Leu Cys Leu Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro 690 695 700 Pro Ala Pro Cys Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys 705 710 715 720 Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe 725 730 735 Pro Ser Pro Thr Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser 740 745 750 Val Ser Cys Glu Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro 755 760 765 Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly 770 775 780 Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys 785 790 795 800 Asn Leu Cys Thr Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro 805 810 815 Cys Glu Pro Pro Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys 820 825 830 Cys Pro Thr Cys Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser 835 840 845 Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr 850 855 860 Cys Gln Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala 865 870 875 880 Gly Ser Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val 885 890 895 Arg Leu Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg 900 905 910 Gly Ser Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu 915 920 925 His Pro Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser 930 935 940 Cys Val Cys His Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile 945 950 955 960 Ser Ser Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln 965 970 975 Cys Ser Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser 980 985 990 Phe Gln Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln 995 1000 1005 Pro Glu Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser 1010 1015 1020 Leu Val Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His 1025 1030 1035 1040 Cys Cys Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu 1045 1050 1055 Leu Gly Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys 1060 1065 1070 Gln Asp Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser 1075 1080 1085 Cys Pro Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val 1090 1095 1100 Cys Arg Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly 1105 1110 1115 1120 Glu Ser Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His 1125 1130 1135 Arg Gly His Val Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys 1140 1145 1150 Pro His Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg 1155 1160 1165 Cys Gln Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala 1170 1175 1180 Ser Gly Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met 1185 1190 1195 1200 Ala Gly Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys 1205 1210 1215 Gly Pro Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg 1220 1225 1230 Cys Leu Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr 1235 1240 1245 Arg Thr Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr 1250 1255 1260 Val Leu Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr 1265 1270 1275 1280 Asn Asp Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala 1285 1290 1295 Val Leu Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val 1300 1305 1310 Thr Val Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu 1315 1320 1325 Leu Tyr Val Glu Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro 1330 1335 1340 Gly Leu Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val 1345 1350 1355 1360 Pro Gly Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn 1365 1370 1375 Gly Phe Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro 1380 1385 1390 Ser Glu Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp 1395 1400 1405 Pro Gly Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala 1410 1415 1420 Ala Gly Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu 1425 1430 1435 1440 Lys Ser Ser Pro Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro 1445 1450 1455 Phe Phe Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser 1460 1465 1470 Ser Ala Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His 1475 1480 1485 Cys Arg Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys 1490 1495 1500 Val Val Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly 1505 1510 1515 1520 Pro Pro Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu 1525 1530 1535 Leu Ala Ala His Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro 1540 1545 1550 Ala Gly Leu Val Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys 1555 1560 1565 Pro Gln Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser 1570 1575 1580 Pro Ser Arg Glu Pro Gln Glu Thr Pro 1585 1590 5 3173 DNA homo sapiens 5 atgcccactg ccagcctcgc ccctgcccca gggccccctg tgcccacccg ctgcctggga 60 cctgctgccc gaacgactgc agcggctgtg cctttggcgg gaaagagtac cccagcggag 120 cggacttccc ccacccctct gacccctgcc gtctgtgtcg ctgtctgagc ggcaacgtgc 180 agtgcctggc ccgccgctgc gtgccgctgc cctgtccaga gcctgtcctg ctgccgggag 240 agtgctgccc gcagtgccca gccgccccag cccccgccgg ctgcccacgg cccggcgcgg 300 cccacgcccg ccaccaggag tacttctccc cgcccggcga tccctgccgc cgctgcctct 360 gcctcgacgg ctccgtgtcc tgccagcggc tgccctgccc gcccgcgccc tgcgcgcacc 420 cgcgccaggg gccttgctgc ccctcctgcg acggctgcct gtaccagggg aaggagtttg 480 ccagcgggga gcgcttccca tcgcccactg ctgcctgcca cctctgcctt tgctgggagg 540 gcagcgtgag ctgcgagccc aaggcatgtg cccctgcact gtgccccttc cctgccaggg 600 gcgactgctg ccctgactgt gatggctgtg agtacctggg ggagtcctac ctgagtaacc 660 aggagttccc agacccccga gaaccctgca acctgtgtac ctgtcttgga ggcttcgtga 720 cctgcggccg ccggccctgt gagcctccgg gctgcagcca cccactcatc ccctctgggc 780 actgctgccc gacctgccag ggatgccgct accatggcgt cactactgcc tccggagaga 840 cccttcctga cccacttgac cctacctgct ccctctgcac ctgccaggaa ggttccatgc 900 gctgccaaaa gaagccatgt gccccagctc tctgccccca cccctctcca ggcccctgct 960 tctgccctgt ttgccacagt tgtctctctc agggccggga gcaccaggat ggggaggagt 1020 ttgagggacc agcaggcagc tgtgagtggt gtcgctgtca ggctggccag gtcagctgtg 1080 tgcggctgca gtgcccaccc cttccctgca agctccaggt caccgagcgg gggagctgct 1140 gccctcgctg cagaggctgc ctggctcatg gggaagagca ccccgaaggc agtagatggg 1200 tgccccccga cagtgcctgc tcctcctgtg tgtgtcacga gggcgtcgtc acctgtgcac 1260 gcatccagtg catcagctct tgcgcccagc cccgccaagg gccccatgac tgctgtcctc 1320 aatgctctga ctgtgagcat gagggccgga agtacgagcc tggggagagc ttccagcctg 1380 gggcagaccc ctgtgaagtg tgcatctgcg agccacagcc tgaggggcct cccagccttc 1440 gctgtcaccg gcggcagtgt cccagcctgg tgggctgccc ccccagccag ctcctgcccc 1500 ctgggcccca gcactgctgt cccacctgtg ccgaggcctt gagtaactgt tcagagggcc 1560 tgctgggatc tgagctagcc ccaccagacc cctgctacac gtgccagtgc caggacctga 1620 catggctctg catccaccag gcttgtcctg agctcagctg tcccctctca gagcgccaca 1680 ctccccctgg gagctgctgc cccgtatgcc gggaatgtgt ggtggaggcc gagggccgga 1740 gagtggcaga tggagagagc tggcgggacc ccagcaatgc gtgcatcgcc tgcacctgcc 1800 atcggggcca tgtggagtgc cacctcgagg agtgccaggc cctctcctgc ccccatggct 1860 gggcgaaggt gccccaggct gacagctgct gtgagcgatg ccaagctccc acccagtcct 1920 gcgtgcacca gggccgtgag gtggcctctg gagagcgctg gactgtggac acctgcacca 1980 gctgctcctg catggcgggc accgtgcgtt gccagagcca gcgctgctca ccgctctcgt 2040 gtggccccga caaggcccct gccctgagtc ctggcagctg ctgcccccgc tgcctgcctc 2100 ggcccgcttc ctgcatggcc ttcggagacc cccattaccg caccttcgac ggccgcctgc 2160 tgcacttcca gggcagttgc agctatgtgc tggccaagga ctgccacagc ggggacttca 2220 gtgtgcacgt gaccaatgat gaccggggcc ggagcggtgt ggcctggacc caggaggtgg 2280 cggtgctgct gggagacatg gccgtgcggc tgctgcagga cggggcagtc acggtggatg 2340 ggcacccggt ggccttgccc ttcctgcagg agccgctgct gtatgtggag ctgcgaggac 2400 acactgtgat cctgcacgcc cagcccgggc tccaggtgct gtgggatggg cagtcccagg 2460 tggaggtgag cgtacctggc tcctaccagg gccggacttg tgggctctgt gggaacttca 2520 atggctttgc ccaggacgat ctgcagggcc ctgaggggct gctcctgccc tcggaggctg 2580 cgtttgggaa tagctggcag gtctcagagg ggctgtggcc tggccggccc tgttctgcag 2640 gccgagaggt ggatccgtgc cgggcagcag gttaccgtgc caggcgtgag gccaatgccc 2700 ggtgtggggt gctgaagtcc tccccattca gtcgctgcca tgctgtggtg ccaccggagc 2760 ccttctttgc cgcctgtgtg tatgacctgt gtgcctgtgg ccctggctcc tccgctgatg 2820 cctgcctctg tgatgccctg gaagcctacg ccagtcactg tcgccaggca ggagtgacac 2880 ctacctggcg aggccccacg ctgtgtgtgg taggctgccc cctggagcgt ggcttcgtgt 2940 ttgatgagtg cggcccaccc tgtccccgca cctgcttcaa tcagcatatc cccctggggg 3000 agctggcagc ccactgcgtg aggccctgcg tgcccggctg ccagtgccct gcaggcctgg 3060 tggagcatga ggcccactgc atcccacccg aggcctgccc ccaagtcctg ctcactggag 3120 accagccact tggtgctcgg cccagcccca gccgggagcc ccaggagaca ccc 3173 6 1057 PRT homo sapiens 6 Met Pro Thr Ala Ser Leu Ala Pro Ala Pro Gly Pro Pro Val Pro Thr 1 5 10 15 Arg Cys Leu Gly Pro Ala Ala Arg Thr Thr Ala Ala Ala Val Pro Leu 20 25 30 Ala Gly Lys Ser Thr Pro Ala Glu Arg Thr Ser Pro Thr Pro Leu Thr 35 40 45 Pro Ala Val Cys Val Ala Val Ser Gly Asn Val Gln Cys Leu Ala Arg 50 55 60 Arg Cys Val Pro Leu Pro Cys Pro Glu Pro Val Leu Leu Pro Gly Glu 65 70 75 80 Cys Cys Pro Gln Cys Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro Arg 85 90 95 Pro Gly Ala Ala His Ala Arg His Gln Glu Tyr Phe Ser Pro Pro Gly 100 105 110 Asp Pro Cys Arg Arg Cys Leu Cys Leu Asp Gly Ser Val Ser Cys Gln 115 120 125 Arg Leu Pro Cys Pro Pro Ala Pro Cys Ala His Pro Arg Gln Gly Pro 130 135 140 Cys Cys Pro Ser Cys Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe Ala 145 150 155 160 Ser Gly Glu Arg Phe Pro Ser Pro Thr Ala Ala Cys His Leu Cys Leu 165 170 175 Cys Trp Glu Gly Ser Val Ser Cys Glu Pro Lys Ala Cys Ala Pro Ala 180 185 190 Leu Cys Pro Phe Pro Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp Gly 195 200 205 Cys Glu Tyr Leu Gly Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro Asp 210 215 220 Pro Arg Glu Pro Cys Asn Leu Cys Thr Cys Leu Gly Gly Phe Val Thr 225 230 235 240 Cys Gly Arg Arg Pro Cys Glu Pro Pro Gly Cys Ser His Pro Leu Ile 245 250 255 Pro Ser Gly His Cys Cys Pro Thr Cys Gln Gly Cys Arg Tyr His Gly 260 265 270 Val Thr Thr Ala Ser Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro Thr 275 280 285 Cys Ser Leu Cys Thr Cys Gln Glu Gly Ser Met Arg Cys Gln Lys Lys 290 295 300 Pro Cys Ala Pro Ala Leu Cys Pro His Pro Ser Pro Gly Pro Cys Phe 305 310 315 320 Cys Pro Val Cys His Ser Cys Leu Ser Gln Gly Arg Glu His Gln Asp 325 330 335 Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser Cys Glu Trp Cys Arg Cys 340 345 350 Gln Ala Gly Gln Val Ser Cys Val Arg Leu Gln Cys Pro Pro Leu Pro 355 360 365 Cys Lys Leu Gln Val Thr Glu Arg Gly Ser Cys Cys Pro Arg Cys Arg 370 375 380 Gly Cys Leu Ala His Gly Glu Glu His Pro Glu Gly Ser Arg Trp Val 385 390 395 400 Pro Pro Asp Ser Ala Cys Ser Ser Cys Val Cys His Glu Gly Val Val 405 410 415 Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser Cys Ala Gln Pro Arg Gln 420 425 430 Gly Pro His Asp Cys Cys Pro Gln Cys Ser Asp Cys Glu His Glu Gly 435 440 445 Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln Pro Gly Ala Asp Pro Cys 450 455 460 Glu Val Cys Ile Cys Glu Pro Gln Pro Glu Gly Pro Pro Ser Leu Arg 465 470 475 480 Cys His Arg Arg Gln Cys Pro Ser Leu Val Gly Cys Pro Pro Ser Gln 485 490 495 Leu Leu Pro Pro Gly Pro Gln His Cys Cys Pro Thr Cys Ala Glu Ala 500 505 510 Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly Ser Glu Leu Ala Pro Pro 515 520 525 Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp Leu Thr Trp Leu Cys Ile 530 535 540 His Gln Ala Cys Pro Glu Leu Ser Cys Pro Leu Ser Glu Arg His Thr 545 550 555 560 Pro Pro Gly Ser Cys Cys Pro Val Cys Arg Glu Cys Val Val Glu Ala 565 570 575 Glu Gly Arg Arg Val Ala Asp Gly Glu Ser Trp Arg Asp Pro Ser Asn 580 585 590 Ala Cys Ile Ala Cys Thr Cys His Arg Gly His Val Glu Cys His Leu 595 600 605 Glu Glu Cys Gln Ala Leu Ser Cys Pro His Gly Trp Ala Lys Val Pro 610 615 620 Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln Ala Pro Thr Gln Ser Cys 625 630 635 640 Val His Gln Gly Arg Glu Val Ala Ser Gly Glu Arg Trp Thr Val Asp 645 650 655 Thr Cys Thr Ser Cys Ser Cys Met Ala Gly Thr Val Arg Cys Gln Ser 660 665 670 Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro Asp Lys Ala Pro Ala Leu 675 680 685 Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu Pro Arg Pro Ala Ser Cys 690 695 700 Met Ala Phe Gly Asp Pro His Tyr Arg Thr Phe Asp Gly Arg Leu Leu 705 710 715 720 His Phe Gln Gly Ser Cys Ser Tyr Val Leu Ala Lys Asp Cys His Ser 725 730 735 Gly Asp Phe Ser Val His Val Thr Asn Asp Asp Arg Gly Arg Ser Gly 740 745 750 Val Ala Trp Thr Gln Glu Val Ala Val Leu Leu Gly Asp Met Ala Val 755 760 765 Arg Leu Leu Gln Asp Gly Ala Val Thr Val Asp Gly His Pro Val Ala 770 775 780 Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr Val Glu Leu Arg Gly His 785 790 795 800 Thr Val Ile Leu His Ala Gln Pro Gly Leu Gln Val Leu Trp Asp Gly 805 810 815 Gln Ser Gln Val Glu Val Ser Val Pro Gly Ser Tyr Gln Gly Arg Thr 820 825 830 Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe Ala Gln Asp Asp Leu Gln 835 840 845 Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu Ala Ala Phe Gly Asn Ser 850 855 860 Trp Gln Val Ser Glu Gly Leu Trp Pro Gly Arg Pro Cys Ser Ala Gly 865 870 875 880 Arg Glu Val Asp Pro Cys Arg Ala Ala Gly Tyr Arg Ala Arg Arg Glu 885 890 895 Ala Asn Ala Arg Cys Gly Val Leu Lys Ser Ser Pro Phe Ser Arg Cys 900 905 910 His Ala Val Val Pro Pro Glu Pro Phe Phe Ala Ala Cys Val Tyr Asp 915 920 925 Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala Asp Ala Cys Leu Cys Asp 930 935 940 Ala Leu Glu Ala Tyr Ala Ser His Cys Arg Gln Ala Gly Val Thr Pro 945 950 955 960 Thr Trp Arg Gly Pro Thr Leu Cys Val Val Gly Cys Pro Leu Glu Arg 965 970 975 Gly Phe Val Phe Asp Glu Cys Gly Pro Pro Cys Pro Arg Thr Cys Phe 980 985 990 Asn Gln His Ile Pro Leu Gly Glu Leu Ala Ala His Cys Val Arg Pro 995 1000 1005 Cys Val Pro Gly Cys Gln Cys Pro Ala Gly Leu Val Glu His Glu Ala 1010 1015 1020 His Cys Ile Pro Pro Glu Ala Cys Pro Gln Val Leu Leu Thr Gly Asp 1025 1030 1035 1040 Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser Arg Glu Pro Gln Glu Thr 1045 1050 1055 Pro 7 4431 DNA homo sapiens 7 atggccgggg tcggggccgc tgcgctgtcc cttctcctgc acctcggggc cctggcgctg 60 gccgcgggcg cggaaggtgg ggctgtcccc agggagcccc ctgggcagca gacaactgcc 120 cattcctcag tccttgctgg gaactcccag gagcagtggc accccctgcg agagtggctg 180 gggcgactgg aggctgcagt gatggagctc agagaacaga ataaggacct gcagacgagg 240 gtgaggcagc tggagtcctg tgagtgccac cctgcatctc cccagtgctg ggggctgggg 300 cgtgcctggc ccgagggggc acgctgggag cctgacgcct gcacagcctg cgtctgccag 360 gatggggccg ctcactgtgg cccccaagca cacctgcccg gctgcacaga aggtggctct 420 cactgggaac atggccaaga gtggacaaca cctggggacc cctgccgaat ctgccggtgc 480 ctggagggtc acatccagtg ccgccagcga gaatgtgcca gcctgtgtcc atacccagcc 540 cggcccctcc caggcacctg ctgccctgtg tgtgatggct gtttcctaaa cgggcgggag 600 caccgcagcg gggagcctgt gggctcaggg gacccctgct cgcactgccg ctgtgctaat 660 gggagtgtcc agtgtgagcc tctgccctgc ccgccagtgc cctgcagaca cccaggcaag 720 atccctgggc agtgctgccc tgtctgcgat ggctgtgagt accagggaca ccagtatcag 780 agccaggaga ccttcagact ccaagagcgg ggcctctgtg tccgctgctc ctgccaggct 840 ggcgaggtct cctgtgagga gcaggagtgc ccagtcaccc cctgtgccct gcctgcctct 900 ggccgccagc tctgcccagc ctgtgagctg gatggagagg agtttgctga gggagtccag 960 tgggagcctg atggtcggcc ctgcaccgcc tgcgtctgtc aagatggggt acccaagtgc 1020 ggggctgtgc tctgcccccc agccccctgc cagcacccca cccagccccc tggtgcctgc 1080 tgccccagct gtgacagctg cacctaccac agccaagtgt atgccaatgg gcagaacttc 1140 acggatgcag acagcccttg ccatgcctgc cactgtcagg atggaactgt gacatgctcc 1200 ttggttgact gccctcccac gacctgtgcc aggccccaga gtggaccagg ccagtgttgc 1260 cccaggtgcc cagactgcat cctggaggaa gaggtgtttg tggacggcga gagcttctcc 1320 cacccccgag acccctgcca ggagtgccga tgccaggaag gccatgccca ctgccagcct 1380 cgcccctgcc ccagggcccc ctgtgcccac ccgctgcctg ggacctgctg cccgaacgac 1440 tgcagcggct gtgcctttgg cgggaaagag taccccagcg gagcggactt cccccacccc 1500 tctgacccct gccgtctgtg tcgctgtctg agcggcaacg tgcagtgcct ggcccgccgc 1560 tgcgtgccgc tgccctgtcc agagcctgtc ctgctgccgg gagagtgctg cccgcagtgc 1620 ccagccgccc cagcccccgc cggctgccca cggcccggcg cggcccacgc ccgccaccag 1680 gagtacttct ccccgcccgg cgatccctgc cgccgctgcc tctgcctcga cggctccgtg 1740 tcctgccagc ggctgccctg cccgcccgcg ccctgcgcgc acccgcgcca ggggccttgc 1800 tgcccctcct gcgacggctg cctgtaccag gggaaggagt ttgccagcgg ggagcgcttc 1860 ccatcgccca ctgctgcctg ccacctctgc ctttgctggg agggcagcgt gagctgcgag 1920 cccaaggcat gtgcccctgc actgtgcccc ttccctgcca ggggcgactg ctgccctgac 1980 tgtgatggct gtgagtacct gggggagtcc tacctgagta accaggagtt cccagacccc 2040 cgagaaccct gcaacctgtg tacctgtctt ggaggcttcg tgacctgcgg ccgccggccc 2100 tgtgagcctc cgggctgcag ccacccactc atcccctctg ggcactgctg cccgacctgc 2160 cagggatgcc gctaccatgg cgtcactact gcctccggag agacccttcc tgacccactt 2220 gaccctacct gctccctctg cacctgccag ggccgggagc accaggatgg ggaggagttt 2280 gagggaccag caggcagctg tgagtggtgt cgctgtcagg ctggccaggt cagctgtgtg 2340 cggctgcagt gcccacccct tccctgcaag ctccaggtca ccgagcgggg gagctgctgc 2400 cctcgctgca gaggctgcct ggctcatggg gaagagcacc ccgaaggcag tagatgggtg 2460 ccccccgaca gtgcctgctc ctcctgtgtg tgtcacgagg gcgtcgtcac ctgtgcacgc 2520 atccagtgca tcagctcttg cgcccagccc cgccaagggc cccatgactg ctgtcctcaa 2580 tgctctgact gtgagcatga gggccggaag tacgagcctg gggagagctt ccagcctggg 2640 gcagacccct gtgaagtgtg catctgcgag ccacagcctg aggggcctcc cagccttcgc 2700 tgtcaccggc ggcagtgtcc cagcctggtg ggctgccccc ccagccagct cctgccccct 2760 gggccccagc actgctgtcc cacctgtgcc gaggccttga gtaactgttc agagggcctg 2820 ctgggatctg agctagcccc accagacccc tgctacacgt gccagtgcca ggacctgaca 2880 tggctctgca tccaccaggc ttgtcctgag ctcagctgtc ccctctcaga gcgccacact 2940 ccccctggga gctgctgccc cgtatgccgg gaatgtgtgg tggaggccga gggccggaga 3000 gtggcagatg gagagagctg gcgggacccc agcaatgcgt gcatcgcctg cacctgccat 3060 cggggccatg tggagtgcca cctcgaggag tgccaggccc tctcctgccc ccatggctgg 3120 gcgaaggtgc cccaggctga cagctgctgt gagcgatgcc aagctcccac ccagtcctgc 3180 gtgcaccagg gccgtgaggt ggcctctgga gagcgctgga ctgtggacac ctgcaccagc 3240 tgctcctgca tggcgggcac cgtgcgttgc cagagccagc gctgctcacc gctctcgtgt 3300 ggccccgaca aggcccctgc cctgagtcct ggcagctgct gcccccgctg cctgcctcgg 3360 cccgcttcct gcatggcctt cggagacccc cattaccgca ccttcgacgg ccgcctgctg 3420 cacttccagg gcagttgcag ctatgtgctg gccaaggact gccacagcgg ggacttcagt 3480 gtgcacgtga ccaatgatga ccggggccgg agcggtgtgg cctggaccca ggaggtggcg 3540 gtgctgctgg gagacatggc cgtgcggctg ctgcaggacg gggcagtcac ggtggatggg 3600 cacccggtgg ccttgccctt cctgcaggag ccgctgctgt atgtggagct gcgaggacac 3660 actgtgatcc tgcacgccca gcccgggctc caggtgctgt gggatgggca gtcccaggtg 3720 gaggtgagcg tacctggctc ctaccagggc cggacttgtg ggctctgtgg gaacttcaat 3780 ggctttgccc aggacgatct gcagggccct gaggggctgc tcctgccctc ggaggctgcg 3840 tttgggaata gctggcaggt ctcagagggg ctgtggcctg gccggccctg ttctgcaggc 3900 cgagaggtgg atccgtgccg ggcagcaggt taccgtgcca ggcgtgaggc caatgcccgg 3960 tgtggggtgc tgaagtcctc cccattcagt cgctgccatg ctgtggtgcc accggagccc 4020 ttctttgccg cctgtgtgta tgacctgtgt gcctgtggcc ctggctcctc cgctgatgcc 4080 tgcctctgtg atgccctgga agcctacgcc agtcactgtc gccaggcagg agtgacacct 4140 acctggcgag gccccacgct gtgtgtggta ggctgccccc tggagcgtgg cttcgtgttt 4200 gatgagtgcg gcccaccctg tccccgcacc tgcttcaatc agcatatccc cctgggggag 4260 ctggcagccc actgcgtgag gccctgcgtg cccggctgcc agtgccctgc aggcctggtg 4320 gagcatgagg cccactgcat cccacccgag gcctgccccc aagtcctgct cactggagac 4380 cagccacttg gtgctcggcc cagccccagc cgggagcccc aggagacacc c 4431 8 1477 PRT homo sapiens 8 Met Ala Gly Val Gly Ala Ala Ala Leu Ser Leu Leu Leu His Leu Gly 1 5 10 15 Ala Leu Ala Leu Ala Ala Gly Ala Glu Gly Gly Ala Val Pro Arg Glu 20 25 30 Pro Pro Gly Gln Gln Thr Thr Ala His Ser Ser Val Leu Ala Gly Asn 35 40 45 Ser Gln Glu Gln Trp His Pro Leu Arg Glu Trp Leu Gly Arg Leu Glu 50 55 60 Ala Ala Val Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg 65 70 75 80 Val Arg Gln Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys 85 90 95 Trp Gly Leu Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp 100 105 110 Ala Cys Thr Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro 115 120 125 Gln Ala His Leu Pro Gly Cys Thr Glu Gly Gly Ser His Trp Glu His 130 135 140 Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg Ile Cys Arg Cys 145 150 155 160 Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys Ala Ser Leu Cys 165 170 175 Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys Pro Val Cys Asp 180 185 190 Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly Glu Pro Val Gly 195 200 205 Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn Gly Ser Val Gln 210 215 220 Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg His Pro Gly Lys 225 230 235 240 Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys Glu Tyr Gln Gly 245 250 255 His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln Glu Arg Gly Leu 260 265 270 Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser Cys Glu Glu Gln 275 280 285 Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser Gly Arg Gln Leu 290 295 300 Cys Pro Ala Cys Glu Leu Asp Gly Glu Glu Phe Ala Glu Gly Val Gln 305 310 315 320 Trp Glu Pro Asp Gly Arg Pro Cys Thr Ala Cys Val Cys Gln Asp Gly 325 330 335 Val Pro Lys Cys Gly Ala Val Leu Cys Pro Pro Ala Pro Cys Gln His 340 345 350 Pro Thr Gln Pro Pro Gly Ala Cys Cys Pro Ser Cys Asp Ser Cys Thr 355 360 365 Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe Thr Asp Ala Asp 370 375 380 Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr Val Thr Cys Ser 385 390 395 400 Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro Gln Ser Gly Pro 405 410 415 Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu Glu Glu Glu Val 420 425 430 Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp Pro Cys Gln Glu 435 440 445 Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro Arg Pro Cys Pro 450 455 460 Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys Cys Pro Asn Asp 465 470 475 480 Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro Ser Gly Ala Asp 485 490 495 Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg Cys Leu Ser Gly 500 505 510 Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu Pro Cys Pro Glu 515 520 525 Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys Pro Ala Ala Pro 530 535 540 Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His Ala Arg His Gln 545 550 555 560 Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg Cys Leu Cys Leu 565 570 575 Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro Pro Ala Pro Cys 580 585 590 Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys Asp Gly Cys Leu 595 600 605 Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe Pro Ser Pro Thr 610 615 620 Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser Val Ser Cys Glu 625 630 635 640 Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro Ala Arg Gly Asp 645 650 655 Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly Glu Ser Tyr Leu 660 665 670 Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys Asn Leu Cys Thr 675 680 685 Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro Cys Glu Pro Pro 690 695 700 Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys Cys Pro Thr Cys 705 710 715 720 Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser Gly Glu Thr Leu 725 730 735 Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr Cys Gln Gly Arg 740 745 750 Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser Cys Glu 755 760 765 Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg Leu Gln Cys 770 775 780 Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly Ser Cys Cys 785 790 795 800 Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu His Pro Glu Gly 805 810 815 Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys Val Cys His 820 825 830 Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser Cys Ala 835 840 845 Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys Ser Asp Cys 850 855 860 Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln Pro Gly 865 870 875 880 Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro Glu Gly Pro 885 890 895 Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu Val Gly Cys 900 905 910 Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys Cys Pro Thr 915 920 925 Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly Ser Glu 930 935 940 Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp Leu Thr 945 950 955 960 Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys Pro Leu Ser 965 970 975 Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys Arg Glu Cys 980 985 990 Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu Ser Trp Arg 995 1000 1005 Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg Gly His Val 1010 1015 1020 Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro His Gly Trp 1025 1030 1035 1040 Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln Ala Pro 1045 1050 1055 Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala Ser Gly Glu Arg 1060 1065 1070 Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala Gly Thr Val 1075 1080 1085 Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro Asp Lys 1090 1095 1100 Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu Pro Arg 1105 1110 1115 1120 Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg Thr Phe Asp 1125 1130 1135 Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val Leu Ala Lys 1140 1145 1150 Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr Asn Asp Asp Arg 1155 1160 1165 Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val Leu Leu Gly 1170 1175 1180 Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr Val Asp Gly 1185 1190 1195 1200 His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr Val Glu 1205 1210 1215 Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro Gly Leu Gln Val 1220 1225 1230 Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro Gly Ser Tyr 1235 1240 1245 Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe Ala Gln 1250 1255 1260 Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu Ala Ala 1265 1270 1275 1280 Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro Gly Arg Pro 1285 1290 1295 Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala Gly Tyr Arg 1300 1305 1310 Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys Ser Ser Pro 1315 1320 1325 Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro Phe Phe Ala Ala 1330 1335 1340 Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala Asp Ala 1345 1350 1355 1360 Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys Arg Gln Ala 1365 1370 1375 Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val Val Gly Cys 1380 1385 1390 Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro Pro Cys Pro 1395 1400 1405 Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu Ala Ala His 1410 1415 1420 Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala Gly Leu Val 1425 1430 1435 1440 Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro Gln Val Leu 1445 1450 1455 Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser Arg Glu 1460 1465 1470 Pro Gln Glu Thr Pro 1475 9 4536 DNA homo sapiens 9 atggccgggg tcggggccgc tgcgctgtcc cttctcctgc acctcggggc cctggcgctg 60 gccgcgggcg cggaaggtgg ggctgtcccc agggagcccc ctgggcagca gacaactgcc 120 cattcctcag tccttgctgg gaactcccag gagcagtggc accccctgcg agagtggctg 180 gggcgactgg aggctgcagt gatggagctc agagaacaga ataaggacct gcagacgagg 240 gtgaggcagc tggagtcctg tgagtgccac cctgcatctc cccagtgctg ggggctgggg 300 cgtgcctggc ccgagggggc acgctgggag cctgacgcct gcacagcctg cgtctgccag 360 gatggggccg ctcactgtgg cccccaagca cacctgcccg gctgcacaga aggtggctct 420 cactgggaac atggccaaga gtggacaaca cctggggacc cctgccgaat ctgccggtgc 480 ctggagggtc acatccagtg ccgccagcga gaatgtgcca gcctgtgtcc atacccagcc 540 cggcccctcc caggcacctg ctgccctgtg tgtgatggct gtttcctaaa cgggcgggag 600 caccgcagcg gggagcctgt gggctcaggg gacccctgct cgcactgccg ctgtgctaat 660 gggagtgtcc agtgtgagcc tctgccctgc ccgccagtgc cctgcagaca cccaggcaag 720 atccctgggc agtgctgccc tgtctgcgat ggctgtgagt accagggaca ccagtatcag 780 agccaggaga ccttcagact ccaagagcgg ggcctctgtg tccgctgctc ctgccaggct 840 ggcgaggtct cctgtgagga gcaggagtgc ccagtcaccc cctgtgccct gcctgcctct 900 ggccgccagc tctgcccagc ctgtgagctg gatggagagg agtttgctga gggagtccag 960 tgggagcctg atggtcggcc ctgcaccgcc tgcgtctgtc aagatggggt acccaagtgc 1020 ggggctgtgc tctgcccccc agccccctgc cagcacccca cccagccccc tggtgcctgc 1080 tgccccagct gtgacagctg cacctaccac agccaagtgt atgccaatgg gcagaacttc 1140 acggatgcag acagcccttg ccatgcctgc cactgtcagg atggaactgt gacatgctcc 1200 ttggttgact gccctcccac gacctgtgcc aggccccaga gtggaccagg ccagtgttgc 1260 cccaggtgcc cagactgcat cctggaggaa gaggtgtttg tggacggcga gagcttctcc 1320 cacccccgag acccctgcca ggagtgccga tgccaggaag gccatgccca ctgccagcct 1380 cgcccctgcc ccagggcccc ctgtgcccac ccgctgcctg ggacctgctg cccgaacgac 1440 tgcagcggct gtgcctttgg cgggaaagag taccccagcg gagcggactt cccccacccc 1500 tctgacccct gccgtctgtg tcgctgtctg agcggcaacg tgcagtgcct ggcccgccgc 1560 tgcgtgccgc tgccctgtcc agagcctgtc ctgctgccgg gagagtgctg cccgcagtgc 1620 ccagccgccc cagcccccgc cggctgccca cggcccggcg cggcccacgc ccgccaccag 1680 gagtacttct ccccgcccgg cgatccctgc cgccgctgcc tctgcctcga cggctccgtg 1740 tcctgccagc ggctgccctg cccgcccgcg ccctgcgcgc acccgcgcca ggggccttgc 1800 tgcccctcct gcgacggctg cctgtaccag gggaaggagt ttgccagcgg ggagcgcttc 1860 ccatcgccca ctgctgcctg ccacctctgc ctttgctggg agggcagcgt gagctgcgag 1920 cccaaggcat gtgcccctgc actgtgcccc ttccctgcca ggggcgactg ctgccctgac 1980 tgtgatggct gtgagtacct gggggagtcc tacctgagta accaggagtt cccagacccc 2040 cgagaaccct gcaacctgtg tacctgtctt ggaggcttcg tgacctgcgg ccgccggccc 2100 tgtgagcctc cgggctgcag ccacccactc atcccctctg ggcactgctg cccgacctgc 2160 cagggatgcc gctaccatgg cgtcactact gcctccggag agacccttcc tgacccactt 2220 gaccctacct gctccctctg cacctgccag gaaggttcca tgcgctgcca aaagaagcca 2280 tgtgccccag ctctctgccc ccacccctct ccaggcccct gcttctgccc tgtttgccac 2340 agttgtctct ctcagggccg ggagcaccag gatggggagg agtttgaggg accagcaggc 2400 agctgtgagt ggtgtcgctg tcaggctggc caggtcagct gtgtgcggct gcagtgccca 2460 ccccttccct gcaagctcca ggtcaccgag cgggggagct gctgccctcg ctgcagaggc 2520 tgcctggctc atggggaaga gcaccccgaa ggcagtagat gggtgccccc cgacagtgcc 2580 tgctcctcct gtgtgtgtca cgagggcgtc gtcacctgtg cacgcatcca gtgcatcagc 2640 tcttgcgccc agccccgcca agggccccat gactgctgtc ctcaatgctc tgactgtgag 2700 catgagggcc ggaagtacga gcctggggag agcttccagc ctggggcaga cccctgtgaa 2760 gtgtgcatct gcgagccaca gcctgagggg cctcccagcc ttcgctgtca ccggcggcag 2820 tgtcccagcc tggtgggctg cccccccagc cagctcctgc cccctgggcc ccagcactgc 2880 tgtcccacct gtgccgaggc cttgagtaac tgttcagagg gcctgctggg atctgagcta 2940 gccccaccag acccctgcta cacgtgccag tgccaggacc tgacatggct ctgcatccac 3000 caggcttgtc ctgagctcag ctgtcccctc tcagagcgcc acactccccc tgggagctgc 3060 tgccccgtat gccgggaatg tgtggtggag gccgagggcc ggagagtggc agatggagag 3120 agctggcggg accccagcaa tgcgtgcatc gcctgcacct gccatcgggg ccatgtggag 3180 tgccacctcg aggagtgcca ggccctctcc tgcccccatg gctgggcgaa ggtgccccag 3240 gctgacagct gctgtgagcg atgccaagct cccacccagt cctgcgtgca ccagggccgt 3300 gaggtggcct ctggagagcg ctggactgtg gacacctgca ccagctgctc ctgcatggcg 3360 ggcaccgtgc gttgccagag ccagcgctgc tcaccgctct cgtgtggccc cgacaaggcc 3420 cctgccctga gtcctggcag ctgctgcccc cgctgcctgc ctcggcccgc ttcctgcatg 3480 gccttcggag acccccatta ccgcaccttc gacggccgcc tgctgcactt ccagggcagt 3540 tgcagctatg tgctggccaa ggactgccac agcggggact tcagtgtgca cgtgaccaat 3600 gatgaccggg gccggagcgg tgtggcctgg acccaggagg tggcggtgct gctgggagac 3660 atggccgtgc ggctgctgca ggacggggca gtcacggtgg atgggcaccc ggtggccttg 3720 cccttcctgc aggagccgct gctgtatgtg gagctgcgag gacacactgt gatcctgcac 3780 gcccagcccg ggctccaggt gctgtgggat gggcagtccc aggtggaggt gagcgtacct 3840 ggctcctacc agggccggac ttgtgggctc tgtgggaact tcaatggctt tgcccaggac 3900 gatctgcagg gccctgaggg gctgctcctg ccctcggagg ctgcgtttgg gaatagctgg 3960 caggtctcag aggggctgtg gcctggccgg ccctgttctg caggccgaga ggtggatccg 4020 tgccgggcag caggttaccg tgccaggcgt gaggccaatg cccggtgtgg ggtgctgaag 4080 tcctccccat tcagtcgctg ccatgctgtg gtgccaccgg agcccttctt tgccgcctgt 4140 gtgtatgacc tgtgtgcctg tggccctggc tcctccgctg atgcctgcct ctgtgatgcc 4200 ctggaagcct acgccagtca ctgtcgccag gcaggagtga cacctacctg gcgaggcccc 4260 acgctgtgtg tggtaggctg ccccctggag cgtggcttcg tgtttgatga gtgcggccca 4320 ccctgtcccc gcacctgctt caatcagcat atccccctgg gggagctggc agcccactgc 4380 gtgaggccct gcgtgcccgg ctgccagtgc cctgcaggcc tggtggagca tgaggcccac 4440 tgcatcccac ccgaggcctg cccccaagtc ctgctcactg gagaccagcc acttggtgct 4500 cggcccagcc ccagccggga gccccaggag acaccc 4536 10 1512 PRT homo sapiens 10 Met Ala Gly Val Gly Ala Ala Ala Leu Ser Leu Leu Leu His Leu Gly 1 5 10 15 Ala Leu Ala Leu Ala Ala Gly Ala Glu Gly Gly Ala Val Pro Arg Glu 20 25 30 Pro Pro Gly Gln Gln Thr Thr Ala His Ser Ser Val Leu Ala Gly Asn 35 40 45 Ser Gln Glu Gln Trp His Pro Leu Arg Glu Trp Leu Gly Arg Leu Glu 50 55 60 Ala Ala Val Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg 65 70 75 80 Val Arg Gln Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys 85 90 95 Trp Gly Leu Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp 100 105 110 Ala Cys Thr Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro 115 120 125 Gln Ala His Leu Pro Gly Cys Thr Glu Gly Gly Ser His Trp Glu His 130 135 140 Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg Ile Cys Arg Cys 145 150 155 160 Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys Ala Ser Leu Cys 165 170 175 Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys Pro Val Cys Asp 180 185 190 Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly Glu Pro Val Gly 195 200 205 Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn Gly Ser Val Gln 210 215 220 Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg His Pro Gly Lys 225 230 235 240 Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys Glu Tyr Gln Gly 245 250 255 His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln Glu Arg Gly Leu 260 265 270 Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser Cys Glu Glu Gln 275 280 285 Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser Gly Arg Gln Leu 290 295 300 Cys Pro Ala Cys Glu Leu Asp Gly Glu Glu Phe Ala Glu Gly Val Gln 305 310 315 320 Trp Glu Pro Asp Gly Arg Pro Cys Thr Ala Cys Val Cys Gln Asp Gly 325 330 335 Val Pro Lys Cys Gly Ala Val Leu Cys Pro Pro Ala Pro Cys Gln His 340 345 350 Pro Thr Gln Pro Pro Gly Ala Cys Cys Pro Ser Cys Asp Ser Cys Thr 355 360 365 Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe Thr Asp Ala Asp 370 375 380 Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr Val Thr Cys Ser 385 390 395 400 Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro Gln Ser Gly Pro 405 410 415 Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu Glu Glu Glu Val 420 425 430 Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp Pro Cys Gln Glu 435 440 445 Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro Arg Pro Cys Pro 450 455 460 Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys Cys Pro Asn Asp 465 470 475 480 Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro Ser Gly Ala Asp 485 490 495 Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg Cys Leu Ser Gly 500 505 510 Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu Pro Cys Pro Glu 515 520 525 Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys Pro Ala Ala Pro 530 535 540 Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His Ala Arg His Gln 545 550 555 560 Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg Cys Leu Cys Leu 565 570 575 Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro Pro Ala Pro Cys 580 585 590 Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys Asp Gly Cys Leu 595 600 605 Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe Pro Ser Pro Thr 610 615 620 Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser Val Ser Cys Glu 625 630 635 640 Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro Ala Arg Gly Asp 645 650 655 Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly Glu Ser Tyr Leu 660 665 670 Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys Asn Leu Cys Thr 675 680 685 Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro Cys Glu Pro Pro 690 695 700 Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys Cys Pro Thr Cys 705 710 715 720 Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser Gly Glu Thr Leu 725 730 735 Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr Cys Gln Glu Gly 740 745 750 Ser Met Arg Cys Gln Lys Lys Pro Cys Ala Pro Ala Leu Cys Pro His 755 760 765 Pro Ser Pro Gly Pro Cys Phe Cys Pro Val Cys His Ser Cys Leu Ser 770 775 780 Gln Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly 785 790 795 800 Ser Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg 805 810 815 Leu Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly 820 825 830 Ser Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu His 835 840 845 Pro Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys 850 855 860 Val Cys His Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser 865 870 875 880 Ser Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys 885 890 895 Ser Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe 900 905 910 Gln Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro 915 920 925 Glu Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu 930 935 940 Val Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys 945 950 955 960 Cys Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu 965 970 975 Gly Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln 980 985 990 Asp Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys 995 1000 1005 Pro Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys 1010 1015 1020 Arg Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu 1025 1030 1035 1040 Ser Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg 1045 1050 1055 Gly His Val Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro 1060 1065 1070 His Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys 1075 1080 1085 Gln Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala Ser 1090 1095 1100 Gly Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala 1105 1110 1115 1120 Gly Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly 1125 1130 1135 Pro Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys 1140 1145 1150 Leu Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg 1155 1160 1165 Thr Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val 1170 1175 1180 Leu Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr Asn 1185 1190 1195 1200 Asp Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val 1205 1210 1215 Leu Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr 1220 1225 1230 Val Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu 1235 1240 1245 Tyr Val Glu Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro Gly 1250 1255 1260 Leu Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro 1265 1270 1275 1280 Gly Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly 1285 1290 1295 Phe Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser 1300 1305 1310 Glu Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro 1315 1320 1325 Gly Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala 1330 1335 1340 Gly Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys 1345 1350 1355 1360 Ser Ser Pro Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro Phe 1365 1370 1375 Phe Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser 1380 1385 1390 Ala Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys 1395 1400 1405 Arg Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val 1410 1415 1420 Val Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro 1425 1430 1435 1440 Pro Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu 1445 1450 1455 Ala Ala His Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala 1460 1465 1470 Gly Leu Val Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro 1475 1480 1485 Gln Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro 1490 1495 1500 Ser Arg Glu Pro Gln Glu Thr Pro 1505 1510 11 4710 DNA homo sapiens 11 atggagctca gagaacagaa taaggacctg cagacgaggg tgaggcagct ggagtcctgt 60 gagtgccacc ctgcatctcc ccagtgctgg gggctggggc gtgcctggcc cgagggggca 120 cgctgggagc ctgacgcctg cacagcctgc gtctgccagg atggggccgc tcactgtggc 180 ccccaagcac acctgcccca ttgcaggggc tgcagccaaa atggccagac ctacggcaac 240 ggggagacct tctccccaga tgcctgcacc acctgccgct gtctggaagg taccatcact 300 tgcaaccaga agccatgccc aagaggaccc tgccctgagc caggagcatg ctgcccgcac 360 tgtaagccag gctgtgatta tgaggggcag ctttatgagg agggggtcac cttcctgtcc 420 agctccaacc cttgtctaca gtgcacctgc ctgaggagcc gagttcgctg catggccctg 480 aagtgcccgc ctagcccctg cccagagcca gtgctgaggc ctgggcactg ctgcccaacc 540 tgccaaggct gcacagaagg tggctctcac tgggaacatg gccaagagtg gacaacacct 600 ggggacccct gccgaatctg ccggtgcctg gagggtcaca tccagtgccg ccagcgagaa 660 tgtgccagcc tgtgtccata cccagcccgg cccctcccag gcacctgctg ccctgtgtgt 720 gatggctgtt tcctaaacgg gcgggagcac cgcagcgggg agcctgtggg ctcaggggac 780 ccctgctcgc actgccgctg tgctaatggg agtgtccagt gtgagcctct gccctgcccg 840 ccagtgccct gcagacaccc aggcaagatc cctgggcagt gctgccctgt ctgcgatggc 900 tgtgagtacc agggacacca gtatcagagc caggagacct tcagactcca agagcggggc 960 ctctgtgtcc gctgctcctg ccaggctggc gaggtctcct gtgaggagca ggagtgccca 1020 gtcaccccct gtgccctgcc tgcctctggc cgccagctct gcccagctca ccctgaccag 1080 cctgccccac ccacctgtga gctggatgga gaggagtttg ctgagggagt ccagtgggag 1140 cctgatggtc ggccctgcac cgcctgcgtc tgtcaagatg gggtacccaa gtgcggggct 1200 gtgctctgcc ccccagcccc ctgccagcac cccacccagc cccctggtgc ctgctgcccc 1260 agctgtgaca gctgcaccta ccacagccaa gtgtatgcca atgggcagaa cttcacggat 1320 gcagacagcc cttgccatgc ctgccactgt caggatggaa ctgtgacatg ctccttggtt 1380 gactgccctc ccacgacctg tgccaggccc cagagtggac caggccagtg ttgccccagg 1440 tgcccagact gcatcctgga ggaagaggtg tttgtggacg gcgagagctt ctcccacccc 1500 cgagacccct gccaggagtg ccgatgccag gaaggccatg cccactgcca gcctcgcccc 1560 tgccccaggg ccccctgtgc ccacccgctg cctgggacct gctgcccgaa cgactgcagc 1620 ggctgtgcct ttggcgggaa agagtacccc agcggagcgg acttccccca cccctctgac 1680 ccctgccgtc tgtgtcgctg tctgagcggc aacgtgcagt gcctggcccg ccgctgcgtg 1740 ccgctgccct gtccagagcc tgtcctgctg ccgggagagt gctgcccgca gtgcccagcc 1800 gccccagccc ccgccggctg cccacggccc ggcgcggccc acgcccgcca ccaggagtac 1860 ttctccccgc ccggcgatcc ctgccgccgc tgcctctgcc tcgacggctc cgtgtcctgc 1920 cagcggctgc cctgcccgcc cgcgccctgc gcgcacccgc gccaggggcc ttgctgcccc 1980 tcctgcgacg gctgcctgta ccaggggaag gagtttgcca gcggggagcg cttcccatcg 2040 cccactgctg cctgccacct ctgcctttgc tgggagggca gcgtgagctg cgagcccaag 2100 gcatgtgccc ctgcactgtg ccccttccct gccaggggcg actgctgccc tgactgtgat 2160 ggctgtgagt acctggggga gtcctacctg agtaaccagg agttcccaga cccccgagaa 2220 ccctgcaacc tgtgtacctg tcttggaggc ttcgtgacct gcggccgccg gccctgtgag 2280 cctccgggct gcagccaccc actcatcccc tctgggcact gctgcccgac ctgccaggga 2340 tgccgctacc atggcgtcac tactgcctcc ggagagaccc ttcctgaccc acttgaccct 2400 acctgctccc tctgcacctg ccaggaaggt tccatgcgct gccaaaagaa gccatgtgcc 2460 ccagctctct gcccccaccc ctctccaggc ccctgcttct gccctgtttg ccacagttgt 2520 ctctctcagg gccgggagca ccaggatggg gaggagtttg agggaccagc aggcagctgt 2580 gagtggtgtc gctgtcaggc tggccaggtc agctgtgtgc ggctgcagtg cccacccctt 2640 ccctgcaagc tccaggtcac cgagcggggg agctgctgcc ctcgctgcag aggctgcctg 2700 gctcatgggg aagagcaccc cgaaggcagt agatgggtgc cccccgacag tgcctgctcc 2760 tcctgtgtgt gtcacgaggg cgtcgtcacc tgtgcacgca tccagtgcat cagctcttgc 2820 gcccagcccc gccaagggcc ccatgactgc tgtcctcaat gctctgactg tgagcatgag 2880 ggccggaagt acgagcctgg ggagagcttc cagcctgggg cagacccctg tgaagtgtgc 2940 atctgcgagc cacagcctga ggggcctccc agccttcgct gtcaccggcg gcagtgtccc 3000 agcctggtgg gctgcccccc cagccagctc ctgccccctg ggccccagca ctgctgtccc 3060 acctgtgccg aggccttgag taactgttca gagggcctgc tgggatctga gctagcccca 3120 ccagacccct gctacacgtg ccagtgccag gacctgacat ggctctgcat ccaccaggct 3180 tgtcctgagc tcagctgtcc cctctcagag cgccacactc cccctgggag ctgctgcccc 3240 gtatgccggg aatgtgtggt ggaggccgag ggccggagag tggcagatgg agagagctgg 3300 cgggacccca gcaatgcgtg catcgcctgc acctgccatc ggggccatgt ggagtgccac 3360 ctcgaggagt gccaggccct ctcctgcccc catggctggg cgaaggtgcc ccaggctgac 3420 agctgctgtg agcgatgcca agctcccacc cagtcctgcg tgcaccaggg ccgtgaggtg 3480 gcctctggag agcgctggac tgtggacacc tgcaccagct gctcctgcat ggcgggcacc 3540 gtgcgttgcc agagccagcg ctgctcaccg ctctcgtgtg gccccgacaa ggcccctgcc 3600 ctgagtcctg gcagctgctg cccccgctgc ctgcctcggc ccgcttcctg catggccttc 3660 ggagaccccc attaccgcac cttcgacggc cgcctgctgc acttccaggg cagttgcagc 3720 tatgtgctgg ccaaggactg ccacagcggg gacttcagtg tgcacgtgac caatgatgac 3780 cggggccgga gcggtgtggc ctggacccag gaggtggcgg tgctgctggg agacatggcc 3840 gtgcggctgc tgcaggacgg ggcagtcacg gtggatgggc acccggtggc cttgcccttc 3900 ctgcaggagc cgctgctgta tgtggagctg cgaggacaca ctgtgatcct gcacgcccag 3960 cccgggctcc aggtgctgtg ggatgggcag tcccaggtgg aggtgagcgt acctggctcc 4020 taccagggcc ggacttgtgg gctctgtggg aacttcaatg gctttgccca ggacgatctg 4080 cagggccctg aggggctgct cctgccctcg gaggctgcgt ttgggaatag ctggcaggtc 4140 tcagaggggc tgtggcctgg ccggccctgt tctgcaggcc gagaggtgga tccgtgccgg 4200 gcagcaggtt accgtgccag gcgtgaggcc aatgcccggt gtggggtgct gaagtcctcc 4260 ccattcagtc gctgccatgc tgtggtgcca ccggagccct tctttgccgc ctgtgtgtat 4320 gacctgtgtg cctgtggccc tggctcctcc gctgatgcct gcctctgtga tgccctggaa 4380 gcctacgcca gtcactgtcg ccaggcagga gtgacaccta cctggcgagg ccccacgctg 4440 tgtgtggtag gctgccccct ggagcgtggc ttcgtgtttg atgagtgcgg cccaccctgt 4500 ccccgcacct gcttcaatca gcatatcccc ctgggggagc tggcagccca ctgcgtgagg 4560 ccctgcgtgc ccggctgcca gtgccctgca ggcctggtgg agcatgaggc ccactgcatc 4620 ccacccgagg cctgccccca agtcctgctc actggagacc agccacttgg tgctcggccc 4680 agccccagcc gggagcccca ggagacaccc 4710 12 1570 PRT homo sapiens 12 Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg Val Arg Gln 1 5 10 15 Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys Trp Gly Leu 20 25 30 Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp Ala Cys Thr 35 40 45 Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro Gln Ala His 50 55 60 Leu Pro His Cys Arg Gly Cys Ser Gln Asn Gly Gln Thr Tyr Gly Asn 65 70 75 80 Gly Glu Thr Phe Ser Pro Asp Ala Cys Thr Thr Cys Arg Cys Leu Glu 85 90 95 Gly Thr Ile Thr Cys Asn Gln Lys Pro Cys Pro Arg Gly Pro Cys Pro 100 105 110 Glu Pro Gly Ala Cys Cys Pro His Cys Lys Pro Gly Cys Asp Tyr Glu 115 120 125 Gly Gln Leu Tyr Glu Glu Gly Val Thr Phe Leu Ser Ser Ser Asn Pro 130 135 140 Cys Leu Gln Cys Thr Cys Leu Arg Ser Arg Val Arg Cys Met Ala Leu 145 150 155 160 Lys Cys Pro Pro Ser Pro Cys Pro Glu Pro Val Leu Arg Pro Gly His 165 170 175 Cys Cys Pro Thr Cys Gln Gly Cys Thr Glu Gly Gly Ser His Trp Glu 180 185 190 His Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg Ile Cys Arg 195 200 205 Cys Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys Ala Ser Leu 210 215 220 Cys Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys Pro Val Cys 225 230 235 240 Asp Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly Glu Pro Val 245 250 255 Gly Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn Gly Ser Val 260 265 270 Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg His Pro Gly 275 280 285 Lys Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys Glu Tyr Gln 290 295 300 Gly His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln Glu Arg Gly 305 310 315 320 Leu Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser Cys Glu Glu 325 330 335 Gln Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser Gly Arg Gln 340 345 350 Leu Cys Pro Ala His Pro Asp Gln Pro Ala Pro Pro Thr Cys Glu Leu 355 360 365 Asp Gly Glu Glu Phe Ala Glu Gly Val Gln Trp Glu Pro Asp Gly Arg 370 375 380 Pro Cys Thr Ala Cys Val Cys Gln Asp Gly Val Pro Lys Cys Gly Ala 385 390 395 400 Val Leu Cys Pro Pro Ala Pro Cys Gln His Pro Thr Gln Pro Pro Gly 405 410 415 Ala Cys Cys Pro Ser Cys Asp Ser Cys Thr Tyr His Ser Gln Val Tyr 420 425 430 Ala Asn Gly Gln Asn Phe Thr Asp Ala Asp Ser Pro Cys His Ala Cys 435 440 445 His Cys Gln Asp Gly Thr Val Thr Cys Ser Leu Val Asp Cys Pro Pro 450 455 460 Thr Thr Cys Ala Arg Pro Gln Ser Gly Pro Gly Gln Cys Cys Pro Arg 465 470 475 480 Cys Pro Asp Cys Ile Leu Glu Glu Glu Val Phe Val Asp Gly Glu Ser 485 490 495 Phe Ser His Pro Arg Asp Pro Cys Gln Glu Cys Arg Cys Gln Glu Gly 500 505 510 His Ala His Cys Gln Pro Arg Pro Cys Pro Arg Ala Pro Cys Ala His 515 520 525 Pro Leu Pro Gly Thr Cys Cys Pro Asn Asp Cys Ser Gly Cys Ala Phe 530 535 540 Gly Gly Lys Glu Tyr Pro Ser Gly Ala Asp Phe Pro His Pro Ser Asp 545 550 555 560 Pro Cys Arg Leu Cys Arg Cys Leu Ser Gly Asn Val Gln Cys Leu Ala 565 570 575 Arg Arg Cys Val Pro Leu Pro Cys Pro Glu Pro Val Leu Leu Pro Gly 580 585 590 Glu Cys Cys Pro Gln Cys Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro 595 600 605 Arg Pro Gly Ala Ala His Ala Arg His Gln Glu Tyr Phe Ser Pro Pro 610 615 620 Gly Asp Pro Cys Arg Arg Cys Leu Cys Leu Asp Gly Ser Val Ser Cys 625 630 635 640 Gln Arg Leu Pro Cys Pro Pro Ala Pro Cys Ala His Pro Arg Gln Gly 645 650 655 Pro Cys Cys Pro Ser Cys Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe 660 665 670 Ala Ser Gly Glu Arg Phe Pro Ser Pro Thr Ala Ala Cys His Leu Cys 675 680 685 Leu Cys Trp Glu Gly Ser Val Ser Cys Glu Pro Lys Ala Cys Ala Pro 690 695 700 Ala Leu Cys Pro Phe Pro Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp 705 710 715 720 Gly Cys Glu Tyr Leu Gly Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro 725 730 735 Asp Pro Arg Glu Pro Cys Asn Leu Cys Thr Cys Leu Gly Gly Phe Val 740 745 750 Thr Cys Gly Arg Arg Pro Cys Glu Pro Pro Gly Cys Ser His Pro Leu 755 760 765 Ile Pro Ser Gly His Cys Cys Pro Thr Cys Gln Gly Cys Arg Tyr His 770 775 780 Gly Val Thr Thr Ala Ser Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro 785 790 795 800 Thr Cys Ser Leu Cys Thr Cys Gln Glu Gly Ser Met Arg Cys Gln Lys 805 810 815 Lys Pro Cys Ala Pro Ala Leu Cys Pro His Pro Ser Pro Gly Pro Cys 820 825 830 Phe Cys Pro Val Cys His Ser Cys Leu Ser Gln Gly Arg Glu His Gln 835 840 845 Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser Cys Glu Trp Cys Arg 850 855 860 Cys Gln Ala Gly Gln Val Ser Cys Val Arg Leu Gln Cys Pro Pro Leu 865 870 875 880 Pro Cys Lys Leu Gln Val Thr Glu Arg Gly Ser Cys Cys Pro Arg Cys 885 890 895 Arg Gly Cys Leu Ala His Gly Glu Glu His Pro Glu Gly Ser Arg Trp 900 905 910 Val Pro Pro Asp Ser Ala Cys Ser Ser Cys Val Cys His Glu Gly Val 915 920 925 Val Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser Cys Ala Gln Pro Arg 930 935 940 Gln Gly Pro His Asp Cys Cys Pro Gln Cys Ser Asp Cys Glu His Glu 945 950 955 960 Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln Pro Gly Ala Asp Pro 965 970 975 Cys Glu Val Cys Ile Cys Glu Pro Gln Pro Glu Gly Pro Pro Ser Leu 980 985 990 Arg Cys His Arg Arg Gln Cys Pro Ser Leu Val Gly Cys Pro Pro Ser 995 1000 1005 Gln Leu Leu Pro Pro Gly Pro Gln His Cys Cys Pro Thr Cys Ala Glu 1010 1015 1020 Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly Ser Glu Leu Ala Pro 1025 1030 1035 1040 Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp Leu Thr Trp Leu Cys 1045 1050 1055 Ile His Gln Ala Cys Pro Glu Leu Ser Cys Pro Leu Ser Glu Arg His 1060 1065 1070 Thr Pro Pro Gly Ser Cys Cys Pro Val Cys Arg Glu Cys Val Val Glu 1075 1080 1085 Ala Glu Gly Arg Arg Val Ala Asp Gly Glu Ser Trp Arg Asp Pro Ser 1090 1095 1100 Asn Ala Cys Ile Ala Cys Thr Cys His Arg Gly His Val Glu Cys His 1105 1110 1115 1120 Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro His Gly Trp Ala Lys Val 1125 1130 1135 Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln Ala Pro Thr Gln Ser 1140 1145 1150 Cys Val His Gln Gly Arg Glu Val Ala Ser Gly Glu Arg Trp Thr Val 1155 1160 1165 Asp Thr Cys Thr Ser Cys Ser Cys Met Ala Gly Thr Val Arg Cys Gln 1170 1175 1180 Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro Asp Lys Ala Pro Ala 1185 1190 1195 1200 Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu Pro Arg Pro Ala Ser 1205 1210 1215 Cys Met Ala Phe Gly Asp Pro His Tyr Arg Thr Phe Asp Gly Arg Leu 1220 1225 1230 Leu His Phe Gln Gly Ser Cys Ser Tyr Val Leu Ala Lys Asp Cys His 1235 1240 1245 Ser Gly Asp Phe Ser Val His Val Thr Asn Asp Asp Arg Gly Arg Ser 1250 1255 1260 Gly Val Ala Trp Thr Gln Glu Val Ala Val Leu Leu Gly Asp Met Ala 1265 1270 1275 1280 Val Arg Leu Leu Gln Asp Gly Ala Val Thr Val Asp Gly His Pro Val 1285 1290 1295 Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr Val Glu Leu Arg Gly 1300 1305 1310 His Thr Val Ile Leu His Ala Gln Pro Gly Leu Gln Val Leu Trp Asp 1315 1320 1325 Gly Gln Ser Gln Val Glu Val Ser Val Pro Gly Ser Tyr Gln Gly Arg 1330 1335 1340 Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe Ala Gln Asp Asp Leu 1345 1350 1355 1360 Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu Ala Ala Phe Gly Asn 1365 1370 1375 Ser Trp Gln Val Ser Glu Gly Leu Trp Pro Gly Arg Pro Cys Ser Ala 1380 1385 1390 Gly Arg Glu Val Asp Pro Cys Arg Ala Ala Gly Tyr Arg Ala Arg Arg 1395 1400 1405 Glu Ala Asn Ala Arg Cys Gly Val Leu Lys Ser Ser Pro Phe Ser Arg 1410 1415 1420 Cys His Ala Val Val Pro Pro Glu Pro Phe Phe Ala Ala Cys Val Tyr 1425 1430 1435 1440 Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala Asp Ala Cys Leu Cys 1445 1450 1455 Asp Ala Leu Glu Ala Tyr Ala Ser His Cys Arg Gln Ala Gly Val Thr 1460 1465 1470 Pro Thr Trp Arg Gly Pro Thr Leu Cys Val Val Gly Cys Pro Leu Glu 1475 1480 1485 Arg Gly Phe Val Phe Asp Glu Cys Gly Pro Pro Cys Pro Arg Thr Cys 1490 1495 1500 Phe Asn Gln His Ile Pro Leu Gly Glu Leu Ala Ala His Cys Val Arg 1505 1510 1515 1520 Pro Cys Val Pro Gly Cys Gln Cys Pro Ala Gly Leu Val Glu His Glu 1525 1530 1535 Ala His Cys Ile Pro Pro Glu Ala Cys Pro Gln Val Leu Leu Thr Gly 1540 1545 1550 Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser Arg Glu Pro Gln Glu 1555 1560 1565 Thr Pro 1570 13 4605 DNA homo sapiens 13 atggagctca gagaacagaa taaggacctg cagacgaggg tgaggcagct ggagtcctgt 60 gagtgccacc ctgcatctcc ccagtgctgg gggctggggc gtgcctggcc cgagggggca 120 cgctgggagc ctgacgcctg cacagcctgc gtctgccagg atggggccgc tcactgtggc 180 ccccaagcac acctgcccca ttgcaggggc tgcagccaaa atggccagac ctacggcaac 240 ggggagacct tctccccaga tgcctgcacc acctgccgct gtctggaagg taccatcact 300 tgcaaccaga agccatgccc aagaggaccc tgccctgagc caggagcatg ctgcccgcac 360 tgtaagccag gctgtgatta tgaggggcag ctttatgagg agggggtcac cttcctgtcc 420 agctccaacc cttgtctaca gtgcacctgc ctgaggagcc gagttcgctg catggccctg 480 aagtgcccgc ctagcccctg cccagagcca gtgctgaggc ctgggcactg ctgcccaacc 540 tgccaaggct gcacagaagg tggctctcac tgggaacatg gccaagagtg gacaacacct 600 ggggacccct gccgaatctg ccggtgcctg gagggtcaca tccagtgccg ccagcgagaa 660 tgtgccagcc tgtgtccata cccagcccgg cccctcccag gcacctgctg ccctgtgtgt 720 gatggctgtt tcctaaacgg gcgggagcac cgcagcgggg agcctgtggg ctcaggggac 780 ccctgctcgc actgccgctg tgctaatggg agtgtccagt gtgagcctct gccctgcccg 840 ccagtgccct gcagacaccc aggcaagatc cctgggcagt gctgccctgt ctgcgatggc 900 tgtgagtacc agggacacca gtatcagagc caggagacct tcagactcca agagcggggc 960 ctctgtgtcc gctgctcctg ccaggctggc gaggtctcct gtgaggagca ggagtgccca 1020 gtcaccccct gtgccctgcc tgcctctggc cgccagctct gcccagctca ccctgaccag 1080 cctgccccac ccacctgtga gctggatgga gaggagtttg ctgagggagt ccagtgggag 1140 cctgatggtc ggccctgcac cgcctgcgtc tgtcaagatg gggtacccaa gtgcggggct 1200 gtgctctgcc ccccagcccc ctgccagcac cccacccagc cccctggtgc ctgctgcccc 1260 agctgtgaca gctgcaccta ccacagccaa gtgtatgcca atgggcagaa cttcacggat 1320 gcagacagcc cttgccatgc ctgccactgt caggatggaa ctgtgacatg ctccttggtt 1380 gactgccctc ccacgacctg tgccaggccc cagagtggac caggccagtg ttgccccagg 1440 tgcccagact gcatcctgga ggaagaggtg tttgtggacg gcgagagctt ctcccacccc 1500 cgagacccct gccaggagtg ccgatgccag gaaggccatg cccactgcca gcctcgcccc 1560 tgccccaggg ccccctgtgc ccacccgctg cctgggacct gctgcccgaa cgactgcagc 1620 ggctgtgcct ttggcgggaa agagtacccc agcggagcgg acttccccca cccctctgac 1680 ccctgccgtc tgtgtcgctg tctgagcggc aacgtgcagt gcctggcccg ccgctgcgtg 1740 ccgctgccct gtccagagcc tgtcctgctg ccgggagagt gctgcccgca gtgcccagcc 1800 gccccagccc ccgccggctg cccacggccc ggcgcggccc acgcccgcca ccaggagtac 1860 ttctccccgc ccggcgatcc ctgccgccgc tgcctctgcc tcgacggctc cgtgtcctgc 1920 cagcggctgc cctgcccgcc cgcgccctgc gcgcacccgc gccaggggcc ttgctgcccc 1980 tcctgcgacg gctgcctgta ccaggggaag gagtttgcca gcggggagcg cttcccatcg 2040 cccactgctg cctgccacct ctgcctttgc tgggagggca gcgtgagctg cgagcccaag 2100 gcatgtgccc ctgcactgtg ccccttccct gccaggggcg actgctgccc tgactgtgat 2160 ggctgtgagt acctggggga gtcctacctg agtaaccagg agttcccaga cccccgagaa 2220 ccctgcaacc tgtgtacctg tcttggaggc ttcgtgacct gcggccgccg gccctgtgag 2280 cctccgggct gcagccaccc actcatcccc tctgggcact gctgcccgac ctgccaggga 2340 tgccgctacc atggcgtcac tactgcctcc ggagagaccc ttcctgaccc acttgaccct 2400 acctgctccc tctgcacctg ccagggccgg gagcaccagg atggggagga gtttgaggga 2460 ccagcaggca gctgtgagtg gtgtcgctgt caggctggcc aggtcagctg tgtgcggctg 2520 cagtgcccac cccttccctg caagctccag gtcaccgagc gggggagctg ctgccctcgc 2580 tgcagaggct gcctggctca tggggaagag caccccgaag gcagtagatg ggtgcccccc 2640 gacagtgcct gctcctcctg tgtgtgtcac gagggcgtcg tcacctgtgc acgcatccag 2700 tgcatcagct cttgcgccca gccccgccaa gggccccatg actgctgtcc tcaatgctct 2760 gactgtgagc atgagggccg gaagtacgag cctggggaga gcttccagcc tggggcagac 2820 ccctgtgaag tgtgcatctg cgagccacag cctgaggggc ctcccagcct tcgctgtcac 2880 cggcggcagt gtcccagcct ggtgggctgc ccccccagcc agctcctgcc ccctgggccc 2940 cagcactgct gtcccacctg tgccgaggcc ttgagtaact gttcagaggg cctgctggga 3000 tctgagctag ccccaccaga cccctgctac acgtgccagt gccaggacct gacatggctc 3060 tgcatccacc aggcttgtcc tgagctcagc tgtcccctct cagagcgcca cactccccct 3120 gggagctgct gccccgtatg ccgggaatgt gtggtggagg ccgagggccg gagagtggca 3180 gatggagaga gctggcggga ccccagcaat gcgtgcatcg cctgcacctg ccatcggggc 3240 catgtggagt gccacctcga ggagtgccag gccctctcct gcccccatgg ctgggcgaag 3300 gtgccccagg ctgacagctg ctgtgagcga tgccaagctc ccacccagtc ctgcgtgcac 3360 cagggccgtg aggtggcctc tggagagcgc tggactgtgg acacctgcac cagctgctcc 3420 tgcatggcgg gcaccgtgcg ttgccagagc cagcgctgct caccgctctc gtgtggcccc 3480 gacaaggccc ctgccctgag tcctggcagc tgctgccccc gctgcctgcc tcggcccgct 3540 tcctgcatgg ccttcggaga cccccattac cgcaccttcg acggccgcct gctgcacttc 3600 cagggcagtt gcagctatgt gctggccaag gactgccaca gcggggactt cagtgtgcac 3660 gtgaccaatg atgaccgggg ccggagcggt gtggcctgga cccaggaggt ggcggtgctg 3720 ctgggagaca tggccgtgcg gctgctgcag gacggggcag tcacggtgga tgggcacccg 3780 gtggccttgc ccttcctgca ggagccgctg ctgtatgtgg agctgcgagg acacactgtg 3840 atcctgcacg cccagcccgg gctccaggtg ctgtgggatg ggcagtccca ggtggaggtg 3900 agcgtacctg gctcctacca gggccggact tgtgggctct gtgggaactt caatggcttt 3960 gcccaggacg atctgcaggg ccctgagggg ctgctcctgc cctcggaggc tgcgtttggg 4020 aatagctggc aggtctcaga ggggctgtgg cctggccggc cctgttctgc aggccgagag 4080 gtggatccgt gccgggcagc aggttaccgt gccaggcgtg aggccaatgc ccggtgtggg 4140 gtgctgaagt cctccccatt cagtcgctgc catgctgtgg tgccaccgga gcccttcttt 4200 gccgcctgtg tgtatgacct gtgtgcctgt ggccctggct cctccgctga tgcctgcctc 4260 tgtgatgccc tggaagccta cgccagtcac tgtcgccagg caggagtgac acctacctgg 4320 cgaggcccca cgctgtgtgt ggtaggctgc cccctggagc gtggcttcgt gtttgatgag 4380 tgcggcccac cctgtccccg cacctgcttc aatcagcata tccccctggg ggagctggca 4440 gcccactgcg tgaggccctg cgtgcccggc tgccagtgcc ctgcaggcct ggtggagcat 4500 gaggcccact gcatcccacc cgaggcctgc ccccaagtcc tgctcactgg agaccagcca 4560 cttggtgctc ggcccagccc cagccgggag ccccaggaga caccc 4605 14 1535 PRT homo sapiens 14 Met Glu Leu Arg Glu Gln Asn Lys Asp Leu Gln Thr Arg Val Arg Gln 1 5 10 15 Leu Glu Ser Cys Glu Cys His Pro Ala Ser Pro Gln Cys Trp Gly Leu 20 25 30 Gly Arg Ala Trp Pro Glu Gly Ala Arg Trp Glu Pro Asp Ala Cys Thr 35 40 45 Ala Cys Val Cys Gln Asp Gly Ala Ala His Cys Gly Pro Gln Ala His 50 55 60 Leu Pro His Cys Arg Gly Cys Ser Gln Asn Gly Gln Thr Tyr Gly Asn 65 70 75 80 Gly Glu Thr Phe Ser Pro Asp Ala Cys Thr Thr Cys Arg Cys Leu Glu 85 90 95 Gly Thr Ile Thr Cys Asn Gln Lys Pro Cys Pro Arg Gly Pro Cys Pro 100 105 110 Glu Pro Gly Ala Cys Cys Pro His Cys Lys Pro Gly Cys Asp Tyr Glu 115 120 125 Gly Gln Leu Tyr Glu Glu Gly Val Thr Phe Leu Ser Ser Ser Asn Pro 130 135 140 Cys Leu Gln Cys Thr Cys Leu Arg Ser Arg Val Arg Cys Met Ala Leu 145 150 155 160 Lys Cys Pro Pro Ser Pro Cys Pro Glu Pro Val Leu Arg Pro Gly His 165 170 175 Cys Cys Pro Thr Cys Gln Gly Cys Thr Glu Gly Gly Ser His Trp Glu 180 185 190 His Gly Gln Glu Trp Thr Thr Pro Gly Asp Pro Cys Arg Ile Cys Arg 195 200 205 Cys Leu Glu Gly His Ile Gln Cys Arg Gln Arg Glu Cys Ala Ser Leu 210 215 220 Cys Pro Tyr Pro Ala Arg Pro Leu Pro Gly Thr Cys Cys Pro Val Cys 225 230 235 240 Asp Gly Cys Phe Leu Asn Gly Arg Glu His Arg Ser Gly Glu Pro Val 245 250 255 Gly Ser Gly Asp Pro Cys Ser His Cys Arg Cys Ala Asn Gly Ser Val 260 265 270 Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro Cys Arg His Pro Gly 275 280 285 Lys Ile Pro Gly Gln Cys Cys Pro Val Cys Asp Gly Cys Glu Tyr Gln 290 295 300 Gly His Gln Tyr Gln Ser Gln Glu Thr Phe Arg Leu Gln Glu Arg Gly 305 310 315 320 Leu Cys Val Arg Cys Ser Cys Gln Ala Gly Glu Val Ser Cys Glu Glu 325 330 335 Gln Glu Cys Pro Val Thr Pro Cys Ala Leu Pro Ala Ser Gly Arg Gln 340 345 350 Leu Cys Pro Ala His Pro Asp Gln Pro Ala Pro Pro Thr Cys Glu Leu 355 360 365 Asp Gly Glu Glu Phe Ala Glu Gly Val Gln Trp Glu Pro Asp Gly Arg 370 375 380 Pro Cys Thr Ala Cys Val Cys Gln Asp Gly Val Pro Lys Cys Gly Ala 385 390 395 400 Val Leu Cys Pro Pro Ala Pro Cys Gln His Pro Thr Gln Pro Pro Gly 405 410 415 Ala Cys Cys Pro Ser Cys Asp Ser Cys Thr Tyr His Ser Gln Val Tyr 420 425 430 Ala Asn Gly Gln Asn Phe Thr Asp Ala Asp Ser Pro Cys His Ala Cys 435 440 445 His Cys Gln Asp Gly Thr Val Thr Cys Ser Leu Val Asp Cys Pro Pro 450 455 460 Thr Thr Cys Ala Arg Pro Gln Ser Gly Pro Gly Gln Cys Cys Pro Arg 465 470 475 480 Cys Pro Asp Cys Ile Leu Glu Glu Glu Val Phe Val Asp Gly Glu Ser 485 490 495 Phe Ser His Pro Arg Asp Pro Cys Gln Glu Cys Arg Cys Gln Glu Gly 500 505 510 His Ala His Cys Gln Pro Arg Pro Cys Pro Arg Ala Pro Cys Ala His 515 520 525 Pro Leu Pro Gly Thr Cys Cys Pro Asn Asp Cys Ser Gly Cys Ala Phe 530 535 540 Gly Gly Lys Glu Tyr Pro Ser Gly Ala Asp Phe Pro His Pro Ser Asp 545 550 555 560 Pro Cys Arg Leu Cys Arg Cys Leu Ser Gly Asn Val Gln Cys Leu Ala 565 570 575 Arg Arg Cys Val Pro Leu Pro Cys Pro Glu Pro Val Leu Leu Pro Gly 580 585 590 Glu Cys Cys Pro Gln Cys Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro 595 600 605 Arg Pro Gly Ala Ala His Ala Arg His Gln Glu Tyr Phe Ser Pro Pro 610 615 620 Gly Asp Pro Cys Arg Arg Cys Leu Cys Leu Asp Gly Ser Val Ser Cys 625 630 635 640 Gln Arg Leu Pro Cys Pro Pro Ala Pro Cys Ala His Pro Arg Gln Gly 645 650 655 Pro Cys Cys Pro Ser Cys Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe 660 665 670 Ala Ser Gly Glu Arg Phe Pro Ser Pro Thr Ala Ala Cys His Leu Cys 675 680 685 Leu Cys Trp Glu Gly Ser Val Ser Cys Glu Pro Lys Ala Cys Ala Pro 690 695 700 Ala Leu Cys Pro Phe Pro Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp 705 710 715 720 Gly Cys Glu Tyr Leu Gly Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro 725 730 735 Asp Pro Arg Glu Pro Cys Asn Leu Cys Thr Cys Leu Gly Gly Phe Val 740 745 750 Thr Cys Gly Arg Arg Pro Cys Glu Pro Pro Gly Cys Ser His Pro Leu 755 760 765 Ile Pro Ser Gly His Cys Cys Pro Thr Cys Gln Gly Cys Arg Tyr His 770 775 780 Gly Val Thr Thr Ala Ser Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro 785 790 795 800 Thr Cys Ser Leu Cys Thr Cys Gln Gly Arg Glu His Gln Asp Gly Glu 805 810 815 Glu Phe Glu Gly Pro Ala Gly Ser Cys Glu Trp Cys Arg Cys Gln Ala 820 825 830 Gly Gln Val Ser Cys Val Arg Leu Gln Cys Pro Pro Leu Pro Cys Lys 835 840 845 Leu Gln Val Thr Glu Arg Gly Ser Cys Cys Pro Arg Cys Arg Gly Cys 850 855 860 Leu Ala His Gly Glu Glu His Pro Glu Gly Ser Arg Trp Val Pro Pro 865 870 875 880 Asp Ser Ala Cys Ser Ser Cys Val Cys His Glu Gly Val Val Thr Cys 885 890 895 Ala Arg Ile Gln Cys Ile Ser Ser Cys Ala Gln Pro Arg Gln Gly Pro 900 905 910 His Asp Cys Cys Pro Gln Cys Ser Asp Cys Glu His Glu Gly Arg Lys 915 920 925 Tyr Glu Pro Gly Glu Ser Phe Gln Pro Gly Ala Asp Pro Cys Glu Val 930 935 940 Cys Ile Cys Glu Pro Gln Pro Glu Gly Pro Pro Ser Leu Arg Cys His 945 950 955 960 Arg Arg Gln Cys Pro Ser Leu Val Gly Cys Pro Pro Ser Gln Leu Leu 965 970 975 Pro Pro Gly Pro Gln His Cys Cys Pro Thr Cys Ala Glu Ala Leu Ser 980 985 990 Asn Cys Ser Glu Gly Leu Leu Gly Ser Glu Leu Ala Pro Pro Asp Pro 995 1000 1005 Cys Tyr Thr Cys Gln Cys Gln Asp Leu Thr Trp Leu Cys Ile His Gln 1010 1015 1020 Ala Cys Pro Glu Leu Ser Cys Pro Leu Ser Glu Arg His Thr Pro Pro 1025 1030 1035 1040 Gly Ser Cys Cys Pro Val Cys Arg Glu Cys Val Val Glu Ala Glu Gly 1045 1050 1055 Arg Arg Val Ala Asp Gly Glu Ser Trp Arg Asp Pro Ser Asn Ala Cys 1060 1065 1070 Ile Ala Cys Thr Cys His Arg Gly His Val Glu Cys His Leu Glu Glu 1075 1080 1085 Cys Gln Ala Leu Ser Cys Pro His Gly Trp Ala Lys Val Pro Gln Ala 1090 1095 1100 Asp Ser Cys Cys Glu Arg Cys Gln Ala Pro Thr Gln Ser Cys Val His 1105 1110 1115 1120 Gln Gly Arg Glu Val Ala Ser Gly Glu Arg Trp Thr Val Asp Thr Cys 1125 1130 1135 Thr Ser Cys Ser Cys Met Ala Gly Thr Val Arg Cys Gln Ser Gln Arg 1140 1145 1150 Cys Ser Pro Leu Ser Cys Gly Pro Asp Lys Ala Pro Ala Leu Ser Pro 1155 1160 1165 Gly Ser Cys Cys Pro Arg Cys Leu Pro Arg Pro Ala Ser Cys Met Ala 1170 1175 1180 Phe Gly Asp Pro His Tyr Arg Thr Phe Asp Gly Arg Leu Leu His Phe 1185 1190 1195 1200 Gln Gly Ser Cys Ser Tyr Val Leu Ala Lys Asp Cys His Ser Gly Asp 1205 1210 1215 Phe Ser Val His Val Thr Asn Asp Asp Arg Gly Arg Ser Gly Val Ala 1220 1225 1230 Trp Thr Gln Glu Val Ala Val Leu Leu Gly Asp Met Ala Val Arg Leu 1235 1240 1245 Leu Gln Asp Gly Ala Val Thr Val Asp Gly His Pro Val Ala Leu Pro 1250 1255 1260 Phe Leu Gln Glu Pro Leu Leu Tyr Val Glu Leu Arg Gly His Thr Val 1265 1270 1275 1280 Ile Leu His Ala Gln Pro Gly Leu Gln Val Leu Trp Asp Gly Gln Ser 1285 1290 1295 Gln Val Glu Val Ser Val Pro Gly Ser Tyr Gln Gly Arg Thr Cys Gly 1300 1305 1310 Leu Cys Gly Asn Phe Asn Gly Phe Ala Gln Asp Asp Leu Gln Gly Pro 1315 1320 1325 Glu Gly Leu Leu Leu Pro Ser Glu Ala Ala Phe Gly Asn Ser Trp Gln 1330 1335 1340 Val Ser Glu Gly Leu Trp Pro Gly Arg Pro Cys Ser Ala Gly Arg Glu 1345 1350 1355 1360 Val Asp Pro Cys Arg Ala Ala Gly Tyr Arg Ala Arg Arg Glu Ala Asn 1365 1370 1375 Ala Arg Cys Gly Val Leu Lys Ser Ser Pro Phe Ser Arg Cys His Ala 1380 1385 1390 Val Val Pro Pro Glu Pro Phe Phe Ala Ala Cys Val Tyr Asp Leu Cys 1395 1400 1405 Ala Cys Gly Pro Gly Ser Ser Ala Asp Ala Cys Leu Cys Asp Ala Leu 1410 1415 1420 Glu Ala Tyr Ala Ser His Cys Arg Gln Ala Gly Val Thr Pro Thr Trp 1425 1430 1435 1440 Arg Gly Pro Thr Leu Cys Val Val Gly Cys Pro Leu Glu Arg Gly Phe 1445 1450 1455 Val Phe Asp Glu Cys Gly Pro Pro Cys Pro Arg Thr Cys Phe Asn Gln 1460 1465 1470 His Ile Pro Leu Gly Glu Leu Ala Ala His Cys Val Arg Pro Cys Val 1475 1480 1485 Pro Gly Cys Gln Cys Pro Ala Gly Leu Val Glu His Glu Ala His Cys 1490 1495 1500 Ile Pro Pro Glu Ala Cys Pro Gln Val Leu Leu Thr Gly Asp Gln Pro 1505 1510 1515 1520 Leu Gly Ala Arg Pro Ser Pro Ser Arg Glu Pro Gln Glu Thr Pro 1525 1530 1535 15 3753 DNA homo sapiens 15 atgggagtgt ccagtgtgag cctctgccct gcccgccagt gccctgcaga cacccaggca 60 agatccctgg gcagtgctgc cctgtctgcg atggctgtga gtaccaggga caccagtatc 120 agagccagga gaccttcaga ctccaagagc ggggcctctg tgtccgctgc tcctgccagg 180 ctggcgaggt ctcctgtgag gagcaggagt gcccagtcac cccctgtgcc ctgcctgcct 240 ctggccgcca gctctgccca gctcaccctg accagcctgc cccacccagg tgcctgctgc 300 cccagctgtg acagctgcac ctaccacagc caagtgtatg ccaatgggca gaacttcacg 360 gatgcagaca gcccttgcca tgcctgccac tgtcaggatg gaactgtgac atgctccttg 420 gttgactgcc ctcccacgac ctgtgccagg ccccagagtg gaccaggcca gtgttgcccc 480 aggtgcccag actgcatcct ggaggaagag gtgtttgtgg acggcgagag cttctcccac 540 ccccgagacc cctgccagga gtgccgatgc caggaaggcc atgcccactg ccagcctcgc 600 ccctgcccca gggccccctg tgcccacccg ctgcctggga cctgctgccc gaacgactgc 660 agcggctgtg cctttggcgg gaaagagtac cccagcggag cggacttccc ccacccctct 720 gacccctgcc gtctgtgtcg ctgtctgagc ggcaacgtgc agtgcctggc ccgccgctgc 780 gtgccgctgc cctgtccaga gcctgtcctg ctgccgggag agtgctgccc gcagtgccca 840 gccgccccag cccccgccgg ctgcccacgg cccggcgcgg cccacgcccg ccaccaggag 900 tacttctccc cgcccggcga tccctgccgc cgctgcctct gcctcgacgg ctccgtgtcc 960 tgccagcggc tgccctgccc gcccgcgccc tgcgcgcacc cgcgccaggg gccttgctgc 1020 ccctcctgcg acggctgcct gtaccagggg aaggagtttg ccagcgggga gcgcttccca 1080 tcgcccactg ctgcctgcca cctctgcctt tgctgggagg gcagcgtgag ctgcgagccc 1140 aaggcatgtg cccctgcact gtgccccttc cctgccaggg gcgactgctg ccctgactgt 1200 gatggctgtg agtacctggg ggagtcctac ctgagtaacc aggagttccc agacccccga 1260 gaaccctgca acctgtgtac ctgtcttgga ggcttcgtga cctgcggccg ccggccctgt 1320 gagcctccgg gctgcagcca cccactcatc ccctctgggc actgctgccc gacctgccag 1380 ggatgccgct accatggcgt cactactgcc tccggagaga cccttcctga cccacttgac 1440 cctacctgct ccctctgcac ctgccaggaa ggttccatgc gctgccaaaa gaagccatgt 1500 gccccagctc tctgccccca cccctctcca ggcccctgct tctgccctgt ttgccacagt 1560 tgtctctctc agggccggga gcaccaggat ggggaggagt ttgagggacc agcaggcagc 1620 tgtgagtggt gtcgctgtca ggctggccag gtcagctgtg tgcggctgca gtgcccaccc 1680 cttccctgca agctccaggt caccgagcgg gggagctgct gccctcgctg cagaggctgc 1740 ctggctcatg gggaagagca ccccgaaggc agtagatggg tgccccccga cagtgcctgc 1800 tcctcctgtg tgtgtcacga gggcgtcgtc acctgtgcac gcatccagtg catcagctct 1860 tgcgcccagc cccgccaagg gccccatgac tgctgtcctc aatgctctga ctgtgagcat 1920 gagggccgga agtacgagcc tggggagagc ttccagcctg gggcagaccc ctgtgaagtg 1980 tgcatctgcg agccacagcc tgaggggcct cccagccttc gctgtcaccg gcggcagtgt 2040 cccagcctgg tgggctgccc ccccagccag ctcctgcccc ctgggcccca gcactgctgt 2100 cccacctgtg ccgaggcctt gagtaactgt tcagagggcc tgctgggatc tgagctagcc 2160 ccaccagacc cctgctacac gtgccagtgc caggacctga catggctctg catccaccag 2220 gcttgtcctg agctcagctg tcccctctca gagcgccaca ctccccctgg gagctgctgc 2280 cccgtatgcc gggaatgtgt ggtggaggcc gagggccgga gagtggcaga tggagagagc 2340 tggcgggacc ccagcaatgc gtgcatcgcc tgcacctgcc atcggggcca tgtggagtgc 2400 cacctcgagg agtgccaggc cctctcctgc ccccatggct gggcgaaggt gccccaggct 2460 gacagctgct gtgagcgatg ccaagctccc acccagtcct gcgtgcacca gggccgtgag 2520 gtggcctctg gagagcgctg gactgtggac acctgcacca gctgctcctg catggcgggc 2580 accgtgcgtt gccagagcca gcgctgctca ccgctctcgt gtggccccga caaggcccct 2640 gccctgagtc ctggcagctg ctgcccccgc tgcctgcctc ggcccgcttc ctgcatggcc 2700 ttcggagacc cccattaccg caccttcgac ggccgcctgc tgcacttcca gggcagttgc 2760 agctatgtgc tggccaagga ctgccacagc ggggacttca gtgtgcacgt gaccaatgat 2820 gaccggggcc ggagcggtgt ggcctggacc caggaggtgg cggtgctgct gggagacatg 2880 gccgtgcggc tgctgcagga cggggcagtc acggtggatg ggcacccggt ggccttgccc 2940 ttcctgcagg agccgctgct gtatgtggag ctgcgaggac acactgtgat cctgcacgcc 3000 cagcccgggc tccaggtgct gtgggatggg cagtcccagg tggaggtgag cgtacctggc 3060 tcctaccagg gccggacttg tgggctctgt gggaacttca atggctttgc ccaggacgat 3120 ctgcagggcc ctgaggggct gctcctgccc tcggaggctg cgtttgggaa tagctggcag 3180 gtctcagagg ggctgtggcc tggccggccc tgttctgcag gccgagaggt ggatccgtgc 3240 cgggcagcag gttaccgtgc caggcgtgag gccaatgccc ggtgtggggt gctgaagtcc 3300 tccccattca gtcgctgcca tgctgtggtg ccaccggagc ccttctttgc cgcctgtgtg 3360 tatgacctgt gtgcctgtgg ccctggctcc tccgctgatg cctgcctctg tgatgccctg 3420 gaagcctacg ccagtcactg tcgccaggca ggagtgacac ctacctggcg aggccccacg 3480 ctgtgtgtgg taggctgccc cctggagcgt ggcttcgtgt ttgatgagtg cggcccaccc 3540 tgtccccgca cctgcttcaa tcagcatatc cccctggggg agctggcagc ccactgcgtg 3600 aggccctgcg tgcccggctg ccagtgccct gcaggcctgg tggagcatga ggcccactgc 3660 atcccacccg aggcctgccc ccaagtcctg ctcactggag accagccact tggtgctcgg 3720 cccagcccca gccgggagcc ccaggagaca ccc 3753 16 1251 PRT homo sapiens 16 Met Gly Val Ser Ser Val Ser Leu Cys Pro Ala Arg Gln Cys Pro Ala 1 5 10 15 Asp Thr Gln Ala Arg Ser Leu Gly Ser Ala Ala Leu Ser Ala Met Ala 20 25 30 Val Ser Thr Arg Asp Thr Ser Ile Arg Ala Arg Arg Pro Ser Asp Ser 35 40 45 Lys Ser Gly Ala Ser Val Ser Ala Ala Pro Ala Arg Leu Ala Arg Ser 50 55 60 Pro Val Arg Ser Arg Ser Ala Gln Ser Pro Pro Val Pro Cys Leu Pro 65 70 75 80 Leu Ala Ala Ser Ser Ala Gln Leu Thr Leu Thr Ser Leu Pro His Pro 85 90 95 Gly Ala Cys Cys Pro Ser Cys Asp Ser Cys Thr Tyr His Ser Gln Val 100 105 110 Tyr Ala Asn Gly Gln Asn Phe Thr Asp Ala Asp Ser Pro Cys His Ala 115 120 125 Cys His Cys Gln Asp Gly Thr Val Thr Cys Ser Leu Val Asp Cys Pro 130 135 140 Pro Thr Thr Cys Ala Arg Pro Gln Ser Gly Pro Gly Gln Cys Cys Pro 145 150 155 160 Arg Cys Pro Asp Cys Ile Leu Glu Glu Glu Val Phe Val Asp Gly Glu 165 170 175 Ser Phe Ser His Pro Arg Asp Pro Cys Gln Glu Cys Arg Cys Gln Glu 180 185 190 Gly His Ala His Cys Gln Pro Arg Pro Cys Pro Arg Ala Pro Cys Ala 195 200 205 His Pro Leu Pro Gly Thr Cys Cys Pro Asn Asp Cys Ser Gly Cys Ala 210 215 220 Phe Gly Gly Lys Glu Tyr Pro Ser Gly Ala Asp Phe Pro His Pro Ser 225 230 235 240 Asp Pro Cys Arg Leu Cys Arg Cys Leu Ser Gly Asn Val Gln Cys Leu 245 250 255 Ala Arg Arg Cys Val Pro Leu Pro Cys Pro Glu Pro Val Leu Leu Pro 260 265 270 Gly Glu Cys Cys Pro Gln Cys Pro Ala Ala Pro Ala Pro Ala Gly Cys 275 280 285 Pro Arg Pro Gly Ala Ala His Ala Arg His Gln Glu Tyr Phe Ser Pro 290 295 300 Pro Gly Asp Pro Cys Arg Arg Cys Leu Cys Leu Asp Gly Ser Val Ser 305 310 315 320 Cys Gln Arg Leu Pro Cys Pro Pro Ala Pro Cys Ala His Pro Arg Gln 325 330 335 Gly Pro Cys Cys Pro Ser Cys Asp Gly Cys Leu Tyr Gln Gly Lys Glu 340 345 350 Phe Ala Ser Gly Glu Arg Phe Pro Ser Pro Thr Ala Ala Cys His Leu 355 360 365 Cys Leu Cys Trp Glu Gly Ser Val Ser Cys Glu Pro Lys Ala Cys Ala 370 375 380 Pro Ala Leu Cys Pro Phe Pro Ala Arg Gly Asp Cys Cys Pro Asp Cys 385 390 395 400 Asp Gly Cys Glu Tyr Leu Gly Glu Ser Tyr Leu Ser Asn Gln Glu Phe 405 410 415 Pro Asp Pro Arg Glu Pro Cys Asn Leu Cys Thr Cys Leu Gly Gly Phe 420 425 430 Val Thr Cys Gly Arg Arg Pro Cys Glu Pro Pro Gly Cys Ser His Pro 435 440 445 Leu Ile Pro Ser Gly His Cys Cys Pro Thr Cys Gln Gly Cys Arg Tyr 450 455 460 His Gly Val Thr Thr Ala Ser Gly Glu Thr Leu Pro Asp Pro Leu Asp 465 470 475 480 Pro Thr Cys Ser Leu Cys Thr Cys Gln Glu Gly Ser Met Arg Cys Gln 485 490 495 Lys Lys Pro Cys Ala Pro Ala Leu Cys Pro His Pro Ser Pro Gly Pro 500 505 510 Cys Phe Cys Pro Val Cys His Ser Cys Leu Ser Gln Gly Arg Glu His 515 520 525 Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser Cys Glu Trp Cys 530 535 540 Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg Leu Gln Cys Pro Pro 545 550 555 560 Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly Ser Cys Cys Pro Arg 565 570 575 Cys Arg Gly Cys Leu Ala His Gly Glu Glu His Pro Glu Gly Ser Arg 580 585 590 Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys Val Cys His Glu Gly 595 600 605 Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser Cys Ala Gln Pro 610 615 620 Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys Ser Asp Cys Glu His 625 630 635 640 Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln Pro Gly Ala Asp 645 650 655 Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro Glu Gly Pro Pro Ser 660 665 670 Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu Val Gly Cys Pro Pro 675 680 685 Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys Cys Pro Thr Cys Ala 690 695 700 Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly Ser Glu Leu Ala 705 710 715 720 Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp Leu Thr Trp Leu 725 730 735 Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys Pro Leu Ser Glu Arg 740 745 750 His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys Arg Glu Cys Val Val 755 760 765 Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu Ser Trp Arg Asp Pro 770 775 780 Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg Gly His Val Glu Cys 785 790 795 800 His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro His Gly Trp Ala Lys 805 810 815 Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln Ala Pro Thr Gln 820 825 830 Ser Cys Val His Gln Gly Arg Glu Val Ala Ser Gly Glu Arg Trp Thr 835 840 845 Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala Gly Thr Val Arg Cys 850 855 860 Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro Asp Lys Ala Pro 865 870 875 880 Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu Pro Arg Pro Ala 885 890 895 Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg Thr Phe Asp Gly Arg 900 905 910 Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val Leu Ala Lys Asp Cys 915 920 925 His Ser Gly Asp Phe Ser Val His Val Thr Asn Asp Asp Arg Gly Arg 930 935 940 Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val Leu Leu Gly Asp Met 945 950 955 960 Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr Val Asp Gly His Pro 965 970 975 Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr Val Glu Leu Arg 980 985 990 Gly His Thr Val Ile Leu His Ala Gln Pro Gly Leu Gln Val Leu Trp 995 1000 1005 Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro Gly Ser Tyr Gln Gly 1010 1015 1020 Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe Ala Gln Asp Asp 1025 1030 1035 1040 Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu Ala Ala Phe Gly 1045 1050 1055 Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro Gly Arg Pro Cys Ser 1060 1065 1070 Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala Gly Tyr Arg Ala Arg 1075 1080 1085 Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys Ser Ser Pro Phe Ser 1090 1095 1100 Arg Cys His Ala Val Val Pro Pro Glu Pro Phe Phe Ala Ala Cys Val 1105 1110 1115 1120 Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala Asp Ala Cys Leu 1125 1130 1135 Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys Arg Gln Ala Gly Val 1140 1145 1150 Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val Val Gly Cys Pro Leu 1155 1160 1165 Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro Pro Cys Pro Arg Thr 1170 1175 1180 Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu Ala Ala His Cys Val 1185 1190 1195 1200 Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala Gly Leu Val Glu His 1205 1210 1215 Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro Gln Val Leu Leu Thr 1220 1225 1230 Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser Arg Glu Pro Gln 1235 1240 1245 Glu Thr Pro 1250 17 3576 DNA homo sapiens 17 atggccaaga gtggacaaca cctggggacc cctgccgaat ctgccggtgc ctggagggtc 60 acatccagtg ccgccagcga gaatgtgcca gcctgtgtcc atacccagcc cggcccctcc 120 caggcacctg ctgccctgtg tgtgatgaat gggagtgtcc agtgtgagcc tctgccctgc 180 ccgccagtgc cctgcagaca cccaggcaag atccctgggc agtgctgccc cagctgtgac 240 agctgcacct accacagcca agtgtatgcc aatgggcaga acttcacgga tgcagacagc 300 ccttgccatg cctgccactg tcaggatgga actgtgacat gctccttggt tgactgccct 360 cccacgacct gtgccaggcc ccagagtgga ccaggccagt gttgccccag gtgcccagac 420 tgcatcctgg aggaagaggt gtttgtggac ggcgagagct tctcccaccc ccgagacccc 480 tgccaggagt gccgatgcca ggaaggccat gcccactgcc agcctcgccc ctgccccagg 540 gccccctgtg cccacccgct gcctgggacc tgctgcccga acgactgcag cggctgtgcc 600 tttggcggga aagagtaccc cagcggagcg gacttccccc acccctctga cccctgccgt 660 ctgtgtcgct gtctgagcgg caacgtgcag tgcctggccc gccgctgcgt gccgctgccc 720 tgtccagagc ctgtcctgct gccgggagag tgctgcccgc agtgcccagc cgccccagcc 780 cccgccggct gcccacggcc cggcgcggcc cacgcccgcc accaggagta cttctccccg 840 cccggcgatc cctgccgccg ctgcctctgc ctcgacggct ccgtgtcctg ccagcggctg 900 ccctgcccgc ccgcgccctg cgcgcacccg cgccaggggc cttgctgccc ctcctgcgac 960 ggctgcctgt accaggggaa ggagtttgcc agcggggagc gcttcccatc gcccactgct 1020 gcctgccacc tctgcctttg ctgggagggc agcgtgagct gcgagcccaa ggcatgtgcc 1080 cctgcactgt gccccttccc tgccaggggc gactgctgcc ctgactgtga tggctgtgag 1140 tacctggggg agtcctacct gagtaaccag gagttcccag acccccgaga accctgcaac 1200 ctgtgtacct gtcttggagg cttcgtgacc tgcggccgcc ggccctgtga gcctccgggc 1260 tgcagccacc cactcatccc ctctgggcac tgctgcccga cctgccaggg atgccgctac 1320 catggcgtca ctactgcctc cggagagacc cttcctgacc cacttgaccc tacctgctcc 1380 ctctgcacct gccagggccg ggagcaccag gatggggagg agtttgaggg accagcaggc 1440 agctgtgagt ggtgtcgctg tcaggctggc caggtcagct gtgtgcggct gcagtgccca 1500 ccccttccct gcaagctcca ggtcaccgag cgggggagct gctgccctcg ctgcagaggc 1560 tgcctggctc atggggaaga gcaccccgaa ggcagtagat gggtgccccc cgacagtgcc 1620 tgctcctcct gtgtgtgtca cgagggcgtc gtcacctgtg cacgcatcca gtgcatcagc 1680 tcttgcgccc agccccgcca agggccccat gactgctgtc ctcaatgctc tgactgtgag 1740 catgagggcc ggaagtacga gcctggggag agcttccagc ctggggcaga cccctgtgaa 1800 gtgtgcatct gcgagccaca gcctgagggg cctcccagcc ttcgctgtca ccggcggcag 1860 tgtcccagcc tggtgggctg cccccccagc cagctcctgc cccctgggcc ccagcactgc 1920 tgtcccacct gtgccgaggc cttgagtaac tgttcagagg gcctgctggg atctgagcta 1980 gccccaccag acccctgcta cacgtgccag tgccaggacc tgacatggct ctgcatccac 2040 caggcttgtc ctgagctcag ctgtcccctc tcagagcgcc acactccccc tgggagctgc 2100 tgccccgtat gccgggaatg tgtggtggag gccgagggcc ggagagtggc agatggagag 2160 agctggcggg accccagcaa tgcgtgcatc gcctgcacct gccatcgggg ccatgtggag 2220 tgccacctcg aggagtgcca ggccctctcc tgcccccatg gctgggcgaa ggtgccccag 2280 gctgacagct gctgtgagcg atgccaagct cccacccagt cctgcgtgca ccagggccgt 2340 gaggtggcct ctggagagcg ctggactgtg gacacctgca ccagctgctc ctgcatggcg 2400 ggcaccgtgc gttgccagag ccagcgctgc tcaccgctct cgtgtggccc cgacaaggcc 2460 cctgccctga gtcctggcag ctgctgcccc cgctgcctgc ctcggcccgc ttcctgcatg 2520 gccttcggag acccccatta ccgcaccttc gacggccgcc tgctgcactt ccagggcagt 2580 tgcagctatg tgctggccaa ggactgccac agcggggact tcagtgtgca cgtgaccaat 2640 gatgaccggg gccggagcgg tgtggcctgg acccaggagg tggcggtgct gctgggagac 2700 atggccgtgc ggctgctgca ggacggggca gtcacggtgg atgggcaccc ggtggccttg 2760 cccttcctgc aggagccgct gctgtatgtg gagctgcgag gacacactgt gatcctgcac 2820 gcccagcccg ggctccaggt gctgtgggat gggcagtccc aggtggaggt gagcgtacct 2880 ggctcctacc agggccggac ttgtgggctc tgtgggaact tcaatggctt tgcccaggac 2940 gatctgcagg gccctgaggg gctgctcctg ccctcggagg ctgcgtttgg gaatagctgg 3000 caggtctcag aggggctgtg gcctggccgg ccctgttctg caggccgaga ggtggatccg 3060 tgccgggcag caggttaccg tgccaggcgt gaggccaatg cccggtgtgg ggtgctgaag 3120 tcctccccat tcagtcgctg ccatgctgtg gtgccaccgg agcccttctt tgccgcctgt 3180 gtgtatgacc tgtgtgcctg tggccctggc tcctccgctg atgcctgcct ctgtgatgcc 3240 ctggaagcct acgccagtca ctgtcgccag gcaggagtga cacctacctg gcgaggcccc 3300 acgctgtgtg tggtaggctg ccccctggag cgtggcttcg tgtttgatga gtgcggccca 3360 ccctgtcccc gcacctgctt caatcagcat atccccctgg gggagctggc agcccactgc 3420 gtgaggccct gcgtgcccgg ctgccagtgc cctgcaggcc tggtggagca tgaggcccac 3480 tgcatcccac ccgaggcctg cccccaagtc ctgctcactg gagaccagcc acttggtgct 3540 cggcccagcc ccagccggga gccccaggag acaccc 3576 18 1192 PRT homo sapiens 18 Met Ala Lys Ser Gly Gln His Leu Gly Thr Pro Ala Glu Ser Ala Gly 1 5 10 15 Ala Trp Arg Val Thr Ser Ser Ala Ala Ser Glu Asn Val Pro Ala Cys 20 25 30 Val His Thr Gln Pro Gly Pro Ser Gln Ala Pro Ala Ala Leu Cys Val 35 40 45 Met Asn Gly Ser Val Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro 50 55 60 Cys Arg His Pro Gly Lys Ile Pro Gly Gln Cys Cys Pro Ser Cys Asp 65 70 75 80 Ser Cys Thr Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe Thr 85 90 95 Asp Ala Asp Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr Val 100 105 110 Thr Cys Ser Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro Gln 115 120 125 Ser Gly Pro Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu Glu 130 135 140 Glu Glu Val Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp Pro 145 150 155 160 Cys Gln Glu Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro Arg 165 170 175 Pro Cys Pro Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys Cys 180 185 190 Pro Asn Asp Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro Ser 195 200 205 Gly Ala Asp Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg Cys 210 215 220 Leu Ser Gly Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu Pro 225 230 235 240 Cys Pro Glu Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys Pro 245 250 255 Ala Ala Pro Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His Ala 260 265 270 Arg His Gln Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg Cys 275 280 285 Leu Cys Leu Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro Pro 290 295 300 Ala Pro Cys Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys Asp 305 310 315 320 Gly Cys Leu Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe Pro 325 330 335 Ser Pro Thr Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser Val 340 345 350 Ser Cys Glu Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro Ala 355 360 365 Arg Gly Asp Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly Glu 370 375 380 Ser Tyr Leu Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys Asn 385 390 395 400 Leu Cys Thr Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro Cys 405 410 415 Glu Pro Pro Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys Cys 420 425 430 Pro Thr Cys Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser Gly 435 440 445 Glu Thr Leu Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr Cys 450 455 460 Gln Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly 465 470 475 480 Ser Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg 485 490 495 Leu Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly 500 505 510 Ser Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu His 515 520 525 Pro Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys 530 535 540 Val Cys His Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser 545 550 555 560 Ser Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys 565 570 575 Ser Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe 580 585 590 Gln Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro 595 600 605 Glu Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu 610 615 620 Val Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys 625 630 635 640 Cys Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu 645 650 655 Gly Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln 660 665 670 Asp Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys 675 680 685 Pro Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys 690 695 700 Arg Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu 705 710 715 720 Ser Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg 725 730 735 Gly His Val Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro 740 745 750 His Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys 755 760 765 Gln Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala Ser 770 775 780 Gly Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala 785 790 795 800 Gly Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly 805 810 815 Pro Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys 820 825 830 Leu Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg 835 840 845 Thr Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val 850 855 860 Leu Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr Asn 865 870 875 880 Asp Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val 885 890 895 Leu Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr 900 905 910 Val Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu 915 920 925 Tyr Val Glu Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro Gly 930 935 940 Leu Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro 945 950 955 960 Gly Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly 965 970 975 Phe Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser 980 985 990 Glu Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro 995 1000 1005 Gly Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala 1010 1015 1020 Gly Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys 1025 1030 1035 1040 Ser Ser Pro Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro Phe 1045 1050 1055 Phe Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser 1060 1065 1070 Ala Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys 1075 1080 1085 Arg Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val 1090 1095 1100 Val Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro 1105 1110 1115 1120 Pro Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu 1125 1130 1135 Ala Ala His Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala 1140 1145 1150 Gly Leu Val Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro 1155 1160 1165 Gln Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro 1170 1175 1180 Ser Arg Glu Pro Gln Glu Thr Pro 1185 1190 19 3621 DNA homo sapiens 19 atgggagtgt ccagtgtgag cctctgccct gcccgccagt gccctgcaga cacccaggca 60 agatccctgg gcagtgctgc cctgtctgcg atggctgtga gtaccaggga caccagtatc 120 agagccagga gaccttcaga ctccaagagc ggggcctctg tgtccgctgc tcctgccagg 180 ctggcgaggt ctcctgtgag gagcaggagt gcccagtcac cccctgtgcc ctgcctgcct 240 ctggccgcca gctctgccca gggtgcctgc tgccccagct gtgacagctg cacctaccac 300 agccaagtgt atgccaatgg gcagaacttc acggatgcag acagcccttg ccatgcctgc 360 cactgtcagg atggaactgt gacatgctcc ttggttgact gccctcccac gacctgtgcc 420 aggccccaga gtggaccagg ccagtgttgc cccaggtgcc cagactgcat cctggaggaa 480 gaggtgtttg tggacggcga gagcttctcc cacccccgag acccctgcca ggagtgccga 540 tgccaggaag gccatgccca ctgccagcct cgcccctgcc ccagggcccc ctgtgcccac 600 ccgctgcctg ggacctgctg cccgaacgac tgcagcggct gtgcctttgg cgggaaagag 660 taccccagcg gagcggactt cccccacccc tctgacccct gccgtctgtg tcgctgtctg 720 agcggcaacg tgcagtgcct ggcccgccgc tgcgtgccgc tgccctgtcc agagcctgtc 780 ctgctgccgg gagagtgctg cccgcagtgc ccagccgccc cagcccccgc cggctgccca 840 cggcccggcg cggcccacgc ccgccaccag gagtacttct ccccgcccgg cgatccctgc 900 cgccgctgcc tctgcctcga cggctccgtg tcctgccagc ggctgccctg cccgcccgcg 960 ccctgcgcgc acccgcgcca ggggccttgc tgcccctcct gcgacggctg cctgtaccag 1020 gggaaggagt ttgccagcgg ggagcgcttc ccatcgccca ctgctgcctg ccacctctgc 1080 ctttgctggg agggcagcgt gagctgcgag cccaaggcat gtgcccctgc actgtgcccc 1140 ttccctgcca ggggcgactg ctgccctgac tgtgatggct gtgagtacct gggggagtcc 1200 tacctgagta accaggagtt cccagacccc cgagaaccct gcaacctgtg tacctgtctt 1260 ggaggcttcg tgacctgcgg ccgccggccc tgtgagcctc cgggctgcag ccacccactc 1320 atcccctctg ggcactgctg cccgacctgc cagggatgcc gctaccatgg cgtcactact 1380 gcctccggag agacccttcc tgacccactt gaccctacct gctccctctg cacctgccag 1440 ggccgggagc accaggatgg ggaggagttt gagggaccag caggcagctg tgagtggtgt 1500 cgctgtcagg ctggccaggt cagctgtgtg cggctgcagt gcccacccct tccctgcaag 1560 ctccaggtca ccgagcgggg gagctgctgc cctcgctgca gaggctgcct ggctcatggg 1620 gaagagcacc ccgaaggcag tagatgggtg ccccccgaca gtgcctgctc ctcctgtgtg 1680 tgtcacgagg gcgtcgtcac ctgtgcacgc atccagtgca tcagctcttg cgcccagccc 1740 cgccaagggc cccatgactg ctgtcctcaa tgctctgact gtgagcatga gggccggaag 1800 tacgagcctg gggagagctt ccagcctggg gcagacccct gtgaagtgtg catctgcgag 1860 ccacagcctg aggggcctcc cagccttcgc tgtcaccggc ggcagtgtcc cagcctggtg 1920 ggctgccccc ccagccagct cctgccccct gggccccagc actgctgtcc cacctgtgcc 1980 gaggccttga gtaactgttc agagggcctg ctgggatctg agctagcccc accagacccc 2040 tgctacacgt gccagtgcca ggacctgaca tggctctgca tccaccaggc ttgtcctgag 2100 ctcagctgtc ccctctcaga gcgccacact ccccctggga gctgctgccc cgtatgccgg 2160 gaatgtgtgg tggaggccga gggccggaga gtggcagatg gagagagctg gcgggacccc 2220 agcaatgcgt gcatcgcctg cacctgccat cggggccatg tggagtgcca cctcgaggag 2280 tgccaggccc tctcctgccc ccatggctgg gcgaaggtgc cccaggctga cagctgctgt 2340 gagcgatgcc aagctcccac ccagtcctgc gtgcaccagg gccgtgaggt ggcctctgga 2400 gagcgctgga ctgtggacac ctgcaccagc tgctcctgca tggcgggcac cgtgcgttgc 2460 cagagccagc gctgctcacc gctctcgtgt ggccccgaca aggcccctgc cctgagtcct 2520 ggcagctgct gcccccgctg cctgcctcgg cccgcttcct gcatggcctt cggagacccc 2580 cattaccgca ccttcgacgg ccgcctgctg cacttccagg gcagttgcag ctatgtgctg 2640 gccaaggact gccacagcgg ggacttcagt gtgcacgtga ccaatgatga ccggggccgg 2700 agcggtgtgg cctggaccca ggaggtggcg gtgctgctgg gagacatggc cgtgcggctg 2760 ctgcaggacg gggcagtcac ggtggatggg cacccggtgg ccttgccctt cctgcaggag 2820 ccgctgctgt atgtggagct gcgaggacac actgtgatcc tgcacgccca gcccgggctc 2880 caggtgctgt gggatgggca gtcccaggtg gaggtgagcg tacctggctc ctaccagggc 2940 cggacttgtg ggctctgtgg gaacttcaat ggctttgccc aggacgatct gcagggccct 3000 gaggggctgc tcctgccctc ggaggctgcg tttgggaata gctggcaggt ctcagagggg 3060 ctgtggcctg gccggccctg ttctgcaggc cgagaggtgg atccgtgccg ggcagcaggt 3120 taccgtgcca ggcgtgaggc caatgcccgg tgtggggtgc tgaagtcctc cccattcagt 3180 cgctgccatg ctgtggtgcc accggagccc ttctttgccg cctgtgtgta tgacctgtgt 3240 gcctgtggcc ctggctcctc cgctgatgcc tgcctctgtg atgccctgga agcctacgcc 3300 agtcactgtc gccaggcagg agtgacacct acctggcgag gccccacgct gtgtgtggta 3360 ggctgccccc tggagcgtgg cttcgtgttt gatgagtgcg gcccaccctg tccccgcacc 3420 tgcttcaatc agcatatccc cctgggggag ctggcagccc actgcgtgag gccctgcgtg 3480 cccggctgcc agtgccctgc aggcctggtg gagcatgagg cccactgcat cccacccgag 3540 gcctgccccc aagtcctgct cactggagac cagccacttg gtgctcggcc cagccccagc 3600 cgggagcccc aggagacacc c 3621 20 1207 PRT homo sapiens 20 Met Gly Val Ser Ser Val Ser Leu Cys Pro Ala Arg Gln Cys Pro Ala 1 5 10 15 Asp Thr Gln Ala Arg Ser Leu Gly Ser Ala Ala Leu Ser Ala Met Ala 20 25 30 Val Ser Thr Arg Asp Thr Ser Ile Arg Ala Arg Arg Pro Ser Asp Ser 35 40 45 Lys Ser Gly Ala Ser Val Ser Ala Ala Pro Ala Arg Leu Ala Arg Ser 50 55 60 Pro Val Arg Ser Arg Ser Ala Gln Ser Pro Pro Val Pro Cys Leu Pro 65 70 75 80 Leu Ala Ala Ser Ser Ala Gln Gly Ala Cys Cys Pro Ser Cys Asp Ser 85 90 95 Cys Thr Tyr His Ser Gln Val Tyr Ala Asn Gly Gln Asn Phe Thr Asp 100 105 110 Ala Asp Ser Pro Cys His Ala Cys His Cys Gln Asp Gly Thr Val Thr 115 120 125 Cys Ser Leu Val Asp Cys Pro Pro Thr Thr Cys Ala Arg Pro Gln Ser 130 135 140 Gly Pro Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys Ile Leu Glu Glu 145 150 155 160 Glu Val Phe Val Asp Gly Glu Ser Phe Ser His Pro Arg Asp Pro Cys 165 170 175 Gln Glu Cys Arg Cys Gln Glu Gly His Ala His Cys Gln Pro Arg Pro 180 185 190 Cys Pro Arg Ala Pro Cys Ala His Pro Leu Pro Gly Thr Cys Cys Pro 195 200 205 Asn Asp Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu Tyr Pro Ser Gly 210 215 220 Ala Asp Phe Pro His Pro Ser Asp Pro Cys Arg Leu Cys Arg Cys Leu 225 230 235 240 Ser Gly Asn Val Gln Cys Leu Ala Arg Arg Cys Val Pro Leu Pro Cys 245 250 255 Pro Glu Pro Val Leu Leu Pro Gly Glu Cys Cys Pro Gln Cys Pro Ala 260 265 270 Ala Pro Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala Ala His Ala Arg 275 280 285 His Gln Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys Arg Arg Cys Leu 290 295 300 Cys Leu Asp Gly Ser Val Ser Cys Gln Arg Leu Pro Cys Pro Pro Ala 305 310 315 320 Pro Cys Ala His Pro Arg Gln Gly Pro Cys Cys Pro Ser Cys Asp Gly 325 330 335 Cys Leu Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu Arg Phe Pro Ser 340 345 350 Pro Thr Ala Ala Cys His Leu Cys Leu Cys Trp Glu Gly Ser Val Ser 355 360 365 Cys Glu Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro Phe Pro Ala Arg 370 375 380 Gly Asp Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr Leu Gly Glu Ser 385 390 395 400 Tyr Leu Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu Pro Cys Asn Leu 405 410 415 Cys Thr Cys Leu Gly Gly Phe Val Thr Cys Gly Arg Arg Pro Cys Glu 420 425 430 Pro Pro Gly Cys Ser His Pro Leu Ile Pro Ser Gly His Cys Cys Pro 435 440 445 Thr Cys Gln Gly Cys Arg Tyr His Gly Val Thr Thr Ala Ser Gly Glu 450 455 460 Thr Leu Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu Cys Thr Cys Gln 465 470 475 480 Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser 485 490 495 Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg Leu 500 505 510 Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly Ser 515 520 525 Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu His Pro 530 535 540 Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys Val 545 550 555 560 Cys His Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser 565 570 575 Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys Ser 580 585 590 Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln 595 600 605 Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro Glu 610 615 620 Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu Val 625 630 635 640 Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys Cys 645 650 655 Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly 660 665 670 Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp 675 680 685 Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys Pro 690 695 700 Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys Arg 705 710 715 720 Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu Ser 725 730 735 Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg Gly 740 745 750 His Val Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro His 755 760 765 Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln 770 775 780 Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala Ser Gly 785 790 795 800 Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala Gly 805 810 815 Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro 820 825 830 Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu 835 840 845 Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg Thr 850 855 860 Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val Leu 865 870 875 880 Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr Asn Asp 885 890 895 Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val Leu 900 905 910 Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr Val 915 920 925 Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr 930 935 940 Val Glu Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro Gly Leu 945 950 955 960 Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro Gly 965 970 975 Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe 980 985 990 Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu 995 1000 1005 Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro Gly 1010 1015 1020 Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala Gly 1025 1030 1035 1040 Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys Ser 1045 1050 1055 Ser Pro Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro Phe Phe 1060 1065 1070 Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala 1075 1080 1085 Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys Arg 1090 1095 1100 Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val Val 1105 1110 1115 1120 Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro Pro 1125 1130 1135 Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu Ala 1140 1145 1150 Ala His Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala Gly 1155 1160 1165 Leu Val Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro Gln 1170 1175 1180 Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser 1185 1190 1195 1200 Arg Glu Pro Gln Glu Thr Pro 1205 21 2277 DNA homo sapiens 21 atgcgctgcc aaaagaagcc atgtgcccca gctctctgcc cccacccctc tccaggcccc 60 tgcttctgcc ctgtttgcca cagttgtctc tctcagggcc gggagcacca ggatggggag 120 gagtttgagg gaccagcagg cagctgtgag tggtgtcgct gtcaggctgg ccaggtcagc 180 tgtgtgcggc tgcagtgccc accccttccc tgcaagctcc aggtcaccga gcgggggagc 240 tgctgccctc gctgcagagg ctgcctggct catggggaag agcaccccga aggcagtaga 300 tgggtgcccc ccgacagtgc ctgctcctcc tgtgtgtgtc acgagggcgt cgtcacctgt 360 gcacgcatcc agtgcatcag ctcttgcgcc cagccccgcc aagggcccca tgactgctgt 420 cctcaatgct ctgactgtga gcatgagggc cggaagtacg agcctgggga gagcttccag 480 cctggggcag acccctgtga agtgtgcatc tgcgagccac agcctgaggg gcctcccagc 540 cttcgctgtc accggcggca gtgtcccagc ctggtgggct gcccccccag ccagctcctg 600 ccccctgggc cccagcactg ctgtcccacc tgtgccgagg ccttgagtaa ctgttcagag 660 ggcctgctgg gatctgagct agccccacca gacccctgct acacgtgcca gtgccaggac 720 ctgacatggc tctgcatcca ccaggcttgt cctgagctca gctgtcccct ctcagagcgc 780 cacactcccc ctgggagctg ctgccccgta tgccgggaat gtgtggtgga ggccgagggc 840 cggagagtgg cagatggaga gagctggcgg gaccccagca atgcgtgcat cgcctgcacc 900 tgccatcggg gccatgtgga gtgccacctc gaggagtgcc aggccctctc ctgcccccat 960 ggctgggcga aggtgcccca ggctgacagc tgctgtgagc gatgccaagc tcccacccag 1020 tcctgcgtgc accagggccg tgaggtggcc tctggagagc gctggactgt ggacacctgc 1080 accagctgct cctgcatggc gggcaccgtg cgttgccaga gccagcgctg ctcaccgctc 1140 tcgtgtggcc ccgacaaggc ccctgccctg agtcctggca gctgctgccc ccgctgcctg 1200 cctcggcccg cttcctgcat ggccttcgga gacccccatt accgcacctt cgacggccgc 1260 ctgctgcact tccagggcag ttgcagctat gtgctggcca aggactgcca cagcggggac 1320 ttcagtgtgc acgtgaccaa tgatgaccgg ggccggagcg gtgtggcctg gacccaggag 1380 gtggcggtgc tgctgggaga catggccgtg cggctgctgc aggacggggc agtcacggtg 1440 gatgggcacc cggtggcctt gcccttcctg caggagccgc tgctgtatgt ggagctgcga 1500 ggacacactg tgatcctgca cgcccagccc gggctccagg tgctgtggga tgggcagtcc 1560 caggtggagg tgagcgtacc tggctcctac cagggccgga cttgtgggct ctgtgggaac 1620 ttcaatggct ttgcccagga cgatctgcag ggccctgagg ggctgctcct gccctcggag 1680 gctgcgtttg ggaatagctg gcaggtctca gaggggctgt ggcctggccg gccctgttct 1740 gcaggccgag aggtggatcc gtgccgggca gcaggttacc gtgccaggcg tgaggccaat 1800 gcccggtgtg gggtgctgaa gtcctcccca ttcagtcgct gccatgctgt ggtgccaccg 1860 gagcccttct ttgccgcctg tgtgtatgac ctgtgtgcct gtggccctgg ctcctccgct 1920 gatgcctgcc tctgtgatgc cctggaagcc tacgccagtc actgtcgcca ggcaggagtg 1980 acacctacct ggcgaggccc cacgctgtgt gtggtaggct gccccctgga gcgtggcttc 2040 gtgtttgatg agtgcggccc accctgtccc cgcacctgct tcaatcagca tatccccctg 2100 ggggagctgg cagcccactg cgtgaggccc tgcgtgcccg gctgccagtg ccctgcaggc 2160 ctggtggagc atgaggccca ctgcatccca cccgaggcct gcccccaagt cctgctcact 2220 ggagaccagc cacttggtgc tcggcccagc cccagccggg agccccagga gacaccc 2277 22 759 PRT homo sapiens 22 Met Arg Cys Gln Lys Lys Pro Cys Ala Pro Ala Leu Cys Pro His Pro 1 5 10 15 Ser Pro Gly Pro Cys Phe Cys Pro Val Cys His Ser Cys Leu Ser Gln 20 25 30 Gly Arg Glu His Gln Asp Gly Glu Glu Phe Glu Gly Pro Ala Gly Ser 35 40 45 Cys Glu Trp Cys Arg Cys Gln Ala Gly Gln Val Ser Cys Val Arg Leu 50 55 60 Gln Cys Pro Pro Leu Pro Cys Lys Leu Gln Val Thr Glu Arg Gly Ser 65 70 75 80 Cys Cys Pro Arg Cys Arg Gly Cys Leu Ala His Gly Glu Glu His Pro 85 90 95 Glu Gly Ser Arg Trp Val Pro Pro Asp Ser Ala Cys Ser Ser Cys Val 100 105 110 Cys His Glu Gly Val Val Thr Cys Ala Arg Ile Gln Cys Ile Ser Ser 115 120 125 Cys Ala Gln Pro Arg Gln Gly Pro His Asp Cys Cys Pro Gln Cys Ser 130 135 140 Asp Cys Glu His Glu Gly Arg Lys Tyr Glu Pro Gly Glu Ser Phe Gln 145 150 155 160 Pro Gly Ala Asp Pro Cys Glu Val Cys Ile Cys Glu Pro Gln Pro Glu 165 170 175 Gly Pro Pro Ser Leu Arg Cys His Arg Arg Gln Cys Pro Ser Leu Val 180 185 190 Gly Cys Pro Pro Ser Gln Leu Leu Pro Pro Gly Pro Gln His Cys Cys 195 200 205 Pro Thr Cys Ala Glu Ala Leu Ser Asn Cys Ser Glu Gly Leu Leu Gly 210 215 220 Ser Glu Leu Ala Pro Pro Asp Pro Cys Tyr Thr Cys Gln Cys Gln Asp 225 230 235 240 Leu Thr Trp Leu Cys Ile His Gln Ala Cys Pro Glu Leu Ser Cys Pro 245 250 255 Leu Ser Glu Arg His Thr Pro Pro Gly Ser Cys Cys Pro Val Cys Arg 260 265 270 Glu Cys Val Val Glu Ala Glu Gly Arg Arg Val Ala Asp Gly Glu Ser 275 280 285 Trp Arg Asp Pro Ser Asn Ala Cys Ile Ala Cys Thr Cys His Arg Gly 290 295 300 His Val Glu Cys His Leu Glu Glu Cys Gln Ala Leu Ser Cys Pro His 305 310 315 320 Gly Trp Ala Lys Val Pro Gln Ala Asp Ser Cys Cys Glu Arg Cys Gln 325 330 335 Ala Pro Thr Gln Ser Cys Val His Gln Gly Arg Glu Val Ala Ser Gly 340 345 350 Glu Arg Trp Thr Val Asp Thr Cys Thr Ser Cys Ser Cys Met Ala Gly 355 360 365 Thr Val Arg Cys Gln Ser Gln Arg Cys Ser Pro Leu Ser Cys Gly Pro 370 375 380 Asp Lys Ala Pro Ala Leu Ser Pro Gly Ser Cys Cys Pro Arg Cys Leu 385 390 395 400 Pro Arg Pro Ala Ser Cys Met Ala Phe Gly Asp Pro His Tyr Arg Thr 405 410 415 Phe Asp Gly Arg Leu Leu His Phe Gln Gly Ser Cys Ser Tyr Val Leu 420 425 430 Ala Lys Asp Cys His Ser Gly Asp Phe Ser Val His Val Thr Asn Asp 435 440 445 Asp Arg Gly Arg Ser Gly Val Ala Trp Thr Gln Glu Val Ala Val Leu 450 455 460 Leu Gly Asp Met Ala Val Arg Leu Leu Gln Asp Gly Ala Val Thr Val 465 470 475 480 Asp Gly His Pro Val Ala Leu Pro Phe Leu Gln Glu Pro Leu Leu Tyr 485 490 495 Val Glu Leu Arg Gly His Thr Val Ile Leu His Ala Gln Pro Gly Leu 500 505 510 Gln Val Leu Trp Asp Gly Gln Ser Gln Val Glu Val Ser Val Pro Gly 515 520 525 Ser Tyr Gln Gly Arg Thr Cys Gly Leu Cys Gly Asn Phe Asn Gly Phe 530 535 540 Ala Gln Asp Asp Leu Gln Gly Pro Glu Gly Leu Leu Leu Pro Ser Glu 545 550 555 560 Ala Ala Phe Gly Asn Ser Trp Gln Val Ser Glu Gly Leu Trp Pro Gly 565 570 575 Arg Pro Cys Ser Ala Gly Arg Glu Val Asp Pro Cys Arg Ala Ala Gly 580 585 590 Tyr Arg Ala Arg Arg Glu Ala Asn Ala Arg Cys Gly Val Leu Lys Ser 595 600 605 Ser Pro Phe Ser Arg Cys His Ala Val Val Pro Pro Glu Pro Phe Phe 610 615 620 Ala Ala Cys Val Tyr Asp Leu Cys Ala Cys Gly Pro Gly Ser Ser Ala 625 630 635 640 Asp Ala Cys Leu Cys Asp Ala Leu Glu Ala Tyr Ala Ser His Cys Arg 645 650 655 Gln Ala Gly Val Thr Pro Thr Trp Arg Gly Pro Thr Leu Cys Val Val 660 665 670 Gly Cys Pro Leu Glu Arg Gly Phe Val Phe Asp Glu Cys Gly Pro Pro 675 680 685 Cys Pro Arg Thr Cys Phe Asn Gln His Ile Pro Leu Gly Glu Leu Ala 690 695 700 Ala His Cys Val Arg Pro Cys Val Pro Gly Cys Gln Cys Pro Ala Gly 705 710 715 720 Leu Val Glu His Glu Ala His Cys Ile Pro Pro Glu Ala Cys Pro Gln 725 730 735 Val Leu Leu Thr Gly Asp Gln Pro Leu Gly Ala Arg Pro Ser Pro Ser 740 745 750 Arg Glu Pro Gln Glu Thr Pro 755 23 4026 DNA homo sapiens 23 atggccaaga gtggacaaca cctggggacc cctgccgaat ctgccggtgc ctggagggtc 60 acatccagtg ccgccagcga gaatgtgcca gcctgtgtcc atacccagcc cggcccctcc 120 caggcacctg ctgccctgtg tgtgatgaat gggagtgtcc agtgtgagcc tctgccctgc 180 ccgccagtgc cctgcagaca cccaggcaag atccctgggc agtgctgccc tgtctgcgat 240 ggctgtgagt accagggaca ccagtatcag agccaggaga ccttcagact ccaagagcgg 300 ggcctctgtg tccgctgctc ctgccaggct ggcgaggtct cctgtgagga gcaggagtgc 360 ccagtcaccc cctgtgccct gcctgcctct ggccgccagc tctgcccagc ctgtgagctg 420 gatggagagg agtttgctga gggagtccag tgggagcctg atggtcggcc ctgcaccgcc 480 tgcgtctgtc aagatggggt acccaagtgc ggggctgtgc tctgcccccc agccccctgc 540 cagcacccca cccagccccc tggtgcctgc tgccccagct gtgacagctg cacctaccac 600 agccaagtgt atgccaatgg gcagaacttc acggatgcag acagcccttg ccatgcctgc 660 cactgtcagg atggaactgt gacatgctcc ttggttgact gccctcccac gacctgtgcc 720 aggccccaga gtggaccagg ccagtgttgc cccaggtgcc cagactgcat cctggaggaa 780 gaggtgtttg tggacggcga gagcttctcc cacccccgag acccctgcca ggagtgccga 840 tgccaggaag gccatgccca ctgccagcct cgcccctgcc ccagggcccc ctgtgcccac 900 ccgctgcctg ggacctgctg cccgaacgac tgcagcggct gtgcctttgg cgggaaagag 960 taccccagcg gagcggactt cccccacccc tctgacccct gccgtctgtg tcgctgtctg 1020 agcggcaacg tgcagtgcct ggcccgccgc tgcgtgccgc tgccctgtcc agagcctgtc 1080 ctgctgccgg gagagtgctg cccgcagtgc ccagccgccc cagcccccgc cggctgccca 1140 cggcccggcg cggcccacgc ccgccaccag gagtacttct ccccgcccgg cgatccctgc 1200 cgccgctgcc tctgcctcga cggctccgtg tcctgccagc ggctgccctg cccgcccgcg 1260 ccctgcgcgc acccgcgcca ggggccttgc tgcccctcct gcgacggctg cctgtaccag 1320 gggaaggagt ttgccagcgg ggagcgcttc ccatcgccca ctgctgcctg ccacctctgc 1380 ctttgctggg agggcagcgt gagctgcgag cccaaggcat gtgcccctgc actgtgcccc 1440 ttccctgcca ggggcgactg ctgccctgac tgtgatggct gtgagtacct gggggagtcc 1500 tacctgagta accaggagtt cccagacccc cgagaaccct gcaacctgtg tacctgtctt 1560 ggaggcttcg tgacctgcgg ccgccggccc tgtgagcctc cgggctgcag ccacccactc 1620 atcccctctg ggcactgctg cccgacctgc cagggatgcc gctaccatgg cgtcactact 1680 gcctccggag agacccttcc tgacccactt gaccctacct gctccctctg cacctgccag 1740 gaaggttcca tgcgctgcca aaagaagcca tgtgccccag ctctctgccc ccacccctct 1800 ccaggcccct gcttctgccc tgtttgccac agttgtctct ctcagggccg ggagcaccag 1860 gatggggagg agtttgaggg accagcaggc agctgtgagt ggtgtcgctg tcaggctggc 1920 caggtcagct gtgtgcggct gcagtgccca ccccttccct gcaagctcca ggtcaccgag 1980 cgggggagct gctgccctcg ctgcagaggc tgcctggctc atggggaaga gcaccccgaa 2040 ggcagtagat gggtgccccc cgacagtgcc tgctcctcct gtgtgtgtca cgagggcgtc 2100 gtcacctgtg cacgcatcca gtgcatcagc tcttgcgccc agccccgcca agggccccat 2160 gactgctgtc ctcaatgctc tgactgtgag catgagggcc ggaagtacga gcctggggag 2220 agcttccagc ctggggcaga cccctgtgaa gtgtgcatct gcgagccaca gcctgagggg 2280 cctcccagcc ttcgctgtca ccggcggcag tgtcccagcc tggtgggctg cccccccagc 2340 cagctcctgc cccctgggcc ccagcactgc tgtcccacct gtgccgaggc cttgagtaac 2400 tgttcagagg gcctgctggg atctgagcta gccccaccag acccctgcta cacgtgccag 2460 tgccaggacc tgacatggct ctgcatccac caggcttgtc ctgagctcag ctgtcccctc 2520 tcagagcgcc acactccccc tgggagctgc tgccccgtat gccgggaatg tgtggtggag 2580 gccgagggcc ggagagtggc agatggagag agctggcggg accccagcaa tgcgtgcatc 2640 gcctgcacct gccatcgggg ccatgtggag tgccacctcg aggagtgcca ggccctctcc 2700 tgcccccatg gctgggcgaa ggtgccccag gctgacagct gctgtgagcg atgccaagct 2760 cccacccagt cctgcgtgca ccagggccgt gaggtggcct ctggagagcg ctggactgtg 2820 gacacctgca ccagctgctc ctgcatggcg ggcaccgtgc gttgccagag ccagcgctgc 2880 tcaccgctct cgtgtggccc cgacaaggcc cctgccctga gtcctggcag ctgctgcccc 2940 cgctgcctgc ctcggcccgc ttcctgcatg gccttcggag acccccatta ccgcaccttc 3000 gacggccgcc tgctgcactt ccagggcagt tgcagctatg tgctggccaa ggactgccac 3060 agcggggact tcagtgtgca cgtgaccaat gatgaccggg gccggagcgg tgtggcctgg 3120 acccaggagg tggcggtgct gctgggagac atggccgtgc ggctgctgca ggacggggca 3180 gtcacggtgg atgggcaccc ggtggccttg cccttcctgc aggagccgct gctgtatgtg 3240 gagctgcgag gacacactgt gatcctgcac gcccagcccg ggctccaggt gctgtgggat 3300 gggcagtccc aggtggaggt gagcgtacct ggctcctacc agggccggac ttgtgggctc 3360 tgtgggaact tcaatggctt tgcccaggac gatctgcagg gccctgaggg gctgctcctg 3420 ccctcggagg ctgcgtttgg gaatagctgg caggtctcag aggggctgtg gcctggccgg 3480 ccctgttctg caggccgaga ggtggatccg tgccgggcag caggttaccg tgccaggcgt 3540 gaggccaatg cccggtgtgg ggtgctgaag tcctccccat tcagtcgctg ccatgctgtg 3600 gtgccaccgg agcccttctt tgccgcctgt gtgtatgacc tgtgtgcctg tggccctggc 3660 tcctccgctg atgcctgcct ctgtgatgcc ctggaagcct acgccagtca ctgtcgccag 3720 gcaggagtga cacctacctg gcgaggcccc acgctgtgtg tggtaggctg ccccctggag 3780 cgtggcttcg tgtttgatga gtgcggccca ccctgtcccc gcacctgctt caatcagcat 3840 atccccctgg gggagctggc agcccactgc gtgaggccct gcgtgcccgg ctgccagtgc 3900 cctgcaggcc tggtggagca tgaggcccac tgcatcccac ccgaggcctg cccccaagtc 3960 ctgctcactg gagaccagcc acttggtgct cggcccagcc ccagccggga gccccaggag 4020 acaccc 4026 24 1342 PRT homo sapiens 24 Met Ala Lys Ser Gly Gln His Leu Gly Thr Pro Ala Glu Ser Ala Gly 1 5 10 15 Ala Trp Arg Val Thr Ser Ser Ala Ala Ser Glu Asn Val Pro Ala Cys 20 25 30 Val His Thr Gln Pro Gly Pro Ser Gln Ala Pro Ala Ala Leu Cys Val 35 40 45 Met Asn Gly Ser Val Gln Cys Glu Pro Leu Pro Cys Pro Pro Val Pro 50 55 60 Cys Arg His Pro Gly Lys Ile Pro Gly Gln Cys Cys Pro Val Cys Asp 65 70 75 80 Gly Cys Glu Tyr Gln Gly His Gln Tyr Gln Ser Gln Glu Thr Phe Arg 85 90 95 Leu Gln Glu Arg Gly Leu Cys Val Arg Cys Ser Cys Gln Ala Gly Glu 100 105 110 Val Ser Cys Glu Glu Gln Glu Cys Pro Val Thr Pro Cys Ala Leu Pro 115 120 125 Ala Ser Gly Arg Gln Leu Cys Pro Ala Cys Glu Leu Asp Gly Glu Glu 130 135 140 Phe Ala Glu Gly Val Gln Trp Glu Pro Asp Gly Arg Pro Cys Thr Ala 145 150 155 160 Cys Val Cys Gln Asp Gly Val Pro Lys Cys Gly Ala Val Leu Cys Pro 165 170 175 Pro Ala Pro Cys Gln His Pro Thr Gln Pro Pro Gly Ala Cys Cys Pro 180 185 190 Ser Cys Asp Ser Cys Thr Tyr His Ser Gln Val Tyr Ala Asn Gly Gln 195 200 205 Asn Phe Thr Asp Ala Asp Ser Pro Cys His Ala Cys His Cys Gln Asp 210 215 220 Gly Thr Val Thr Cys Ser Leu Val Asp Cys Pro Pro Thr Thr Cys Ala 225 230 235 240 Arg Pro Gln Ser Gly Pro Gly Gln Cys Cys Pro Arg Cys Pro Asp Cys 245 250 255 Ile Leu Glu Glu Glu Val Phe Val Asp Gly Glu Ser Phe Ser His Pro 260 265 270 Arg Asp Pro Cys Gln Glu Cys Arg Cys Gln Glu Gly His Ala His Cys 275 280 285 Gln Pro Arg Pro Cys Pro Arg Ala Pro Cys Ala His Pro Leu Pro Gly 290 295 300 Thr Cys Cys Pro Asn Asp Cys Ser Gly Cys Ala Phe Gly Gly Lys Glu 305 310 315 320 Tyr Pro Ser Gly Ala Asp Phe Pro His Pro Ser Asp Pro Cys Arg Leu 325 330 335 Cys Arg Cys Leu Ser Gly Asn Val Gln Cys Leu Ala Arg Arg Cys Val 340 345 350 Pro Leu Pro Cys Pro Glu Pro Val Leu Leu Pro Gly Glu Cys Cys Pro 355 360 365 Gln Cys Pro Ala Ala Pro Ala Pro Ala Gly Cys Pro Arg Pro Gly Ala 370 375 380 Ala His Ala Arg His Gln Glu Tyr Phe Ser Pro Pro Gly Asp Pro Cys 385 390 395 400 Arg Arg Cys Leu Cys Leu Asp Gly Ser Val Ser Cys Gln Arg Leu Pro 405 410 415 Cys Pro Pro Ala Pro Cys Ala His Pro Arg Gln Gly Pro Cys Cys Pro 420 425 430 Ser Cys Asp Gly Cys Leu Tyr Gln Gly Lys Glu Phe Ala Ser Gly Glu 435 440 445 Arg Phe Pro Ser Pro Thr Ala Ala Cys His Leu Cys Leu Cys Trp Glu 450 455 460 Gly Ser Val Ser Cys Glu Pro Lys Ala Cys Ala Pro Ala Leu Cys Pro 465 470 475 480 Phe Pro Ala Arg Gly Asp Cys Cys Pro Asp Cys Asp Gly Cys Glu Tyr 485 490 495 Leu Gly Glu Ser Tyr Leu Ser Asn Gln Glu Phe Pro Asp Pro Arg Glu 500 505 510 Pro Cys Asn Leu Cys Thr Cys Leu Gly Gly Phe Val Thr Cys Gly Arg 515 520 525 Arg Pro Cys Glu Pro Pro Gly Cys Ser His Pro Leu Ile Pro Ser Gly 530 535 540 His Cys Cys Pro Thr Cys Gln Gly Cys Arg Tyr His Gly Val Thr Thr 545 550 555 560 Ala Ser Gly Glu Thr Leu Pro Asp Pro Leu Asp Pro Thr Cys Ser Leu 565 570 575 Cys Thr Cys Gln Glu Gly Ser Met Arg Cys Gln Lys Lys Pro Cys Ala 580 585 590 Pro Ala Leu Cys Pro His Pro Ser Pro Gly Pro Cys Phe Cys Pro Val 595 600 605 Cys His Ser Cys Leu Ser Gln Gly Arg Glu His Gln Asp Gly Glu Glu 610 615 620 Phe Glu Gly Pro Ala Gly Ser Cys Glu Trp Cys Arg Cys Gln Ala Gly 625 630 635 640 Gln Val Ser Cys Val Arg Leu Gln Cys Pro Pro Leu Pro Cys Lys Leu 645 650 655 Gln Val Thr Glu Arg Gly Ser Cys Cys Pro Arg Cys Arg Gly Cys Leu 660 665 670 Ala His Gly Glu Glu His Pro Glu Gly Ser Arg Trp Val Pro Pro Asp 675 680 685 Ser Ala Cys Ser Ser Cys Val Cys His Glu Gly Val Val Thr Cys Ala 690 695 700 Arg Ile Gln Cys Ile Ser Ser Cys Ala Gln Pro Arg Gln Gly Pro His 705 710 715 720 Asp Cys Cys Pro Gln Cys Ser Asp Cys Glu His Glu Gly Arg Lys Tyr 725 730 735 Glu Pro Gly Glu Ser Phe Gln Pro Gly Ala Asp Pro Cys Glu Val Cys 740 745 750 Ile Cys Glu Pro Gln Pro Glu Gly Pro Pro Ser Leu Arg Cys His Arg 755 760 765 Arg Gln Cys Pro Ser Leu Val Gly Cys Pro Pro Ser Gln Leu Leu Pro 770 775 780 Pro Gly Pro Gln His Cys Cys Pro Thr Cys Ala Glu Ala Leu Ser Asn 785 790 795 800 Cys Ser Glu Gly Leu Leu Gly Ser Glu Leu Ala Pro Pro Asp Pro Cys 805 810 815 Tyr Thr Cys Gln Cys Gln Asp Leu Thr Trp Leu Cys Ile His Gln Ala 820 825 830 Cys Pro Glu Leu Ser Cys Pro Leu Ser Glu Arg His Thr Pro Pro Gly 835 840 845 Ser Cys Cys Pro Val Cys Arg Glu Cys Val Val Glu Ala Glu Gly Arg 850 855 860 Arg Val Ala Asp Gly Glu Ser Trp Arg Asp Pro Ser Asn Ala Cys Ile 865 870 875 880 Ala Cys Thr Cys His Arg Gly His Val Glu Cys His Leu Glu Glu Cys 885 890 895 Gln Ala Leu Ser Cys Pro His Gly Trp Ala Lys Val Pro Gln Ala Asp 900 905 910 Ser Cys Cys Glu Arg Cys Gln Ala Pro Thr Gln Ser Cys Val His Gln 915 920 925 Gly Arg Glu Val Ala Ser Gly Glu Arg Trp Thr Val Asp Thr Cys Thr 930 935 940 Ser Cys Ser Cys Met Ala Gly Thr Val Arg Cys Gln Ser Gln Arg Cys 945 950 955 960 Ser Pro Leu Ser Cys Gly Pro Asp Lys Ala Pro Ala Leu Ser Pro Gly 965 970 975 Ser Cys Cys Pro Arg Cys Leu Pro Arg Pro Ala Ser Cys Met Ala Phe 980 985 990 Gly Asp Pro His Tyr Arg Thr Phe Asp Gly Arg Leu Leu His Phe Gln 995 1000 1005 Gly Ser Cys Ser Tyr Val Leu Ala Lys Asp Cys His Ser Gly Asp Phe 1010 1015 1020 Ser Val His Val Thr Asn Asp Asp Arg Gly Arg Ser Gly Val Ala Trp 1025 1030 1035 1040 Thr Gln Glu Val Ala Val Leu Leu Gly Asp Met Ala Val Arg Leu Leu 1045 1050 1055 Gln Asp Gly Ala Val Thr Val Asp Gly His Pro Val Ala Leu Pro Phe 1060 1065 1070 Leu Gln Glu Pro Leu Leu Tyr Val Glu Leu Arg Gly His Thr Val Ile 1075 1080 1085 Leu His Ala Gln Pro Gly Leu Gln Val Leu Trp Asp Gly Gln Ser Gln 1090 1095 1100 Val Glu Val Ser Val Pro Gly Ser Tyr Gln Gly Arg Thr Cys Gly Leu 1105 1110 1115 1120 Cys Gly Asn Phe Asn Gly Phe Ala Gln Asp Asp Leu Gln Gly Pro Glu 1125 1130 1135 Gly Leu Leu Leu Pro Ser Glu Ala Ala Phe Gly Asn Ser Trp Gln Val 1140 1145 1150 Ser Glu Gly Leu Trp Pro Gly Arg Pro Cys Ser Ala Gly Arg Glu Val 1155 1160 1165 Asp Pro Cys Arg Ala Ala Gly Tyr Arg Ala Arg Arg Glu Ala Asn Ala 1170 1175 1180 Arg Cys Gly Val Leu Lys Ser Ser Pro Phe Ser Arg Cys His Ala Val 1185 1190 1195 1200 Val Pro Pro Glu Pro Phe Phe Ala Ala Cys Val Tyr Asp Leu Cys Ala 1205 1210 1215 Cys Gly Pro Gly Ser Ser Ala Asp Ala Cys Leu Cys Asp Ala Leu Glu 1220 1225 1230 Ala Tyr Ala Ser His Cys Arg Gln Ala Gly Val Thr Pro Thr Trp Arg 1235 1240 1245 Gly Pro Thr Leu Cys Val Val Gly Cys Pro Leu Glu Arg Gly Phe Val 1250 1255 1260 Phe Asp Glu Cys Gly Pro Pro Cys Pro Arg Thr Cys Phe Asn Gln His 1265 1270 1275 1280 Ile Pro Leu Gly Glu Leu Ala Ala His Cys Val Arg Pro Cys Val Pro 1285 1290 1295 Gly Cys Gln Cys Pro Ala Gly Leu Val Glu His Glu Ala His Cys Ile 1300 1305 1310 Pro Pro Glu Ala Cys Pro Gln Val Leu Leu Thr Gly Asp Gln Pro Leu 1315 1320 1325 Gly Ala Arg Pro Ser Pro Ser Arg Glu Pro Gln Glu Thr Pro 1330 1335 1340 25 5776 DNA homo sapiens 25 ctggctggcc ctggctttcc tctgtgacct cagctccagg cactgaggcc aggtcttagc 60 gtggcattgc agcctccctg ccccctgtgg caaaggctca ggtccactat gggcccagac 120 tctggggcag agaagctgcc gtctccttac tgaagcttta agcttggtgg agagtgggct 180 ggggagacct cagtccctgc ctggtctagg gggaggggtg gcttccgact tctggtcttt 240 atgacaggga gggagagctt tggaagggtt cacagctccg ccctcaatgt tcctttttgc 300 ctgtgagctt cgcctgtgag acccaaccct ctgcttccca gcttcaagga ggagtttccc 360 agcctgtggg cccacaggga cggctgtcct cacttcctcc ctttggcccc ctctgcctgc 420 tgagcccagg gcccagccct gccccctacc caggctcacc ccacagccag gcctgagctc 480 aggagtggga aatggggctg agaccagcca gtgaagggcg gccttggcat ttggggccaa 540 gcctgggact gctgggggtc tcctcctgga tcttaagcgg agacaaggcc tacacccccg 600 ttgggcttcc tgcgagctgg agctgctctc tgggcgcctg ctgagccgcg acgacagacg 660 gcgagccgag cgaggcggag ctagcatggc cggggtcggg gccgctgcgc tgtcccttct 720 cctgcacctc ggggccctgg cgctggccgc gggcgcggaa ggtggggctg tccccaggga 780 gccccctggg cagcagacaa ctgcccattc ctcagtcctt gctgggaact cccaggagca 840 gtggcacccc ctgcgagagt ggctggggcg actggaggct gcagtgatgg agctcagaga 900 acagaataag gacctgcaga cgagggtgag gcagctggag tcctgtgagt gccaccctgc 960 atctccccag tgctgggggc tggggcgtgc ctggcccgag ggggcacgct gggagcctga 1020 cgcctgcaca gcctgcgtct gccaggatgg ggccgctcac tgtggccccc aagcacacct 1080 gccccattgc aggggctgca gccaaaatgg ccagacctac ggcaacgggg agaccttctc 1140 cccagatgcc tgcaccacct gccgctgtct ggaaggtacc atcacttgca accagaagcc 1200 atgcccaaga ggaccctgcc ctgagccagg agcatgctgc ccgcactgta agccaggctg 1260 tgattatgag gggcagcttt atgaggaggg ggtcaccttc ctgtccagct ccaacccttg 1320 tctacagtgc acctgcctga ggagccgagt tcgctgcatg gccctgaagt gcccgcctag 1380 cccctgccca gagccagtgc tgaggcctgg gcactgctgc ccaacctgcc aaggctgcac 1440 agaaggtggc tctcactggg aacatggcca agagtggaca acacctgggg acccctgccg 1500 aatctgccgg tgcctggagg gtcacatcca gtgccgccag cgagaatgtg ccagcctgtg 1560 tccataccca gcccggcccc tcccaggcac ctgctgccct gtgtgtgatg gctgtttcct 1620 aaacgggcgg gagcaccgca gcggggagcc tgtgggctca ggggacccct gctcgcactg 1680 ccgctgtgct aatgggagtg tccagtgtga gcctctgccc tgcccgccag tgccctgcag 1740 acacccaggc aagatccctg ggcagtgctg ccctgtctgc gatggctgtg agtaccaggg 1800 acaccagtat cagagccagg agaccttcag actccaagag cggggcctct gtgtccgctg 1860 ctcctgccag gctggcgagg tctcctgtga ggagcaggag tgcccagtca ccccctgtgc 1920 cctgcctgcc tctggccgcc agctctgccc agcctgtgag ctggatggag aggagtttgc 1980 tgagggagtc cagtgggagc ctgatggtcg gccctgcacc gcctgcgtct gtcaagatgg 2040 ggtacccaag tgcggggctg tgctctgccc cccagccccc tgccagcacc ccacccagcc 2100 ccctggtgcc tgctgcccca gctgtgacag ctgcacctac cacagccaag tgtatgccaa 2160 tgggcagaac ttcacggatg cagacagccc ttgccatgcc tgccactgtc aggatggaac 2220 tgtgacatgc tccttggttg actgccctcc cacgacctgt gccaggcccc agagtggacc 2280 aggccagtgt tgccccaggt gcccagactg catcctggag gaagaggtgt ttgtggacgg 2340 cgagagcttc tcccaccccc gagacccctg ccaggagtgc cgatgccagg aaggccatgc 2400 ccactgccag cctcgcccct gccccagggc cccctgtgcc cacccgctgc ctgggacctg 2460 ctgcccgaac gactgcagcg gctgtgcctt tggcgggaaa gagtacccca gcggagcgga 2520 cttcccccac ccctctgacc cctgccgtct gtgtcgctgt ctgagcggca acgtgcagtg 2580 cctggcccgc cgctgcgtgc cgctgccctg tccagagcct gtcctgctgc cgggagagtg 2640 ctgcccgcag tgcccagccg ccccagcccc cgccggctgc ccacggcccg gcgcggccca 2700 cgcccgccac caggagtact tctccccgcc cggcgatccc tgccgccgct gcctctgcct 2760 cgacggctcc gtgtcctgcc agcggctgcc ctgcccgccc gcgccctgcg cgcacccgcg 2820 ccaggggcct tgctgcccct cctgcgacgg ctgcctgtac caggggaagg agtttgccag 2880 cggggagcgc ttcccatcgc ccactgctgc ctgccacctc tgcctttgct gggagggcag 2940 cgtgagctgc gagcccaagg catgtgcccc tgcactgtgc cccttccctg ccaggggcga 3000 ctgctgccct gactgtgatg gctgtgagta cctgggggag tcctacctga gtaaccagga 3060 gttcccagac ccccgagaac cctgcaacct gtgtacctgt cttggaggct tcgtgacctg 3120 cggccgccgg ccctgtgagc ctccgggctg cagccaccca ctcatcccct ctgggcactg 3180 ctgcccgacc tgccagggat gccgctacca tggcgtcact actgcctccg gagagaccct 3240 tcctgaccca cttgacccta cctgctccct ctgcacctgc caggaaggtt ccatgcgctg 3300 ccaaaagaag ccatgtgccc cagctctctg cccccacccc tctccaggcc cctgcttctg 3360 ccctgtttgc cacagttgtc tctctcaggg ccgggagcac caggatgggg aggagtttga 3420 gggaccagca ggcagctgtg agtggtgtcg ctgtcaggct ggccaggtca gctgtgtgcg 3480 gctgcagtgc ccaccccttc cctgcaagct ccaggtcacc gagcggggga gctgctgccc 3540 tcgctgcaga ggctgcctgg ctcatgggga agagcacccc gaaggcagta gatgggtgcc 3600 ccccgacagt gcctgctcct cctgtgtgtg tcacgagggc gtcgtcacct gtgcacgcat 3660 ccagtgcatc agctcttgcg cccagccccg ccaagggccc catgactgct gtcctcaatg 3720 ctctgactgt gagcatgagg gccggaagta cgagcctggg gagagcttcc agcctggggc 3780 agacccctgt gaagtgtgca tctgcgagcc acagcctgag gggcctccca gccttcgctg 3840 tcaccggcgg cagtgtccca gcctggtggg ctgccccccc agccagctcc tgccccctgg 3900 gccccagcac tgctgtccca cctgtgccga ggccttgagt aactgttcag agggcctgct 3960 gggatctgag ctagccccac cagacccctg ctacacgtgc cagtgccagg acctgacatg 4020 gctctgcatc caccaggctt gtcctgagct cagctgtccc ctctcagagc gccacactcc 4080 ccctgggagc tgctgccccg tatgccggga atgtgtggtg gaggccgagg gccggagagt 4140 ggcagatgga gagagctggc gggaccccag caatgcgtgc atcgcctgca cctgccatcg 4200 gggccatgtg gagtgccacc tcgaggagtg ccaggccctc tcctgccccc atggctgggc 4260 gaaggtgccc caggctgaca gctgctgtga gcgatgccaa gctcccaccc agtcctgcgt 4320 gcaccagggc cgtgaggtgg cctctggaga gcgctggact gtggacacct gcaccagctg 4380 ctcctgcatg gcgggcaccg tgcgttgcca gagccagcgc tgctcaccgc tctcgtgtgg 4440 ccccgacaag gcccctgccc tgagtcctgg cagctgctgc ccccgctgcc tgcctcggcc 4500 cgcttcctgc atggccttcg gagaccccca ttaccgcacc ttcgacggcc gcctgctgca 4560 cttccagggc agttgcagct atgtgctggc caaggactgc cacagcgggg acttcagtgt 4620 gcacgtgacc aatgatgacc ggggccggag cggtgtggcc tggacccagg aggtggcggt 4680 gctgctggga gacatggccg tgcggctgct gcaggacggg gcagtcacgg tggatgggca 4740 cccggtggcc ttgcccttcc tgcaggagcc gctgctgtat gtggagctgc gaggacacac 4800 tgtgatcctg cacgcccagc ccgggctcca ggtgctgtgg gatgggcagt cccaggtgga 4860 ggtgagcgta cctggctcct accagggccg gacttgtggg ctctgtggga acttcaatgg 4920 ctttgcccag gacgatctgc agggccctga ggggctgctc ctgccctcgg aggctgcgtt 4980 tgggaatagc tggcaggtct cagaggggct gtggcctggc cggccctgtt ctgcaggccg 5040 agaggtggat ccgtgccggg cagcaggtta ccgtgccagg cgtgaggcca atgcccggtg 5100 tggggtgctg aagtcctccc cattcagtcg ctgccatgct gtggtgccac cggagccctt 5160 ctttgccgcc tgtgtgtatg acctgtgtgc ctgtggccct ggctcctccg ctgatgcctg 5220 cctctgtgat gccctggaag cctacgccag tcactgtcgc caggcaggag tgacacctac 5280 ctggcgaggc cccacgctgt gtgtggtagg ctgccccctg gagcgtggct tcgtgtttga 5340 tgagtgcggc ccaccctgtc cccgcacctg cttcaatcag catatccccc tgggggagct 5400 ggcagcccac tgcgtgaggc cctgcgtgcc cggctgccag tgccctgcag gcctggtgga 5460 gcatgaggcc cactgcatcc cacccgaggc ctgcccccaa gtcctgctca ctggagacca 5520 gccacttggt gctcggccca gccccagccg ggagccccag gagacaccct gagccaggac 5580 agtgcctgat aagggttcat caggccagga gtctcccctt ggcgagcagt tcccaccctg 5640 gttagggcta tggagagaat gccctgcctg gacactggag cctgggcccc tgccctgcaa 5700 agacccccgc catgttgagt caccagcagt aaactctagg cctgcccgaa ggctaaaaaa 5760 aaaaaaaaaa aaaaaa 5776 

What is claimed is:
 1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or
 23. 2. An isolated nucleic acid molecule comprising a nucleotide sequence that: (a) encodes the amino acid sequence shown in SEQ ID NO:2; and (b) hybridizes under highly stringent conditions to the nucleotide sequence of SEQ ID NO:1 or the complement thereof.
 3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or
 24. 4. A recombinant expression vector comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:2.
 5. A host cell comprising the recombinant expression vector of claim
 4. 